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1. INTRODUCTION 
 
1.1 Learning and memory  
Behaviour is the result of the interaction between genes and the environment. In humans 
the most important mechanisms through which the environment alters behaviour are 
learning and memory. Learning is the process by wich we acquire knowledge about the 
world, while memory is the process by which that knowledge is encoded, stored and 
retrieved.  
Memory is a process that can last a second or forever, and it can be classified 
(Baddeley, 1992) from a time-space point of view in: 
SHORT TERM MEMORY: is a working memory and its duration is at maximum 5 sec. 
It needs repetition over time. 
LONG TERM MEMORY: involves more complicate memory processes to remember 
facts long time after the acquisition. Long term memory strongly correlates to new 
protein synthesis.  
IMPLICIT OR NON DECLARATIVE MEMORY: does not depend on conscious process 
and does not require a conscious search of memory. This type of memory builds up 
slowly, through repetition over many trials, and is expressed primarily in performance, 
not in words. Examples of implicit memory include perceptual and motor skills and the 
learning of certain types of procedures and rules. 
EXPLICIT OR DECLARATIVE MEMORY: it depends on conscious and deliberate 
processes. Example of explicit memory is the factual knowledge of people, places, and 
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things. It can be classified as episodic, a memory for events and personal experiences, 
or semantic, a memory for fact, objects and concepts.  
The analysis of the effects of lesions is the oldest, and still most widely used, approach 
to the problem of determining the neuroanatomy of memory systems in the brain. In 
humans, the behavioural effects of lesions resulting from head injury, tumors, vascular 
accidents or neurosurgery are compared to the behaviour of normal subjects on a variety 
of standardized behavioural tasks (Steinberg and Augustine, 1997;Harrison et al., 1999). 
Similar research has been carried out in nonhuman species like primates and rodents 
(Aggleton and Mishkin, 1985) (Mumby et al., 1993).  
Studies performed on patients with Korsakoff’s syndrome have shown a linkage 
between the medial dorsal thalamic nucleus, region consistently injured in these 
patients, and impaired explicit memory (Graff-Radford et al., 1990;Winocur et al., 
1984). This syndrome is associated with a severe anterograde and retrograde amnesia.  
Patients with medial dorsal thalamic damage following cerebrovascular infarctions also 
demonstrate significant memory impairment (Graff-Radford et al., 1990; Winocur et al., 
1984). 
Hippocampus may mediate the representation of spatial and temporal memories. 
Experimental supports for these ideas has come from many different approaches to the 
study of hippocampal function. When the hippocampus is damaged, animals show 
profound impairment in the ability to store information across a delay interval. The 
most sensitive task that is used to demonstrate memory impairments related to the 
hippocampus is the spatial task that requires the animal to move in the environment 
(O’keefe and Nadel, 1978). In monkeys, hippocampal lesions also impaire memory for 
the spatial location of objects. The hippocampus may temporarily store information that 
has been recently obtained (working memory).  
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The cerebellum is responsible for implicit memories of sensorimotor learning.  
Pharmacological studies in numerous species, using a variety of experimental 
paradigms, have linked ACh to learning and memory processes. In general cholinergic 
agonists, like physostigmine, improve memory whereas cholinergic antagonists, like 
scopolamine, impair memory (Bartus et al., 1985).  
Classic lesion studies have identified a particular set of cholinergic neurons and 
projections that is critical for learning and memory. These neurons are located in the 
basal forebrain and project to the hippocampus and neocortex. The basal forebrain 
region includes the medial septal areas (MSA) and the vertical limb of the diagonal 
band of Broca (dbB), which project primarily to the hippocampus, and the horizontal 
limb of the dbB and nucleus basalis magnocellularis (NBM), which project to the 
neocortex. Lesions of the MSA and NBM in rodents impair performance on a variety of 
mnemonic tasks including spatial reference and working memory tasks such as Morris 
water maze and T-maze alternation (McDonald et al., 1997).  
All these observations confirm that a good functioning of the cholinergic system is 
important for memory and learning, and a therapy to ameliorate the cholinergic system 
could be the key for treatment of Alzheimer’s Disease (AD) and other forms of 
dementia. 
 
1.2 Cholinergic system  
The chemical mediator of the cholinergic system in the mammalian brain is 
acetylcholine (ACh).  
The central cholinergic system was characterized in the eighties using an anti-choline 
acetyltransferase (ChAT) antibody (Kimura et al., 1980) and it was divided into 10 
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relatively well defined populations of cholinergic neurons termed Ch1-Ch10 (Mesulam 
et al., 1983){Mesulam, 1983 753 /id}. Most of these clusters of cholinergic cells are 
formed by projecting neurons, although there are some well characterized populations 
of interneurons (Fig. 1). The most studied central cholinergic neurons are those found in 
the basal forebrain because they undergo degeneration in AD. They constitute an 
aggregate of discontinuous cell islands of large, multipolar cells with extensive 
dendritic trees. The cholinergic neurons of the basal forebrain, named Ch1-Ch4, give 
rise to the main cholinergic input to the cortical mantle and hippocampus, (MS/DBB 
projecting primarily to the hippocampus but also to the cortex, and NB, corresponding 
to the nucleus basalis of Meynert in primates, that projects diffusely to the cortex and to 
the amygdala). 
Other cholinergic projection neurons include cells extending from the peduncolopontine 
tegmental nuclei to the floor of the fourth ventricle (Ch5-Ch8). These cells have 
widespread projections to the forebrain nuclei and to the thalamus, as well as 
descending projections to the spinal cord. These neurons do not show substantial 
degeneration in AD {Schliebs, 1998 2100 /id}. 
The striatum contains large aspiny cholinergic interneurons whose dysfunction plays a 
pathogenetic role in Parkinson’s disease. The existence of cortical cholinergic 
interneurons has been confirmed in the rat cerebral cortex by means of 
immunohistochemical staining for the vesicular ACh transporter {Schafer, 1994 2172 
/id}. Their role needs to be defined. 
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Fig. 1 Cholinergic pathways in human brain. From Pepeu, G.(1999) In: Farmacologia Generale 
e Molecolare. F. Clementi e G. Fumagalli (Eds.), IIa ed, UTET, Torino, p. 386 
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1.3 Nicotinic receptors 
Nicotinic acetylcholine receptors (nAChRs) are a family of ACh-gated ion channels 
consisting of different subtypes, each of which has a specific pharmacology, physiology 
and anatomical distribution in brain and ganglia. Are found on skeletal muscle at the 
neuromuscolar junction, in autonomic ganglia of the peripheral nervous system, on 
sensory nervs and some peripheral nerve terminals, and at numerous sites in the spinal 
cord and brain. The nAChR found on mammalian skeletal muscle is analogous to the 
receptors from electric organ of Torpedo and Electrophorus (Unwin, 1996). This 
receptor consists on five protein subunits (two α and one each of β, γ and δ) 
surrounding a central ion channel (Fig. 2).  
To date, 12 neuronal subunits have been described including nine α  (α2-α10) and three  
β (β2-β4) subunits. The α subunits contain two adjacent cysteine residues for binding of 
ACh, whereas the β subunits lack them (Alkondon and Albuquerque, 1993). The 
combination of these subunits defines the function and affinity of the receptor for 
specific ligands (Sudweeks and Yakel, 2000). Nicotinic receptors are stimulated by 
nicotine and ACh. 
It is generally accepted that the predominant nAChR in the CNS which binds 
[3H]nicotine with high affinity is composed of α4 and β2 subunits (α4β2). This 
conclusion is based on immunoprecipitation studies (Flores et al., 1992), comparison of 
cloned amino acid sequences to immunopurified receptor subunits (Boulter et al., 
1987;Whiting et al., 1991), and correlation of autoradiography data with results from in 
situ hybridization experiments (Clarke and Pert, 1985) (Harfstrang A et al., 1988). 
There is a decreased number of these receptors in the human cortex associated with AD 
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(Perry et al., 1995;Nordberg, 1994), supporting a possible role in cognitive function. 
Radioligand binding, using [3H]nicotine, in mice shows moderate binding in may areas 
of the brain, including hippocampus, amygdala, frontal cortex, thalamus, substantia 
niagra, ventral tegmental area (VTA).  
Initial studies comparing the pharmacology of ACh release in rat hippocampus with 
responses from recombinant chick α4β2 nAChRs suggested the possible involvment of 
this subtype in ACh release (Wilkie et al., 1996).  
Studies on the participation of nAChRs in developmental processes suggest that α4β2 
nAChRs may have a role in neuronal migration (Moser et al., 1996;Zheng et al., 1994). 
Whereas in many neurotransmitter systems prolonged or excessive agonist exposure 
leads to receptor down-regulation (Lohse, 1993), a unique feature of some neuronal 
nAChRs is their up-regulation following chronic treatment with nicotine and other 
nAChR agonist (Schwartz and Kellar, 1985;Gopalakrishnan et al., 1997). Although this 
effect is observed for other subtypes of nAChRs, including the α7 subtype, only the 
α4β2 nAChRs appear to be upregulated by physiologically relevant concentrations of 
nicotine (Lukas, 1995). The extent of up-regulation of presumed α4β2 nAChRs is 
variable by brain region (Collins et al., 1996). 
α-Bungarotoxina (α-Bgt) is a 75-amino acid peptide isolated from a species of East 
Asian snake (Bungarus multicinctus) and has been recognized historically for its high 
affinity to muscle-type nAChRs (Lee, 1979). An additional class of nAChRs in the CNS 
is identified by propensity to bind [125I]-α-Bgt with high affinity and nicotine with 
relatively low affinity (Marks et al., 1986). The overall population of these sites is 
similar to that for α4β2 nAChRs, but the localization is different and varies according to 
species (Williams M. et al., 1994). The subunit composition of this nAChR subtyoes has 
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not been estabilished, but evidence supports the hypothesis that most native mammalian 
α-Bgt receptors are α7 homo-oligomers. The α7 nAChRs have an unusually high 
permeability to calcium compared to other sutypes (Delbono et al., 1997) and exhibit a 
rapid desensitization following exposure to agonists (Castro and Albuquerque, 
1993;Alkondon et al., 1994). Like α4β2, up-regulation of α7 is selective by brain 
region when elicited in vivo (Collins A.C. and Marks MJ., 1996).  
Among the nAChRs, the α7nAChR has major clinical and pharmacological implication 
for AD. In neuronal cells activation of the α7nAChR causes an increase in intracellular 
Ca2+ directly through voltage activated channels (activation of ERK1/2 in a Ca2+ and 
PKA dependent manner) (Dajas-Bailador et al., 2002b) and indirectly from intracellular 
sources following ryanodine receptor channels activation (Dajas-Bailador et al., 2002a). 
In astrocytes, the α7nAChR appears to modulate Ca2+ release from intracellular stores 
(Sharma and Vijayaraghavan, 2001).  
α7nAChR are widely distributed in the brain. Radioligand binding of [I125]α-
bungarotoxin shows a high distribution of the α7nAChR in the CA1 region of the 
hippocampus and enthorinal cortex (Court JA et al., 2000). In the prefrontal and motor 
cortex, the α7nAChR localizes in the pyramidal neurons of the layer II/III, V and VI 
(Wevers et al., 1994). Decline in nicotinic receptors, particularly the α7nAChR in the 
frontal cortex, is associated with aging (Utsugisawa et al., 1999). Decline of α7nAChR 
is also observed in AD patients. These deficits appears early in the disease and correlate 
with the progressive loss of cognitive abilities (Nordberg, 1994;Nordberg, 
2001;Whitehouse and Kalaria, 1995). In AD patients, the α7nAChR protein levels are 
reduced in the cortex and hippocampus (Burghaus et al., 2000;Guan et al., 2000;Martin-
Ruiz et al., 1999).  
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Epidemiological studies show that nicotine decreases the risk of Parkinson’s disease 
(PD) and AD (Fratiglioni and Wang, 2000). This negative association is in agreement 
with postmortem studies showing diminutions of amyloid plaque deposition in former 
smokers with AD (Hellstrom-Lindahl et al., 2004b). Nicotine treatment appears to 
interfere with the formation of the amyloid plaques in vitro and in vivo (Hellstrom-
Lindahl et al., 2004a;Ono et al., 2002;Utsuki et al., 2002) and to reduce the 
accumulation of Aβ42 peptides (Nordberg et al., 2002) through a mechanism mediated 
by α7nAChR (Hellstrom-Lindahl E. et al., 2004a).  
Nicotine seems to protect against the development of AD and PD through anti-
inflammatory mechanisms. Both AD and PD are characterized by local inflammation 
sustained by activated microglial cells (Fiszer et al., 1994;Hirsch et al., 2003;Rogers et 
al., 2007;Barger and Harmon, 1997;Aisen, 1997;Rogers and Shen, 2000). Nicotine 
induces anti-inflammatory mechanisms that diminish local inflammatory responses 
(Streit, 2002) Wang H.Y. et al., 200a, b).  
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Fig. 2 Nicotinic receptor. Made up five subunits (2α, 1β, 1γ, 1δ) surrounding a central ion 
channel. From 2002 Encyclopaedia Britannica, Inc.  
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1.4 Muscarinic receptors  
Muscarinic acetylcholine receptors (mAChRs) are the targets of ACh released from the 
cholinergic nerve endings and in some cases  are located on cholinergic neurons and 
nerve endings (autoreceptors). In the mammalian central nervous system (CNS) both 
nicotinic and mAChRs are present but the density of the muscarinic receptors is much 
larger (Clarke, 1993). 
The first evidence of the existence of more than one muscarinic receptor subtype was 
given by the work of {Riker, 1951 2001 /id} showing the cardioselective action of 
gallamine, but it was only at the end of the ’70s that the use of the muscarinic receptor 
antagonist pirenzepine, with higher selectivity for ganglionic than cardiac muscarinic 
receptors (Hammer et al., 1980){Hammer, 1980 2003 /id}, clearly demonstrated the 
existence of more than one receptor subtype.  
At present, pharmacological, biochemical, immunological, and molecular biological 
evidence indicates the existence of five mammalian genes (m1-m5) encoding 
muscarinic receptors (M1-M5). The cloning (Kubo et al., 1986;Peralta et al., 
1987){Peralta, 1987 2133 /id}{Kubo, 1986 2134 /id} and expression of these receptor 
subtypes in cell lines shed light on their function, potential physiological role as well as 
their signal transduction mechanisms. Recently a gene for a putative sixth muscarinic 
receptor (m6) was cloned and patented by Millennium Pharmaceuticals Inc. (P1); no 
details on its pharmacological or potential physiological role are available yet (Eglen et 
al., 1999){Eglen, 1999 2005 /id}. The five subclasses of mAChRs so far best 
characterized all have the structural features of the seven-transmembrane helix G-
protein-coupled receptor superfamily (Fig. 3). Much of the diversity in the structure 
between the M1/M3/M5 sequences compared with the M2/M4 sequences resides in the 
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postulated third intracellular loop (i3), responsible for the specificity of coupling to G 
proteins and which probably determines the quite specific coupling preferences of these 
two groups (Wess, 1993). The “odd-numbered” M1/M3/M5 mAChRs predominantly 
couple via the α subunits of the Gq/11 proteins that activate the enzyme phospholipase 
Cβ, while the “even-numbered” M2/M4 subtypes couple via Gi and Go α subunits that 
inhibit adenyl cyclase, as well as to G proteins that directly regulate Ca2+ and K+ 
channels. 
While a great diversity of behavioral, physiological and biochemical effects mediated 
by mAChRs have been observed, the identities of the molecular subtypes responsible 
for any given neuronal function remain elusive. The complex pharmacology of the 
mAChR subtypes, together with the lack of drugs with high selectivity has made it 
difficult to determine the individual roles of m1-m5 receptors in the brain. Identification 
of the mAChR subtypes in the brain has been accomplished using in situ hybridization 
to localize their mRNAs (Brann et al., 1988;Vilaro et al., 1993), or highly selective 
antibodies to directly localize the proteins (Levey et al., 1991;Van der Zee and Luiten, 
1999b). All subtypes appear to be present in the brain, although with different densities, 
localization and relative abundance. In the forebrain, the region of interest for AD, the 
major mAChRs subtypes found are the m1, m2 and m4 proteins. For example, 
quantitative immunoprecipitation studies showed that in the hippocampus and several 
areas of human brain neocortex, the m1 receptor accounts for 35-60% whereas the m2 
and m4 each accounts for about 15-25% of all binding sites (Flynn et al., 1995). In 
contrast, m2 is the most prominent subtype in the basal forebrain and m4 is the most 
abundant in caudate-putamen. Immunocytochemistry with specific antibodies has 
enabled researchers to define a detailed regional and cellular localization of mAChRs in 
different brain structures. In the medial temporal lobe, the expression of the m1-m4 
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subtypes shows differences in the regional and laminar patterns (Levey et al., 1995b). In 
neocortical areas and hippocampus, the m1 subtype is expressed on all pyramidal 
neurons, where it is localized in somatodendritic regions, primarily at a postsynaptic 
level. The pattern of cellular staining for mAChRs in the neocortex is characterized by a 
clear laminar distribution (Buwalda et al., 1995), with strong immunoreactivity present 
predominantly in layer 5. Less numerous immunopositive neurons are present in layers 
2, 3 and 6, see {Van der Zee, 1999 2015 /id}. Postsynaptic mAChR subtypes modulate 
excitatory synaptic transmission in the hippocampus (Halliwell, 1990){Halliwell, 1990 
2024 /id}, and an example of this modulation is the enhanced responsiveness of NMDA 
receptors in area CA1 by activation of M1 receptors (Markram and Segal, 1990). Double 
labeling electron microscopic immunocytochemistry has shown that the m1 subunit 
colocalizes with the NR1 subunit of NMDA receptors in CA1 pyramidal neurons, 
indicating an appropriate localization for m1 to modulate the activity of the NMDA 
receptor (Rouse et al., 1999). The m1 receptor has a similar postsynaptic distribution at 
excitatory synapses in the striatum (Hersch et al., 1994){Hersch, 1994 2028 /id} and 
increases the excitability of striatal spiny neurons to the application of NMDA 
(Calabresi et al., 1998), suggesting that this subunit might play a general role in the 
modulation of glutamatergic neurotransmission. 
The m2 subtype, with its prevalent presynaptic localization in the CNS (Mash et al., 
1985), is generally believed to act as an autoreceptor inhibiting ACh release. Recently, 
however, this issue has become controversial. {Levey, 1995 13 /id} using molecular and 
immunocytochemical approaches demonstrated that the m2 subtype is present in the 
basal forebrain not only as a presynaptic cholinergic autoreceptor, but it is also 
expressed by the remaining population of cells (possibly GABAergic) projecting to the 
cortex and hippocampus. Also, electron microscopic analysis has shown that in the 
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hippocampus the m2 receptors are present on axons and axon terminals (Levey et al., 
1995a). The m2 receptor is presynaptic in other regions of the brain, including the 
neocortex (Mrzljak et al., 1993), where most of the m2 receptors are located on intrinsic 
noncholinergic neurons {Levey, 1995 13 /id}, because complete lesion of the projecting 
cholinergic neurons almost completely spare the m2 receptors in the terminal field. In 
the striatum the majority of the m2 receptor acts as an autoreceptor {Hersch, 1994 2028 
/id}.  
Much less is known about the localization of the other mAChR subtypes in the CNS. 
The m3 receptor is present throughout the brain (Levey et al., 1994), particularly in the 
basolateral and central amygdala {Levey, 1994 2032 /id}, while the m4 is mostly 
abundant in the hippocampus and striatum. GABA and glutamate release is inhibited in 
the basolateral amygdala through m3-like receptors (Sugita et al., 1991){Sugita, 1991 
2034 /id}, suggesting a function of these m3 receptors as heteroreceptors. In the 
hippocampus the m3 and m4 subtypes are predominantly postsynaptic to the 
septohippocampal cholinergic terminals (Zang and Creese, 1997). However, the m4 
subtype seems to also be presynaptically located on hippocampal associational and 
commissural projection pathways where it might regulate glutamate release {Levey, 
1995 2020 /id}. The distribution profile of the m5 receptor is distinct from the other four 
subtypes and is enriched in the outer layers of the cortex, specific subfields of the 
hippocampus, caudate putamen, olfactory tubercle and nucleus accumbens (Reever et 
al., 1997). These studies also demonstrated that the levels of m5 receptor protein 
expression are apparently higher and more widespread than anticipated from previous in 
situ hybridization and immunoprecipitation studies. Taken together, the results suggest 
a unique and potentially physiologically important role for the m5 receptor subtype in 
modulating the actions of ACh in the brain. 
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The mAChRs mediate both excitation and inhibition, depending on the receptor 
subtype, distribution, subcellular localization, etc. These receptors are found both 
presynaptically and postsynaptically and, ultimately, their main neuronal effects appear 
to be mediated through alterations in the properties of ion channels. Excitatory effects 
result principally from closure of one or more of a number of different K+ channels 
(Brown et al., 1997), though instances of cation channel openings have also been 
described (Delmas et al., 1996;Haj-Dahmane and Andrade, 1996), while inhibitory 
effects include opening of K+ channels and closure of voltage-gated Ca2+ channels. The 
presynaptic auto- and hetero-receptors constitute important feedback loops that control 
ACh release in an inhibitory manner and represent an important regulatory mechanism 
for short-term modulation of neurotransmitter release.  
Investigations on the physiological role of the various mAChR subtypes are hampered 
by the lack of selective agonists or antagonists for the specific receptor subtypes. Over 
the last few years several knockout mice strains have been developed for the M1 
(Hamilton et al., 1997), M2 (Gomeza et al., 1999a){Gomeza, 1999 2201 /id} , M3 
(Matsui et al., 2000) and M4 receptors (Gomeza et al., 1999b){Gomeza, 1999 2203 /id}. 
The use of knockout animals might help to elucidate the physiological functions and 
pathophysiological implications of each receptor subtype. From these studies it appears 
that mAChR subtypes are involved in different physiological functions in the CNS, the 
M2 receptor being involved in movement, temperature control and nociception 
{Gomeza, 1999 2201 /id}, the M3 in facilitation of food intake (Yamada et al., 2001), 
the M4 in locomotor activity {Gomeza, 1999 2203 /id}, and the M5 in water intake, and 
rewarding brain stimulation (Yeomans et al., 2001){Yeomans, 2001 2229 /id}. Studies 
on M1 receptor knockout mice have given contradictory results concerning their role in 
cognitive mechanisms. (Hamilton et al., 2001) reported that M1R-/- mutant mice showed 
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defects in LTP induction in hippocampal CA1 neurons and severe impairment in the 
consolidation of contextual conditioning. On the other hand, it was shown (Miyakawa et 
al., 2001) that M1R-/- mutant mice have normal working memory, tested with a radial 
arm maze, normal spatial memory, tested using a Morris water maze, and normal 
freezing levels during contextual fear conditioning. The possibility that compensatory 
mechanisms occurring during development may help maintaining proper cognitive 
functions in M1R-/-mice must be considered. 
 
 
 
                                
Fig. 3 Muscarinic receptor.  
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1.5 The brain cholinergic system in the mechanisms of learning and 
memory. 
A consensus exists that brain cholinergic neurotransmission plays a critical role in the 
processes underlying attention, learning, and memory (Everitt and Robbins, 
1997b;Sarter and Bruno, 1997b). Two main cholinergic nuclei of the basal forebrain, 
the medial septum and the NBM projecting to the hippocampus and neocortex subserve 
attentional functions and are considered of crucial importance in learning and memory 
processes (Zola-Morgan and Squire, 1993). 
Experiments with lesions of the forebrain cholinergic neurons made by different 
neurotoxins have helped to enlighten the role of ACh in learning and memory and have 
demonstrated that the decrease in ACh extracellular levels is accompanied by specific  
behavioral deficits. Excitotoxic lesions of the NBM induce a longlasting, significant 
decrease in cortical ACh release both at rest and under K+ depolarization, paralleled by 
disruption of a passive avoidance conditioned response (Casamenti et al., 1988) and 
working memory (Bartolini et al., 1996;Casamenti et al., 1998). 
Disruption of the septo-hippocampal projections impairs choice accuracy in short-term 
memory (Flicker et al., 1983) and results in deficits in a T-maze performance (Rawlins 
and Olton, 1982). The most selective procedure for the disruption of the cholinergic 
neurons is the use of 192IgG-saporin, which, injected intracerebrally (Heckers et al., 
1994), causes an almost complete cholinergic differentiation to the cortex and 
hippocampus and a significant decrease in ACh release from these structures (Rossner 
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et al., 1995). All behavioral studies performed in rats with i.c.v. injections of 192IgG-
saporin indicate that only very extensive lesions involving >90% of cholinergic neurons 
result reliably in severely impaired performances (Wrenn and Wiley, 1998). 
Impairments in water-maze acquisition (Leanza et al., 1995), delayed matching (Leanza 
et al., 1996), and nonmatching to position task (McDonald et al., 1997), as well as 
acquisition, but not retention, of an object discrimination (Vnek and Rothblat, 1996) or 
of spatial working memory (Shen et al., 1996) have been reported in the rat. (Ballmaier 
et al., 2002) demonstrated in rats that bilateral 192IgG-saporin lesions of the NBM 
reduce cortical ACh release below detection limits and abolish prepulse inhibition. 
Restoration of ACh levels to normal levels by a cholinesterase inhibitor was associated 
with reappearance of prepulse inhibition, a finding indicating a role of the forebrain 
cholinergic system in the sensory motor gating. 
Activation of basalocortical cholinergic afferents may foster the attentional processing 
that is central to the memory-related aspects of anxiety caused by threat-related stimuli 
and associations (Berntson et al., 1998). Intraparenchymal injections of 192IgGsaporin 
have been used to study the effects of basal forebrain cholinergic lesions on attentional 
processing (Stoehr et al., 1997). 
Most of the studies report disrupted attentional processing in NBM- or MS-injected 
animals (McGaughy et al., 1996) ((Wrenn and Wiley, 1998), thus confirming the role of 
the cholinergic system in attention. However, a correlation between attentional effort, 
required by the task difficulties, and ACh release has not always been found (Passetti et 
al., 2000). 
A novel environment represents a stressful condition, and the first exposure to it causes 
pronounced behavioral activation (Ceccarelli et al., 1999)(Aloisi et al. 1997;, which 
provides one of the most elementary forms of learning. Rats placed in novel 
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environments, either an arena with objects or a Y maze, showed a 150%–200% increase 
in ACh release from the cerebral cortex (Giovannini et al., 1998). If the rats were placed 
in the arena for only 2 min, no habituation occurred. However, if the rats were left for 
30 min in the arena, habituation developed, as demonstrated by a much smaller increase 
in motor activity and ACh release when the rats were placed again in the arena 60 min 
later, in comparison with the first exposure (Giovannini et al., 2001e).The maximum 
increase was 64% in the cortex and 200% in the hippocampus in the first exploration of 
the arena and 37% and 51%, respectively, in the second exploration. Hippocampal ACh 
release increases during performance of a learned spatial memory task (Stancampiano et 
al., 1999)(; Stancampiano et al. 1999), and, interestingly, the improvement in radial arm 
maze performance is positively correlated to the increase in ACh release during 12 days 
of task learning (Fadda et al., 2000). These results show that the learning of the spatial 
task modifies the function of cholinergic neurons projecting to the hippocampus, which 
become progressively more active. In a behavioral paradigm investigating spatial 
orientation, (Van der Zee et al., 1995) showed that spatial discrimination learning 
selectively increases muscarinic ACh receptor immunoreactivity in cell bodies of CA1–
CA2 pyramidal neurons. Changes were also observed in the neocortex, but not in the 
amygdala (Van der Zee and Luiten, 1999a). During the habituation, that is, the learning 
period, exploration-associated synaptic changes are likely to occur, and variations in 
ACh release accompanied by alterations in mAChRs density might reflect these 
changes. 
Memory processes are mediated, in the intact brain, by parallel, sometimes 
interdependent, but other times independent and even competing, neural systems (White 
and McDonald, 2002). It has recently been demonstrated that hippocampal ACh release 
increases both when rats are tested in a hippocampal dependent spontaneous alternation 
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task and in an amygdala dependent conditioned place preference (CPP) task (McIntyre 
et al., 2002). Interestingly, the magnitude of hippocampal ACh release is negatively 
correlated with good performance in the CPP task, indicating not only a competition 
between the two structures in this type of memory, but also that activation of the 
cholinergic hippocampal system adversely affects the expression of an amygdala-
dependent type of memory (McIntyre et al., 2002). However, competition is not the 
only interaction between the hippocampus and the amygdala, because it has been 
demonstrated (McIntyre et al., 2003) that ACh release in the amygdala is positively 
correlated with performance in a hippocampal spatial working memory task. The two 
structures seem to have a nonreciprocal interaction in that the hippocampus competes 
with the amygdala, whereas the amygdala cooperates with the hippocampus during 
learning. 
 
1.6 Mitogen Activated Protein Kinase pathways  
The components of the Mitogen Activated Protein Kinase (MAPK) signal transduction 
pathways are ubiquitous and well conserved protein kinases involved in relaying 
extracellular signals into intracellular responses. In 1990, among the members of the 
MAPK family, Extracellular signal Regulated Kinases-1 and -2 (ERK1/2) were the first 
to be cloned by Cobb and coworkers (Boulton et al., 1990b). Later, several additional 
members of the MAPK family were cloned and characterized, including p38/HOG 
(Hafner et al., 1994;Han et al., 1994), JNK/SAPK (c-jun N-terminal kinase/stress 
activated protein kinase) (Kaang et al., 1993b;Kyriakis et al., 1994b;Kyriakis et al., 
1994a;Kaang et al., 1993a)), and ERK5 (Zhou et al., 1995b;Lee et al., 1995;Zhou et al., 
1995a). The classic MAPK pathway consists of a three-layered cascade of protein 
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kinases which starts with the kinases Raf-1 or B-Raf. Phosphorylation by either of these 
kinases activates the MAP kinase kinase (MEK) which, in turn, is a dedicated dual-
specificity kinase that phosphorylates and thereby activates only ERK (Seger and 
Krebs, 1995b;Seger and Krebs, 1995a).  
 
1.7 Role of extracellular signal regulated kinase pathway in learning 
and memory  
Two isoforms of ERK have been described, the so called ERK1 (p44 MAPK) and 
ERK2 (p42MAPK). The two isoforms seem to have similar distribution in the brain, 
although, as reported, the amount of ERK1 in rat hippocampus appears to be 
considerably less than ERK2 (Kanterewicz et al., 2000;Giovannini et al., 2001a). 
Furthermore, although it is known that the two isoforms share about 90% homology 
(Boulton et al., 1990a) and have the same substrate specificity in vitro, their specific 
role in vivo remains to be understood. In particular, it has not yet been made clear 
whether the two isoforms subserve different functions and whether either one or both 
isoforms are involved in the learning and memory mechanisms. Several groups have 
found that in neurons the two isoforms seem to be selectively regulated by different 
stimuli (English and Sweatt, 1996;Bading and Greenberg, 1991;Giovannini et al., 
2001c;Fiore et al., 1993c). Possible explanations for selective activation of ERK2 are 
specific activation by upstream kinases, compartmentalization, and binding to 
scaffolding proteins through highly specific docking sites (Sharrocks et al., 2000;Enslen 
and Davis, 2001),but there is no compelling evidence for any of these. Knockout mice 
lacking either ERK1 or ERK2 have been created and, while ERK1 knockout mice are 
viable and appear to be neurologically normal (Selcher et al., 2001b;Selcher et al., 
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2001a), ERK2 knockout mice are embryonic lethal at day 6.5 (Saba-El-Leil et al., 
2003c;Saba-El-Leil et al., 2003b;Yao et al., 2003). Therefore the two isoforms must 
have some important differential functions, at least early in mouse development after 
the implantation stage (Saba-El-Leil et al., 2003a). In the following paragraphs I will be 
using the terminology “ERK1” or “ERK2”, depending upon which isoform I would be 
referring to or “ERK”, referring to both isoforms.  
ERK, first identified and studied extensively as a mediator of cell differentiation and 
proliferation in mitotic cells, was later shown to be highly expressed in the postmitotic 
neurons of the adult mammalian brain (Boulton et al., 1991;Fiore et al., 1993a). In 
particular, immunohistochemistry demonstrated that ERK is localized to the soma and 
dendritic trees of neurons in the neocortex, hippocampus, striatum, and cerebellum 
(Fiore et al., 1993b). ERK was then demonstrated to be required for different types of 
synaptic plasticity, learning and memory (Atkins et al., 1998a;Kaminska et al., 
1999;Blum et al., 1999d;Walz et al., 2000d;Cammarota et al., 2000b).  
All types of memory depend on the integrated activity of various brain structures and 
neurotransmitter systems and involve more than one receptor, signal transduction 
pathways and postsynaptic mechanism (Izquierdo et al., 1998b). Among 
neurotransmitter systems, the cholinergic neurons of the basal forebrain, projecting to 
the hippocampus and neocortex, subserve attentional functions and are considered of 
crucial importance in learning and memory processes (Zola-Morgan and Squire, 
1993;Muir et al., 1996;Everitt and Robbins, 1997a;Sarter and Bruno, 1997a;Sarter and 
Bruno, 2000;Sarter and Bruno, 1997c;Sarter and Bruno, 2000), while those projecting to 
the amygdala are required for both acquisition and expression of Pavlovian fear 
responses (LeDoux, 1995;Maren, 1996a;Maren, 1996b). Nevertheless, much evidence 
indicates that several other neurotransmitters, including glutamate, noradrenaline, 
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serotonin, GABA, and histamine, are involved in the modulation of attention/learning 
processes (Decker and McGaugh, 1991;Passani et al., 2000). Activation of the forebrain 
cholinergic system has been demonstrated in many tasks in which the environment 
requires the analysis of novel stimuli which may represent a threat or offer a reward 
(revised in Pepeu and Giovannini, 2006). As it is well known that cholinergic activation 
subserves the mechanisms of memory encoding (see references in (Sarter et al., 2003) 
and (Pepeu and Giovannini, 2004)), the question is how the increase in ACh release 
resulting from activation of the cholinergic neurons contributes to the learning and 
memory processes. Recent research has shown that many of the neurotransmitters that 
play crucial roles in learning and memory activate ERK, among which ACh via 
muscarinic (Berkeley et al., 2001) or α7 nicotinic receptors (Dineley et al., 2001), 
glutamate via metabotropic (Peavy and Conn, 1998) or ionotropic glutamate receptors 
(Zhu et al., 2002;Krapivinsky et al., 2003), norepinephrine via β-adrenergic receptors 
(Williams et al., 1998;Winder et al., 1999;Watabe et al., 2000b), and histamine via the 
H3 receptor (Drutel et al., 2001;Giovannini et al., 2003b). Thus, each of these 
neurotransmitter systems, alone or in combination, provides a possible mechanism for 
the activation of ERK which can function as biochemical signal integrator and 
coincidence detector (Watabe et al., 2000a) in response to extracellular signals in 
neurons, subserving processes such as synaptic plasticity and learning in the adult brain. 
Thus, the ERKs are poised at a critical position allowing cross-talk between a different 
array of signals and signal transduction pathways. 
The first direct evidence that the ERK cascade is involved in memory processes in vivo 
was reported by the group of Sweatts’ (Atkins et al., 1998b), who showed that ERK 
activation is required for the expression of Long Term Memory (LTM) induced by a 
cued- and cued-contextual fear-conditioning paradigm in the rat. Atkins found that 
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ERK2 phosphorylation was increased in the rat hippocampus 1 h after training. 
Additional studies (Giovannini et al., 2003a;Apergis-Schoute et al., 2005) showed that 
the ERK cascade is required for long-term fear memory, as inhibitors of ERK activation 
caused blockade of memory formation upon testing. In fear conditioning, rats are taught 
to associate a foot shock either with a cue (a tone), a context, or both. Later, the extent 
of the animal’s memory to the cue or the context is quantified by fear-associated 
“freezing” upon testing with either the cue or the context. Contextual fear conditioning 
is dependent on both the amygdala and the hippocampus, while cued fear conditioning 
is dependent only on the amygdala. The initial findings by Atkins were confirmed and 
greatly expanded using intraventricular injection (Schafe et al., 1999a), intra-amygdalar 
infusion of an inhibitor of ERK activation in the rat (Schafe et al., 2000b), and using 
systemic administration in the mouse (Selcher et al., 1999d). Interestingly, fear 
conditioning caused a transient and significant activation of both ERK1 and ERK2 
isoforms 60 min after training in  the basolateral amygdala (Schafe et al., 1999b;Schafe 
et al., 2000a). The authors asserted in their paper that the increased activation of both 
isoforms was specifically associated to the pairing of tone and shock. Pretraining 
inhibition of ERK dose-dependently impaired LTM of Pavlovian fear conditioning, 
leaving STM intact. 
The formation of long-term Conditioned Taste Aversion (CTA) memory in the Insular 
Cortex (IC) requires multiple neuromodulatory and signal transduction mechanisms 
(Berman et al., 1998a;Berman et al., 2000;Naor and Dudai, 1996a;Rosenblum et al., 
1997a) involving cholinergic and β-adrenergic receptors, the ERK cascade, the 
transcription factor Elk-1, and protein synthesis. Berman et al. (Berman et al., 1998b), 
using the CTA paradigm, showed that the ERK cascade is involved in the formation of 
long-term memories for taste in the IC. Indeed, an unfamiliar taste leads to activation of 
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ERK in the IC within 30 min of its presentation and microinjection of a reversible 
inhibitor of MEK shortly before exposure to the novel taste attenuates long-term taste 
aversion memory without significantly affecting short-term memory or the sensory, 
motor, and motivational faculties (Berman et al., 1998c). These data suggest that ERK 
is involved in IC–dependent LTM. The authors propose that activation of the ERK 
signalling cascade is salient for the encoding of novelty during acquisition and initiation 
of long-term storage of taste memory in the IC. A model proposed by the authors to 
explain information encoding involves neuromodulatory systems such as the basal 
forebrain cholinergic pathway (Naor and Dudai, 1996b). The authors propose that 
activation of this cholinergic pathway during acquisition, and the subsequent release of 
ACh in the cortex, possibly leads to activation of muscarinic receptors that in turn 
trigger ERK activation either via PKC (Yasoshima and Yamamoto, 1997) or PYK2 
(Lev et al., 1995). Ca2+ influx via NMDA receptors, necessary for the encoding (but not 
the retrieval) of taste memory in the IC (Rosenblum et al., 1997b), might also act 
synergistically with the cholinergic-dependent signal transduction cascades to activate 
ERK. Thus, not only does ERK appear to be involved in hippocampus-dependent LTM, 
but evidence now also implicates ERK in insular cortex–(taste) and entorhinal cortex–
dependent LTM. On the other hand, CTA memory extinction is dependent on protein 
synthesis and β-adrenergic receptors in the IC, but independent of muscarinic receptors 
and MAPK, since it is not blocked by muscarinic receptor antagonists and by MEK 
inhibition. This indicates that the muscarinic receptors and the MAPK cascade in the IC 
are not essential for the taste-malaise association, further corroborating the notion that 
they play a role in encoding the novelty dimension of the taste stimulus in CTA 
(Berman and Dudai, 2001). 
 30
Later it was demonstrated that ERK is essential for long term spatial memory (Blum et 
al., 1999c;Selcher et al., 1999c), measured with the Morris water maze. In this task 
animals learn to locate a hidden escape platform in a pool of opalescent water using 
various visual cues. Blum et al. (Blum et al., 1999b) reported that behavioural training 
in the Morris water maze increases ERK phosphorylation in pyramidal cells of the 
CA1/CA2 subfield of the dorsal, but not ventral, hippocampus and that ERK activation 
is necessary for long-term spatial memory in rats. The authors (Blum et al., 1999a) 
showed that MEK inhibition, 20 min before training or immediately after training did 
not interfere with acquisition of the task, but attenuated long term memory retention on 
the first trial determined 48 h after training. These results are at variance with those 
published by (Selcher et al., 1999b) who showed that ERK activation is necessary for 
spatial learning in the mouse, since when administered post training in animals that had 
already learned the task blockade of ERK activation had no effect on recall, thus 
indicating that ERK activation is required for memory formation, but not for memory 
maintenance or recall. The authors explain this discrepancy with the different training or 
testing paradigms applied, species of test used, differences in the efficacy and time 
course of ERK inhibition, or in drug administration protocols. Nevertheless, the result 
obtained by (Selcher et al., 1999a) are consistent with the LTP studies involving ERK 
performed by English et al. (English and Sweatt, 1997) and Giovannini et al. 
(Giovannini et al., 2001d) in which MEK inhibition before stimulation blocks LTP 
induction, but when applied 30 min after stimulation MEK inhibition has no effect on 
the expression of established LTP. It seems however that a time-window for ERK 
inhibition to be efficacious must exist, since it has been demonstrated that, at least in 
spatial memory, delayed infusion of MEK inhibitors does not interfere with long term 
spatial memory retention. Akirav and coworkers (2001) demonstrated a differential 
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activation of ERK in the hippocampus and amygdala following spatial learning in 
stressful conditions (Akirav et al., 2001). In CA1 region of the dorsal hippocampus 
activation of ERK2 was present in those animals that had acquired the task, while in the 
amygdala significant activation of ERK2 was found in animals that had acquired the 
task under very stressful conditions, suggesting that this pathway in the amygdala is 
activated in learning situations that are highly arousing, such as fear conditioning. 
ERK is also necessary for step-down inhibitory avoidance (IA) (Walz et al., 
2000c;Cammarota et al., 2000a). Inhibitory avoidance is a paradigm that involves 
learning an association between a footshock and an electric grid on the floor. It differs 
from the Pavlovian contextual fear conditioning in that, although both are emotionally-
arousing paradigms (Izquierdo et al., 1997;Maren, 2001), the step-down inhibitory 
avoidance also entails working memory, as the animal may choose to avoid the aversive 
stimulus (Wilensky et al., 2000). In the step down IA task rodents, put on an elevated 
platform placed by one wall of an arena, learn to associate exploration of the adjacent 
compartment with a foot shock delivered through the floor grid. On a subsequent 
exposure to the same environment, the animal will avoid to step down, or will increase 
the latency before ‘stepping down’ onto the floor grid. Thus, the step-down IA is a form 
of associative learning that is acquired in one trial and involves several sensorial stimuli 
including spatial and visual perceptions, sensitivity to pain, and emotional components 
(Izquierdo, 1989;Izquierdo and Medina, 1997). The IA response is a learning task which 
depends upon the activation of the cholinergic system, as it is impaired by pre- 
(Giovannini et al., 1999;Izquierdo et al., 1998c) or post-training administration of 
muscarinic receptor antagonists (Giovannini et al., 1999;McGaugh and Izquierdo, 
2000;Izquierdo et al., 1998d), and is enhanced by muscarinic receptor agonists (Barros 
et al., 2002;Baratti et al., 1979). Recall can be performed 60 min after acquisition, a 
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time sufficient for short term memory to be formed (Izquierdo et al., 1998a;Izquierdo et 
al., 1998e).  
Work from the group of Izquierdo (Cammarota et al., 2000) demonstrated that learning 
of IA is associated with a similar activation of both isoforms ERK1 and ERK2 in the rat 
hippocampus. Immediate post-training administration of the NMDA receptor antagonist 
APV into the hippocampus blocks ERK activation and causes amnesia for this task, 
indicating that NMDA receptors are necessary upstream activators of ERK intracellular 
cascade in this memory.  In a further series of papers by the same group (Walz et al., 
1999;Walz et al., 2000b) the authors found that inhibition of ERK activation in the area 
CA1 of the dorsal hippocampus, entorhinal cortex, parietal cortex or in amygdala 
impaired retention of the avoidance when tested up to six hours after training, with a 
differential time course in the different brain regions. The authors thus concluded that 
the ERK cascade is  time-dependently involved in the posttraining memory processing 
of IA, with a different time-course in the hippocampus, amygdala, entorhinal cortex, or 
parietal cortex of rats (Walz et al., 2000a). It seems that activation of ERK correlates 
mostly with the aversive, emotional, component of IA acquisition  since it has been 
previously found that ERKs are activated by mild electric footshocks similar in intensity 
and length to that employed during IA training (Bevilaqua et al., 2005a;Bevilaqua et al., 
2005b), but not simply by exposure to the training box in the absence of footshock 
(Alonso et al., 2002b;Alonso et al., 2002a).  
More recently work from the same group (Igaz et al., 2004) demonstrated that single 
trial step down IA caused an increase of total ERK mRNA 3 h and  protein upregulation 
24 h after training. ERK1 protein was neither changed at 3 nor 24 h. These results are 
interesting in that they reveal that ERK activity can possibly be modulated not only by 
activation, but also by increased protein expression in different behavioural tasks.   
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Kelly et al., (2003) (Kelly et al., 2003) found that ERK is activated in distinct 
hippocampal circuits following either consolidation or reconsolidation of an object 
recognition memory in the rat. The task, first developed by Ennaceur and Delacour 
(1987) (Ennaceur and Delacour, 1987), relies on rat innate propensity to explore novel 
objects. This task is run in an open box and does not involve the use of reinforcement 
and does not require any training. Rats are placed in an open box and exposed for a 
limited period of time to two identical objects and then returned to their home cage. 
After a delay rats are returned to the open box where they are exposed to two different 
objects, one identical to the one previously encountered in the previous phase, therefore 
now familiar (F), and the other one novel (N). The times spent in exploration of the 
familiar F and of the new object N are recorded separately and a discrimination index D 
is calculated. A value of D significantly above zero describes animals exploring more 
the novel than the familiar object. A value of D significantly below zero describes 
animals exploring more the familiar than the novel object. Object discrimination 
depends on cholinergic activity since it is impaired by the cholinergic hypofunction 
induced by anticholinergic drugs administration (Ennaceur and Meliani, 1992) and by 
lesions of the cholinergic neurons innervating the cortex (Bartolini, 1996). It was 
demonstrated that ERK1 activation is necessary for consolidation and reconsolidation of 
object recognition memory and a transient activation of ERK1 occurrs in the dentate 
gyrus and CA1 during both processes Kelly et al., (2003).  
 
1.8 p38MAPK and JNK 
Extracellular Regulated Kinase1,2 (ERK1,2) typically regulates growth, proliferation 
and differentiation, whereas p38MAPK and Stress Activated Protein Kinase/JunKinase 
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(JNK), are activated in response to osmotic shock, UV irradiation, inflammatory 
cytokines, oxidative stress (Haddad, 2004). MAP kinases are implicated in various 
cellular processes (Raman et al., 2007), and dysfunction of specific MAP kinases is 
associated with diseases such as cancer and immunological disorders. While it is 
suggested that dysregulation of the MAPK pathway(s) might play a role in the 
intracellular mechanisms of neurodegeneration, their effective involvement is still 
controversial. In the nervous system, as well as in other tissues, activation of JNK and 
p38MAPK has often been correlated with death in various cell types, including neurons 
(Xia et al., 1995;Kummer et al., 1997;Willaime-Morawek et al., 2003). Nevertheless, 
the genuine in vivo physiological functions of MAPK still remain to be fully unravelled. 
Others report that β-amyloid causes mitochondrial impairment in neurons, and 
generates oxidative species (Butterfield and Boyd-Kimball, 2004) that decrease ERK 
activity and activate p38MAPK and JNK (Troy et al., 2001); (Hensley et al., 
1999;Ferrer et al., 2001;Zhu et al., 2000), leading to cell death (Daniels et al., 2001). 
Indeed, given that activated p38MAPK is both upstream and downstream of 
proinflammatory agents, it appears that conditions exist in the AD brain for a self-
propagating cycle of stimulation (Hull et al., 2002;Sun et al., 2003), in which 
p38MAPK plays a prominent role through the production of pro-inflammatory 
cytokines, IL-1β and others, cyclooxygenase-2, iNOS, (Gonzalez-Scarano and Baltuch, 
1999;Harris et al., 1995;Markesbery, 1999;Kaminska, 2005). 
A near complete overlap between activated JNK and p38MAPK in severe AD cases is 
reported, implying that both are activated by the same signals and seem to work 
synergistically in vivo (Zhu et al., 2001a). Three genes encoding for JNKs have been 
identified (JNK1, JNK2 and JNK3). Neurons from JNK3−/− mice are more resistant than 
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normal mice neurons to β-amyloid-induced apoptosis (Morishima et al., 2001) and to 
glutamate-induced excitotoxicity. In human postmortem brains from AD patients, JNK 
phosphorylation is markedly increased and there is pronounced redistribution of JNK 
compared with age-matched controls. JNK2 and JNK3 are associated with 
neurofibrillary pathology, and JNK upregulation has a complete overlap with 
phosphorylated tau (Zhu et al., 2001b). Indeed, increased activation of JNK and 
p38MAPK has been found in brain homogenates in all the tauopathies (Ferrer et al., 
2005b) and aberrantly activated p38MAPKs and JNK have been reported to be 
associated with cells that contain filamentous tau in AD (Atzori et al., 2001) (Ferrer et 
al., 2001), suggesting that β-amyloid triggers activation of stress kinases which may 
phosphorylate tau in neurites surrounding β-amyloid deposits and form tau fibrils 
(Churcher, 2006). Moreover, activated JNK and p38MAPK phosphorylate c-Jun, AP1 
and their target genes in AD (Ferrer et al., 2005a). 
 
1.9 Alzheimer’s disease 
In 1907, Alois Alzheimer (Alois Alzheimer, 1983-1915) described the case of a 51 year 
old woman with dementia and prominent behavioural disturbances. At autopsy, the 
brain was found to be atrophied and microscopic examination with silver staining 
revealed widespread senile plaques and neurofibrillary tangles. Senile plaques were 
seen as dystrophic neuritic processes around a central core and neurofibrillary tangles as 
intensely staining intraneuronal perikaryal inclusions. It was only in 1910 that Emil 
Kraepelin, a famous German psychiatrist, gave a name to the dementia discovered by 
Alzheimer, calling it with his name (Emil Kraepelin, 1856-1926).  
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Alzheimer’s disease (AD) is a cerebral degenerative disorder with gradual loss of 
memory, reasoning, orientation and judgment. The diagnosis of Alzheimer’s disease 
remains clinical unless histological confirmation is available at autopsy. Diagnostic 
criteria have been developed that allow a diagnosis of probable Alzheimer’s disease. 
Many classifications have been proposed based on age of onset, presence of a family 
history, presence of extrapyramidal features and focal cortical disease. One of the most 
widely considered distinctions has been that based on age of onset. Patients with an 
onset below the age of 65 are considered to have presenile dementia in contrast to later 
onset cases of senile dementia of the Alzheimer type. Clinically, it has been suggested 
that early onset cases have a more severe disease with rapid progression, together with a 
predominance of language disturbances. A family history is also more readily apparent 
in young onset cases. A related group are patients with Down’s syndrome trisomy 21 
who develop Alzheimer histopathology and, in many instances, a super-added dementia 
in their third and fourth decade of life.  
The clinical features of Alzheimer’s disease can be divided in two groups: cognitive and 
behavioural deficits.  
Cognitive deficits: the most prominent cognitive deficit in Alzheimer’s disease is 
memory impairment, and this is often the presenting feature. At the beginning of the 
disease there appears a failure of short term memory (STM) but with the ongoing of the 
disease long term memory (LTM) is also affected, and particularly the explicit, episodic 
or autobiographical memory, while the implicit memory is well conserved until the late 
stage of the disease.  
Language deficits and visuospatial deficits appear as the disease progresses. Early 
language preservation may allow the patient to maintain a social façade that can mask 
the cognitive impairment. It is usually clear, however, that although speech may be 
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fluent it is rather empty of meaning or the patient may present with some difficulties 
finding words (anomia).  
Behavioural deficits: non-cognitive symptoms are common and about 40% have 
depression features, usually early in the disease. Delusion, hallucinations, and 
aggression are commonly encountered and can present considerable management 
problems for relatives and caretakers. AD patients also show anxiety and insomnia. 
The above features and the characteristic progression have been incorporated into 
clinical criteria (the NINCDS/ADRDA criteria), which provide levels of probability of 
diagnosis. It goes from Possible to Definite Alzheimer’s disease.  
Possible Alzheimer's disease: a dementia syndrome with atypical onset, presentation or 
progression, and of an unknown etiology is present. No co-morbid diseases capable of 
producing dementia are believed to be at its origin.  
Probable Alzheimer's disease: dementia has been established by clinical and 
neuropsychological examination. Also, cognitive impairments must be progressive and 
must be present in two or more areas of cognition. The onset of the deficits is between 
the age of 40 and 90 years and, finally, there must be an absence of other diseases 
capable of producing a dementia syndrome.  
Definite Alzheimer's disease: the patient meets the criteria for probable Alzheimer's 
disease and has histopathologic evidence of AD, demonstrated via biopsy or autopsy.  
There are several risk factors for AD: age, family history, lifestyle. Only 10% of AD 
cases are familial (FAD) and start before 60 years of age and are caused by autosomic 
dominant mutation on genes that codify for the protein precursor of amyloid (APP), and 
for the presenilin 1 and presenilin 2. These genes are localized in chromosomes 21, 14 
and 1, respectively.  
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1.10 Neuropathology of Alzheimer’s disease  
Alzheimer’s disease is characterized by atrophy in the cerebral cortex with loss of 
synapses and neurons, gliosys, presence of intraneuronal accumulation of paired helical 
filaments in the form of neurofibrillary tangles (NFT), and senile plaques (SP) (Fig. 4).  
Neurofibrillary tangles consist of aberrantly phosphorylated microtubule-associated 
protein (MAP) tau. Tau proteins consist of a developmentally regulated family of 
proteins which in vivo are known to stabilize the microtubule network (Cleveland et al., 
1977;Drubin and Kirschner, 1986). The hyperphosphorilation of MAP tau renders the 
protein insoluble, which thus aggregates in filaments that precipitate (Hanger et al., 
1991). Their presence signifies the failure of the neuron to properly maintain its 
cytoskeleton. Senile plaques are more complex; they consist of extracellular deposit of 
amyloid material and are associates with swollen, distorted neuronal processes called 
dystrophic neurites. The specificity of cerebral amyloid is provided by its major peptide 
component, β-amyloid (Aβ), a short 40-42 amino-acid fragment of the transmembrane 
protein, β-amyloid precursor protein (β-APP). Plaques start as innocuous deposit if 
nonaggregated, putative non-neurotoxic Aβ (diffuse plaques). With time, they undergo 
an orderly sequential transformation into the mature senile neuritic plaques that are 
associated with the development of AD.  The neuritic plaques are more diffuse in the 
cerebral cognitive areas like cortex, hippocampus and amygdala.  
The amyloid is predominantly in the core of senile plaques, surrounded by abnormal 
neurites from degenerated neuronal cells and by glial cells: microglial cells in the centre 
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of the plaque and astrocytes in the periphery (Selkoe, 1999). It is believed that 
activation of glial cells and production of cytochines, nitric oxygen (NO) and reactive 
Oxygen Species (ROS) leads to plaque maturation (Sheng et al., 2000;Ramirez et al., 
2008). Amyloid deposits are not homogeneous. They are made up for more than 90% of 
Aβ, but they also contain α-1-antichimotrypsin (ACT), apolipoprotein E2 and E4 
(apoE2 and apoE4), heparin sulphate proteoglycane (HSPG) and proteins of the 
complement (Selkoe, 1999).  
 
1.11 Role of amyloid-β peptide in Alzheimer’s disease 
APP is a 105-130 kDa secretory protein and is involved in cell-cell or cell-matrix 
interaction. It may also be a component of the acute phase response and accumulates in 
astroglial cells in response to injury and is influenced by cytokines (Kushner, 
1991;Trejo et al., 1994). In 1991 the gene for APP was localized to chromosome 21 by 
John Hardy, at St. Mary’s Medical School, within the region that, when trisomic, is 
responsible for Down’s syndrome (REF). There is a known association between 
Down’s syndrome and AD (Patterson et al., 1988). The level of APP mRNA in the fetal 
brain with trisomy 21 is 50% higher than normal. By the fourth decade all patients with 
Down’s syndrome have preamyloid plaques, containing APP-derived material. The APP 
gene is made of 19 exons and, after alternative splicing, different isoforms are obtained. 
The principal isoforms known are APP 695, APP 751 and APP 770. The APP 695 is the 
predominant isoform expressed in the Central Nervous System, the other isoforms are 
expressed also in other tissues (Selkoe, 1994). The amyloid-β (Aβ) is the product of an 
abnormal cleavage of APP operated by specific enzymes. It is delimitated by aa 672 and 
712-715 of APP and part of it is localized in the transmembranarian tract and the other 
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part in the extracellular tract of the APP. Two different processing pathways of the APP 
have been described: non amyloidogenic and amyloidogenic. Under physiological 
conditions, APP is converted to soluble β-amyloid precursor protein via the non 
amyloidogenic pathway, since the hydrolysis is operated by α-secretases at the aa 
Lys687-Leu688, at the level of the transmembranarian tract of the β-amyloid (Fig. 4). 
Currently, three different enzymes with α-secretase activity have been described: 
ADAM 9, ADAM 10 and ADAM 17. After the cleavage, two different fragments are 
generated, one that origins from the N-terminal tract of the APP (sAPPα) that is 
secreted in the extracellular space, and the other one is a fragment of 83 aa (C83) that 
contains the C-terminal of the APP (CTF, C-terminal fragment), that remains in the 
plasma membrane, and than is hydrolyzed by γ-secretases to give a smaller fragment 
(p3) (Haass et al., 1993;Haass and Selkoe, 1993). The amyloidogenic pathway leads to 
the formation of Aβ. In this case the cleavage is operated by β-secretase at aa Met671-
Asp672 with the release of sAPPβ in the extracellular space and the formation of a 
transmebranarian fragment of 99 aa (C99), where the N-terminus correspond to the first 
aa of the Aβ peptide (Fig. 5). The enzyme responsible for the cleavage is BACE1 (β-
site APP cleaving enzyme) that is a membranarian protein (Vassar et al., 1999;Sinha 
and Lieberburg, 1999). The γ-secretase produces the other extremity of the Aβ by the 
hydrolysis of the aa nearby the residue 712, producing the amyloid peptide and the short 
intracellular fragment AICD (APP intracellular domain) (Fig. 5) (Steiner, 2004;Comery 
et al., 2005). If the cleavage by γ-secretase is at the link 712-713 or 713-714 there is the 
formation of short Aβ (39-40 aa), while the cleavage after the residue 714 leads to the 
formation of a longer Aβ peptide (42-43 aa) (Fig. 5)  that is the major component of the 
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neuritic plaques since it is more amyloidogenic than the shortest peptide, with a greater 
propensity to form amyloid fibrils. 
The genetic basis of AD have been studied on patients with a family history. Four 
different mutated genes have been identified, localized on chromosomes 21, 14,1 and 
19, that are able to cause FAD (familial AD). There are different forms of AD based on 
the age onset: 
-Early onset (EOFAD) when pathology starts before age 65. 
-Late onset (LOFAD) when the pathology starts after age 65. 
This classification is important since different genes are involved in the EOFAD as 
compared to the LOFAD. Studying different families with EOFAD, researchers have 
found that a “missense” mutation at the exon 17 of the APP gene is the cause of the 
disease. The most common mutation is the substitution of an adenine with a guanine 
with the consequent conversion of the Valine 717 to Isoleucine. Other familial forms 
are known, in which there is a mutationof Val to Gly or Phe. This kind of substitution 
makes the transmembranarian domain of the Aβ more hydrophobic, stabilizing the 
deposited form of the peptide.  
Two Swedish families show a different double mutation (Mullan et al., 1992) with the 
substitution of a Lys and a Met, at the N-terminal of the Aβ, with an Asn and a Leu, 
respectively. This substitution facilitates the hydrolysis of APP operated by β-secretase. 
The cleavage of APP can also be operated by a different family of proteases associated 
to apoptosis, the caspases. This cleavage leads to the formation of Aβ, and correlates the 
cellular death with Aβ deposition. Gervais et al. (1999) have demonstrated that the 
cytoplasmatic domain of APP can be cleaved by caspase 3 with the consequent 
formation of Aβ (Gervais et al., 1999). 
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Studies have demonstrated that mutations at the genes for presenilin 1 and 2, localized 
on chromosome 14 and 1, respectively, enhance the probability of apoptosis of different 
types of cells. 
In 1992 three different groups demonstrated independently that there is a linkage 
between the central region of the long arm of chromosome 14 and AD (Van 
Broeckhoven et al., 1992;George-Hyslop et al., 1992;Mullan et al., 1992). In 1995 the 
gene on this chromosome was cloned (PS-1). This gene seems to be responsible for 
70% of the EOFAD. Families with PS-1 show the disease at early age (around 45 years 
of age).  
In the same year, another gene similar to PS-1 was found on chromosome 1, and it was 
called PS-2. Seven families from Volga region and one family from North of Italy have 
shown mutations on this gene.  
In 1994, Potter coined the term “pathological chaperones” (REF), referring to 
apolipoprotein E (ApoE) and α1-antichymotrypsin (αACT). In vitro ApoE and αACT 
act as catalysts, increasing amyloid filament formation by 10-20 fold (Jianyi et al., 
1994). In an oxidant-dependent process, ApoE binds to Aβ in the region delimited by 
amino acids 12-18, the same region that is responsible for fibril formation.  
ApoE is a 34kDa glycosylated protein, and is one of the major risk factor (other than 
age) for the development of AD. It is involved in synaptic repair, particularly in 
response to tissue injury and it has an important role in the maintenance of neuronal 
structure and cholinergic function. In the brain it is produced by microglial cells and 
astrocytes, but not by neurons. ApoE is a major component of lipoprotein and lipid 
complexes in the cerebrospinal fluid. In peripheral nerve regeneration, ApoE 
redistributes lipids to axons during neurite extension and Swann cells during 
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remyelinization (Yankner et al., 1990). The ApoE gene is localized on chromosome 19 
and exists in 3 allelic forms: ε2, ε3 and ε4 with frequencies of 8%, 78% and 14% 
respectively. The ε4 allele increases the risk of developing late and sporadic AD by 5-
15 fold. The prevalence of ApoEε4 appears to vary by population according to the 
prevalence of AD; it is increased in the Finnish, Sudanese, Aborigines and decreased in 
the Chinese and Japanese (Harrington et al., 1994). In vitro ApoEε4 binds more rapidly 
to Aβ than does ApoEε3, forming a denser matrix of monofibrils. On the other hand 
ApoEε3 seems to bind to the protein tau.  
In contrast the ApoEε2 allele has been associated with a reduced risk of AD and 
longevity (Rebeck et al., 1994). In vitro ApoE ε2 inhibits fibrillar aggregation.  
The familial forms of AD are correlated to mutations of the APP gene and other genes 
that alter the metabolism of this precursor, including the increased production of the Aβ 
(1-42) peptide that is the predominant form in the senile plaques. The crucial event for 
the pathogenesis of the disease is the amyloid-β peptide deposition. Studies on 
transgenic mice that present some of the AD alterations, have shown that the 
immunization with Aβ (1-42) interferes with the accumulation and deposition of Aβ and 
with the activation of glial cells, leading to cognitive improvement (Schenk et al., 
1999). The immunization of transgenic mice with Aβ (1−.42) before the onset of AD, 
prevents the formation of plaques and the activation of microglial cells and astrocytes. 
The in vivo injection of Aβ (1-40) in the cortex of a rat produces necrosis around the 
site of the injection, neuritic degeneration and neuronal loss (Scali et al., 1999). 
Aβ binds also to metals like Cu 2+, Zn2+ and Fe2+. In this case the Aβ toxicity is induced 
by the production of hydrogen peroxide that induces the aggregation of the peptide.  
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Fig. 4 The canonical pathology of Alzheimer’s disease. (A) senile plaques and 
neurofibrillary tangles in a hippocampal section stained  with the Naoumenko-Feigen silver 
impregnation method and counterstained with periodic acid-Shiff (PAS). Two classical 
senile plaques are indicated by blue arrows, they consist of an extracellular core of 
amyloid (stained pinkish-red by PAS) encircled by black, distended neuronal 
processes (neurites). Diffuse deposition of Aβ usually lack neurites and are not 
stained by this method. Note also the intracellular NFT (two are marked by red 
arrows); a pale normal appearing neuron is designed by a green arrowhead. 
Bar=100µm. (B) A neocortical senile plaque stained with Congo Red, the definitive 
stain for classically defined “amyloid” (regardless of the identity of the protein 
component); the photograph was taken with crossed polarizing filters, which 
produce a Maltese-cruciform pattern of green orange birefringence in compact, 
fibrillar amyloid deposits(the plaque core, center); Nissl counterstained. (C) A 
cortical senile plaque immunostained with antibody 10D5 to amino acids 3-7 of Aβ. 
Note the central core of β-amyloid, surrounded by a halo, and then an outer ring of 
Aβ, which is typical of many dense-cored plaques in AD; Nissl counterstained. (D) 
A cortical plaque stained with Thioflavin-T, a fluorescent dye that binds to generic 
amyloid. The core is intensely fluorescent, and the peripheral, more diffuse deposits 
also bind Thioflavin. Bar in B=50µm for B, C, D.  
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Fig. 5 Schematic diagrams of the β-amyloid precursor protein (APP) and its principal 
metabolic derivatives. 
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1.12 Role of tau protein in Alzheimer’s disease 
The intracellular decline that is characteristic of AD is accompanied not only by the 
formation of neuritic plaques, but also by the formation of neurofibrillary lesions. The 
presence of these lesions appears to correlate with the clinical severity of the disease 
and are found in cell bodies and apical dendrites as neurofibrillary tangles, in distal 
dendrites as neuropil threads and in the abnormal neurites that are associated with some 
amyloid plaques as neuritic plaques. Ultrastructurally, all three lesions contain abnormal 
paired helical filaments (PHFs) as their major fibrous component. Neurofibrillary 
lesions develop in the vast majority of nerve cells that undergo degeneration in cerebral 
cortex and hippocampal formation. Evidences indicate that PHFs are made entirely of 
microtubule-associates protein tau in a hyperphosphorylated state (Fig. 6). Tau protein 
is an abundant protein in both central and peripheral nervous systems. There are several 
neurodegenerative diseases characterized by the abnormal phosphorylation and 
deposition of tau in neurons and glial cells called tauopathies.  
In brain  tau is found predominantly in nerve cells, where it is concentrated in axons. It 
is a hydrophilic microtubule-associated protein. There are six adult isoforms of tau 
expressed in the human adult brain, which range from 352 to 441 amino acids and differ 
from each other by the presence or the absence of three inserts; the shortest of the six 
corresponds to the fetal isoform. They each contain three or four microtubule-binding 
domains of 31 or 32 amino acids, located at the carboxy-terminal half. These domains 
stabilize the microtubules and facilitate axonal transport of nutrients and 
neurotransmitters. The gene for the different isoforms is made of 16 exons on 
chromosome 17. Tau is subject to developmentally regulated alternative mRNA 
splicing, in that in immature brain only the transcript encoding the shortest isoform with 
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three repeats is expressed. The isoforms with 4 microtubule-binding domains are the 
most efficient in aggregating the microtubules and have more binding affinity as 
compared to the isoforms with 3 domains. On the long isoforms of tau protein there are 
79 Serine (Ser) and Threonine (Thr) that can be phosphorylated, and the 
phosphorylation of 30 of these residues was observed in normal tau proteins. 
Phosphorylation of tau is a regulated process during growth. These phosphorylation 
sites are located in a region closed to the microtubule-binding domains. The 
phosphorylation of some of these site is fundamental for the normal function of the 
protein. For example the phosphorylation of Ser 262, located in the first microtubule- 
binding domain, leads to decrease of microtubule binding (Biernat et al., 1993). The 
same is obtained with the phosphorylation of Ser 396, located in the fourth microtubule-
binding domain. Both these sites are phosphorylated in the fetal isoform and are 
hyperphosphorylated in the six isoforms present in PHFs.  
Tau protein extracted from PHFs runs as three major bands of 60, 64 and 68 kDa, with a 
variable amount of background smear, on an immunoblots gel. These PHF-tau bands 
are retarded on gels relative to normal or recombinant tau. They contain intact tau, as 
they stain with antibodies directed against the amino- and carboxy-termini of tau. After 
treatment with alkaline phosphatase at high temperature the three PHF-tau bands run as 
six bands which align with the recombinant forms in a hyperphosphorylated state. PHF-
tau has greatly reduced ability to bind to microtubules. This loss of function results from 
hyperphosphorilation, since dephosphorilated PHF-tau binds as well to microtubules as 
does normal tau. The reduced binding of PHF-tau to microtubules may destabilise 
microtubules in AD, resulting in the impairment of vital cellular processes, such as 
rapid axonal transport, and leading to the degeneration of affected nerve cells.  
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Hyperphosphorilation means that PHF-tau is phosphorylated at more sites than tau from 
adult brain and that a higher than normal percentage of tau molecules is phosphorylated.  
There are several classes of kinases or kinase activities that can phosphorylated tau in 
vitro. Glycogen synthase kinase-3 (GSK-3), cyclin dependent kinase-5 (cdk-5), 
mitogen-activated kinase, extracellular signal regulated kinase (ERK1 and ERK2), 
stress-activated protein kinase c-jun N-terminal kinase (SAPK/JNK) and p-38 kinase 
(p38MAPK). Several second messenger dependent kinases can phosphorylate tau at non 
Ser-Pro motifs, and this includes some sites inside the microtubule-binding domain. 
Examples are CaM kinase, PKA, PKC or casein kinase II.  
Ser 262 is phosphorylated by microtubule-affinity regulating kinase (MARK), PKA and 
GSK-3 (Anderton et al., 2001). 
In vivo studies have demonstrated that GSK-3 and cdk-5 are mainly implicated in the 
phosphorylation of tau. GSK-3 is a kinase for Ser and Thr that is abundant in the brain 
where it is associated to the microtubules (Ishiguro et al., 1994;Takahashi et al., 
1995;Singh et al., 1995). Cdk-5 is a protein kinase fo Ser an Thr that is abundant in the 
cytoskeleton of neuronal cells (Baumann et al., 1993;Kobayashi et al., 1993;Lew et al., 
1994). 
Immunohistochemical studies have shown increased expression of several kinases, 
including casein kinase, Ca2+/calmoduline-dependent kinase, cdk-5, GSK-3, ERK, 
SAPK/JNK, p38MAPK and PKA, co-localizing hyperphosphorylated tau deposits, in 
individual neurons in AD (Xiao et al., 1996) (Ferrer et al., 2002). Co-localization of 
hyperphosphorylated tau and active kinases in individual cells refers, in most cases, to 
the kinase phosphorylated at specific sites, as revealed with phospho specific antibodies. 
This is an important point since modifications in tau phosphorylation do no necessarily 
parallel total levels of the kinases, and rather depend on the relative abundance of their 
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active and inactive forms. For example the brain levels of non active kinases ERK1 and 
ERK2 are similar in AD and controls, whereas the levels of phosphorylated (active) 
ERK1 and ERK2 are markedly increased in AD brain homogenates, and phospho ERK 
is exclusively expressed in a percentage of neurons with phospho tau deposits in AD but 
not in control cases (Ferrer et al., 2001).  
Several transgenic mice expressing the short and long isoforms of human tau have been 
generated as putative models of tauopathies (Usarek et al., 2006) (Higuchi et al., 2002). 
Some of these mice show axonal degeneration and tau hyperphosphorylation, thus 
mimicking certain aspects of tauopathies, although neurofibrillary tangles are absent.  
Despite the numerous studies on PHFs formation, the basic mechanisms are not known 
yet. It seems that the form of tau not bound to microtubules is more resistant to 
degradation. This observation suggests that an enhanced interaction tau-microtubules 
could be positive.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 6 Scheme of hyperphosphorylation of Tau with subsequent formation of PHF.  
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1.13 Inflammation in Alzheimer’s disease 
The inflammatory response is primarily a host defence reaction. It serves to degrade and 
eliminate the foreign invader. Components of the inflammatory response play essential 
roles when phagocytic cells remove microorganisms, necrotic host tissue and undesired 
deposits of abnormal substances. However, prolonged inflammation often destroys the 
surrounding host tissue. Such a damage is particularly serious if it occurs in brain, 
where regeneration and recovery take place only in a very limited degree. In 
neurodegenerative diseases inflammation could be caused by several events: protein 
aggregates deposition, molecules associated to synapsis or degenerated neurones. In AD 
senile plaques and tangles could be the site of sustained inflammatory response. Several 
studies have demonstrated that amyloid-β deposits in the neuritic plaques are associated 
to numerous immune system proteins, complement proteins, cytokines, protease 
inhibitor, binding proteins (McGeer and McGeer, 1995) (McGeer and McGeer, 1998). 
Activated microglia cells are associated to the neuritic plaques, producing cytokines and 
other neurotoxic components. The presence of molecules of immune system and of 
activated microglia associated to Aβ confirm the hypothesis that inflammation is the 
cause of neuronal degeneration in AD (Rogers et al., 2002). The activation of microglia 
associated with Aβ plaques in the AD brain is paralleled by similar processes in cells in 
culture. Exposure of cultures of white and grey matter microglia from elderly AD and 
non AD patients to Aβ(1-42) results in their activation. As in the AD brain, microglia 
cells increase their cell surface espression of MHCII (Rogers and Lue, 2001), a classic 
marker for the activation of scavenger cells, in addition to showing a dose-dependent 
increase in their secretion of the pro-inflammatory cytokines interleukin-1β (IL-1β), 
interleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α), the chemokines interleukin-
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8 (IL-8), macrophage inflammatory protein-1α (MIP-1 α), and monocyte 
chemoattractant peptide-1 (MCP-1) (Lue et al., 2001). The mRNAs for all these 
proteins have been observed in AD microglia. IL-1β is also increased after Aβ exposure 
to cultured AD microglia (Walker et al., 1995).  
There are likely to be multiple mediators of microglia activation, chemotactic and 
phagocytic responses to Aβ. Evidence for complement mechanisms in microglia 
responses to Aβ has been reported. It seems that the peptide directly interacts with C1 
complement factor that activates microglial cells (Eikelenboom et al., 1998). Activated 
microglia releases cytokines, proinflammatory proteins, complement proteins, reactive 
oxygen intermediates (Banati et al., 1993).  
Inflammatory cytokines amplify and sustain inflammatory and immune responses. They 
are a family of glycoproteins that are important for the regulation of immune and 
inflammatory response. They are not only released by activated microglia but also by 
astrocytes. Cytokines may interact directly or indirectly with neurons, influencing their 
survival. Cytokines, especially IL-1, enhance the production of prostaglandin E2 (PGE2) 
in humans fibroblasts (Salvemini et al., 1993), stimulating cyclooxygenases enzyme 
(COX) activation. Recent studies have shown the importance of microglial IL-1 
secretion in AD pathogenesis, because IL-1 not only can promote neuronal injury, but 
also perpetuate cycles of inflammation (Mrak and Griffinbc, 2001). IL-1 has been 
shown to increase APP production and subsequently increase Aβ, contributing to 
neuronal damage, and simultaneously, neuronal dystrophy (Goldgaber et al., 
1989;Buxbaum et al., 1992). Injection of aggregated Aβ into the NB of rats caused 
upregulation of IL-1β, COX-2, iNOS and phospho p38MAPK in the surrounding tissue 
with microglial activation and cholinergic dysfunction (Giovannini et al., 2002).  
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Several epidemiologic studies have suggested a beneficial effect with chronic 
nonsteroidal anti-inflammatory drugs (NSAIDs) (McGeer et al., 1996). NSAIDs are 
believed to act by inhibiting COX. Two distinct isoforms of COX have now been 
characterized, a constitutive form, COX-1, and a mitogen-inducible form, COX-2. 
Studies have demonstrated that COX-2 may play a role in neurodegenerative 
mechanisms (Pasinetti and Aisen, 1998). A number of cross-sectional and longitudinal 
epidemiologic surveys also indicate that reported use of NSAID is associated with 
delayed onset and/or slowed cognitive decline in AD (Stewart et al., 1997;Halliday et 
al., 2000). However, these studies are not conclusive, and the results are controversial. 
Further examinations of traditional NSAIDs for the treatment of AD has been tempered 
by two considerations. First, NSAIDs are not the ideal class of anti-inflammatory agents 
to inhibit acute-phase response and complement activation, two mechanisms that 
contribute to neurodegeneration in AD. Second, daily use of traditional NSAIDs is 
associated with adverse effects, particularly on the gastrointestinal (GI) tract of elderly 
subjects.  
Recent findings suggest that selective COX-2 inhibitors may have an advantage over 
nonselective NSAIDs as potential therapeutic agents in AD. Studies have shown that 
COX-2 may have a central role in neurodegeneration, supporting clinical evaluation of 
selective COX-2 inhibitors as neuroprotective agents in AD (Pasinetti and Aisen, 
1998;Tocco et al., 1997;Ho et al., 2001). Studies have demonstrated that COX-2 is up-
regulated in response to excitotoxic lesions in animals and cell culture systems 
(Yamagata et al., 1993;Adams et al., 1996). Systemic administration of kainic acid 
(KA) to rats induces excitotoxic neurodegeneration, which may be a model of AD. It 
has been demonstrated that excitotoxic lesions cause up-regulation of COX-2 
expression coincident with the onset of apoptotic neuronal death. COX-2 expression has 
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been shown to be up-regulated in AD brain compared with controls (Pasinetti and 
Aisen, 1998).  
Induction of COX-2 in AD may be stimulated by amyloid peptide, and may involve 
nuclear factor kappa b (NFkB) signalling (Pasinetti and Aisen, 1998;Lukiw and Bazan, 
1998). Evidence that COX-2 is involved in AD neurodegeneration may explain the 
apparent protective effect of NSAIDs. It has been demonstrated that COX-2 inhibitors 
protect neuronal cells from amyloid toxicity in vitro and promote neuronal survival in 
animal models of ischemic and excitotoxic neurodegeneration (Fagarasan and 
Efthimiopoulos, 1996;Graham et al., 1996). Epidemiologic evidence suggests a 
neuroprotective effect of non-selective NSAIDs from either COX-1 or COX-2 
inhibition, or inhibition of both enzymes. Because COX-1 is constitutively expressed in 
brain, it is plausible that COX-1 catalytic activity may also contribute to 
neurodegenerative mechanisms (Pasinetti and Aisen, 1998). Recent studies have 
demonstrated that ibuprofen therapy reduces inflammatory activity and amyloid 
deposition in transgenic mice (Lim et al., 2000). 
Recent trials (Lim et al., 2000) have been done using two different drugs: Naproxene, a 
non-selective NSAIDs, at low doses (220 mg) to minimize the risk of serious GI 
toxicity, to one group of patients, and Rofecoxib, a selective COX-2 inhibitor at 
standard doses, to a second group. A third group of patients was treated with placebo. It 
was a one year study and the results don’t show any positive effect on memory , 
attention, speech and orientation of treated patients as compared to controls. An 
explanation for the negative results obtained could be the not sufficient doses of both 
drugs, or the short period of time of therapy. It has been demonstrated that a two year 
treatment with anti-inflammatory drugs is necessary to reduce AD risk (Ruitenberg et 
al., 2001).  
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It has been shown that in AD brains there is a colocalization of hyperphosphorylated tau 
and phosphorylated p38 MAPK in dystrophic neurons and neurites that are associated to 
activated microglia that over express IL-1 (Sheng et al., 2001).  
Recent studies have demonstrated that there are different molecules involved in neuron-
glia intercommunication, such as CD200 and HMGB1. CD200 is a membrane 
glycoprotein expressed by neurons that binds to a structurally similar receptor that is 
expressed by microglia. Their intercommunication holds microglia in a quiescent state 
(Hoek et al., 2000;Lyons et al., 2007;Frank et al., 2007). HMGB1 is a non-histone 
DNA-binding protein that has a pro-inflammatory cytokine-like function that may 
influence the activation of microglia following injury or insult (Kim et al., 2006). 
HMGB1 levels are low in resting glia but are increased in the brains of patients with 
Alzheimer’s disease (Takata et al., 2004). Extracellular HMGB1 has also been 
described as a mediator of lipopolysaccharide (LPS) toxicity (Ulloa and Messmer, 
2006). 
 
1. 14 Animal models of Alzheimer’s Disease 
Transgenic mice overexpressing Aβ offer a new powerful in vivo model to study the 
pathogenetic mechanisms related to Aβ neurodegeneration and allow to test possible 
therapeutic interventions. Among the mice strains recently developed (Hsiao et al., 
1996;Masliah et al., 1996), transgenic TgCRND8 mice (Chishti et al., 2001) expressing 
a double mutant form of human APP (K670/M671L and V717F) have been produced. 
Hemizygous  TgCRND8 mice exhibit extensive cerebral amyloid deposition, cortical 
and hippocampal atrophy and memory impairment by 3 months of age (Chishti et al., 
2001) and represent one of the transgenic mouse models which more closely resemble 
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the human pathology. In 7-month old TgCRND8 mice, extensive Aβ deposition in the 
cortex, hippocampus, thalamus and basal forebrain is accompanied by significant 
microglia and astrocyte activation, and by cholinergic dysfunction and cognitive 
impairment (Bellucci et al., 2006). This transgenic line is a good model of Aβ 
deposition, neurodegeneration and memory defects, and can be useful to clarify 
involvement of MAPK dysregulation in AD and in developing new therapeutic 
treatments.  
 
1.15 Alzheimer’s therapy  
Knowledge of the neurotransmitters disturbances in Alzheimer’s disease has led to the 
development of drugs with symptomatic effects, which are approved in many countries. 
Research advances in the molecular pathogenesis of Alzheimer’s disease have also led 
to new drug candidates with disease-modifying potential, which have now come to 
testing in clinical trials. Epidemiological data have suggested additional drug 
candidates, some of which have been investigated in randomised trials.  
The cholinergic hypothesis of Alzheimer’s disease states that degeneration of 
cholinergic neurones in the basal forebrain nuclei causes disturbances in the presynaptic  
memory disturbances and other cognitive symptoms.  
The loss of forebrain cholinergic neurons and the ensuing reduced synthesis and release 
of ACh is considered a crucial pathogenetic feature of AD since the historical paper of 
Davies and Maloney (1976). Cholinesterase Inhibitors (ChEIs) have been considered 
the best tool for restoring an adequate level of ACh in the synaptic gap since they 
prevent the hydrolysis of the residual ACh in the brain of AD patients. The question 
arises as to whether ChEIs really increase brain ACh. In the rat an increase in brain ACh 
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extracellular levels, measured by microdialysis, has been consistently demonstrated 
(Rosi et al., 2004;Cerbai et al., 2007). 
Since ChEIs are typically used in long-term therapy, the question has been asked 
whether tolerance, and consequent decrease in acetylcholinesterase (AChE) inhibition, 
develops after repeated administration of the inhibitor. Moreover, whether the persisting 
high level of ACh results in decreased ACh synthesis and modifications in 
cholinoceptor function. From the animal experiments investigating the effects of 
prolonged ChEI treatments it may be concluded that AChE, Cholineacetyltransferase 
(ChAT), and the transport mechanisms of choline and ACh do not undergo adaptive 
changes resulting in reduced AChE inhibition and ACh synthesis and ACh levels 
remain elevated. Muscarinic M2 autoreceptors only appear to undergo some adaptation.  
The AChE inhibitors donepezil, rivastigmine and galantamine are approved for clinical 
use in Alzheimer’s disease. Donepezil and galantamine are selective AChE inhibitors, 
whereas rivastigmine inhibits AChE and butirrylcholinesterase (BuChE) with similar 
affinity. Both donepezil and galantamine are metabolised in the liver by cytochrome  
P450 enzymes, and can thus interact with drugs that inhibit these enzymes. 
Rivastigmine has a non-hepatic metabolism. The half-life of the drugs also varies thus  
determining the need for one or two doses per day. The efficacy of these drugs has been 
studied in more than 30 randomised double-blind clinical trials. Most trials have been 
for 3-6 months and have shown modest positive effects on cognitive symptoms. 
Benefits of AChE inhibitors are also seen for functional and behavioural symptoms.  
Considering the mechanism of action for the AChE inhibitors, they are not expected to 
change the natural course of Alzheimer’s disease, but only to temporarily mitigate some 
of the symptoms. Overall, they are safe drugs, and side-effects are generally limited to 
gastrointestinal symptoms, including nausea, vomiting, and diarrhoea, which however 
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may decrease the patient’s complience. For this reason, much effort is being dedicated 
to the development of novel cholinesterase inhibitors that show fewer side effects. 
In healthy human brain, AChE predominates over BuChE activity (Giacobini, 2003), 
but the latter likely has been previously underestimated (Li et al., 2000). 
Whereas AChE is localized mainly to neurons, BChE is associated primarily with glial 
cells, as well as with endothelial cells and neurons (Darvesh and Hopkins, 2003). A 
possible role for brain BChE, particularly when associated with glia, is for supportive 
hydrolysis of ACh. The close spatial relationship of glial BChE would allow synergistic 
BChE-mediated hydrolysis to assist in the regulation of local ACh levels to permit the 
maintenance of normal cholinergic function. The survival of AChE knockout mice (Li 
et al., 2000) with normal levels and localization of BChE (Mesulam et al., 2002) 
supports the concept that BChE has a key role that can partly compensate for the action 
of AChE. 
In AD, AChE is lost early by up to 85% in specific brain regions, whereas BChE levels 
(Perry et al., 1978b;Arendt et al., 1992) rise with disease progression. The ratio of 
BChE to AChE changes dramatically in cortical regions affected by AD from 0.2 up to 
as much as 11 (Giacobini, 2003). Clearly, this altered ratio in AD brain could modify 
the normally supportive role of BChE in hydrolyzing excess ACh only. Selective BChE 
inhibition may therefore be useful in ameliorating a cholinergic deficit, which likely 
worsens in AD due to increased activity of BChE. 
Histochemical studies show that some cholinergic neurons contain BChE instead of 
AChE (Graybiel and Ragsdale, Jr., 1982). In fact, 10–15% of ChE-positive cells in 
human amygdala and hippocampus are regulated by BuChE independently of AChE 
(Darvesh et al., 1998). Augmenting cholinergic function by inhibiting these pathways 
may be of clinical value. Finally, it is pertinent to mention that BuChE is increased in 
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the cerebral cortex of Alzheimer’s disease patients (Perry et al., 1978a;Perry et al., 
1978c) and it is associated with the amyloid plaques. It has been suggested that BuChE, 
together with AChE (Alvarez et al., 1997), may participate in the transformation of the 
β-amyloid deposit into neuritic plaques (Guillozet et al., 1997a;Guillozet et al., 1997b). 
Inhibition of the enzyme may therefore delay plaque formation, thus suggesting the 
possibility to use BuChE inhibitors in the treatment of Alzheimer’s disease not only to 
increase the availability of acetylcholine at the synapses, but also to reduce the number 
of plaques. Indeed, clinical studies with the dual ChEI, rivastigmine, support a role for 
the central inhibition of BuChE in addition to AChE inAD therapy, based on the high 
correlation of the former with cognitive improvement (Giacobini et al., 2002). The 
findings by (Bartorelli et al., 2005b;Bartorelli et al., 2005a) , that AD patients 
deteriorating on selective AChE inhibitor treatment can benefit from switching to a dual 
AChE-BuChE inhibitor, in terms of stabilization of disease and improvement in 
cognitive functions, has prompted the development of novel inhibitors directed towards 
BuChE inhibition.   
Glutamate is the major excitatory neurotrasnsmitter in the brain. Under normal 
conditions, glutamate and the N-methyl-D-aspartate (NMDA) receptor have important 
roles for learning and memory processes. Under abnormal conditions, such as in 
Alzheimer’s disease, increased glutamatergic activity can lead to sustained low-level 
activation of NMDA receptors, which may impair neuronal function.  
Memantine is a non-competitive NMDA-receptor antagonist that is believed to protect 
neurons from glutamate-mediated excitotoxicity without preventing the physiological 
NMDA-receptor activation needed for cognitive functioning (Wilcock, 2003). 
Randomised double-blind clinical trials show modest positive effects on cognitive and 
behavioural symptoms, and improved ability to perform activities of daily living at 6 
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months in people with moderate to severe Alzheimer’s disease (Wilcock, 2003). 
Additionally, in moderate to severe disease, combination therapy with donepezil and 
memantine show positive effects on symptoms relative to donepezil alone (Tariot et al., 
2004). 
Despite the theoretical rationale for neuroprotective properties of memantine, current 
trials are too short to asses if the drugs has any disease-modifying effects. Nevertheless, 
the drug is well tolerated in general, with few adverse events, and may be a useful 
therapeutic adjunction in patients with moderate to severe disease.  
Behavioural signs, such as aggression, psychomotor agitation, and psychosis 
(hallucinations and delusions), are very common in patients with Alzheimer’s disease, 
especially in the late stages of the disease. Such symptoms not only affect quality of life 
for patients and caregivers, but also contribute to care burden and economic cost.  
Several short-term trials show efficacy of risperidone and olanzapine in reducing the 
rate of aggression, agitation, and psychosis (Brodaty et al., 2003;Street et al., 2000). 
Alternative treatments include anticonvulsants, such as divalproate and carbamazepine, 
and short-acting benzodiazepines, such as lorazepam and oxazepam (Materman D, 
2003). Additionally, the cholinergic deficits can contribute to the development of 
behavioural symptoms, and treatment with AChE inhibitors also shows improvements 
in behavioural symptoms (Terry, Jr. and Buccafusco, 2003).  
Substantial efforts have been made to translate the advances in the molecular 
pathogenesis of AD into therapeutic strategies. The major focus has been to inhibit 
brain Aβ production and aggregation, and to increase Aβ clearance from the brain.  
Drugs candidates with potential disease-modifying effects are: secretase modulator, Aβ 
immunotherapy, anti tau-drugs.  
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For the first group of drugs, the finding that BACE1 knockout mice have abolished Aβ 
production without any clinical phenotype (Luo et al., 2001) made BACE1 inhibitors an 
attractive therapeutic strategy. β-secretase inhibitors have been developed to reduce 
brain Aβ concentrations in Alzheimer’s disease transgenic mice. Drugs that stimulate α-
secretase can shift APP processing towards the non-amyloidogenic pathway, thus 
reducing Aβ production. Bryostatin, a protein kinase C activator currently tested in 
clinical trials as an anticancer drug, substantially enhances α-secretase processing of 
APP and reduces brain Aβ(1−42) concentrations in AD transgenic mice 
(Etcheberrigaray et al., 2004).  
The principal of Aβ immunotherapy was first reported in a paper showing that active 
immunisation of AD transgenic mice with fibrillar Aβ attenuated Aβ deposition 
(Schenk et al., 1999). Similar results were obtained by use of passive immunisation with 
antibodies against Aβ (Bard et al., 2000). The effect might be mediated by anti- 
Aβ antibodies that bind to Aβ plaques and induce Aβ clearance by microglia (Bard et 
al., 2000;Schenk et al., 2004).  
These results were the basis for initiating clinical trials with active immunisation with 
the vaccine AN1792, composed of preaggregated Aβ42 (Schenk et al., 2004). However, 
the phase IIa AN1792 trial had to be interrupted because 6% of cases developed 
encephalitis (Orgogozo et al., 2003). This side-effect has been suggested to be due to a 
T-cell response against the mid-terminal and C-terminal part of the peptide. The second 
generation of immunotherapy , Αβ immunoconjugates composed of the N-terminal part 
of Aβ conjugated to a carrier protein (Schenk et al., 2004), or virus-like particles, could 
allow for active immunisation with reduced risk of Th-1 mediated side-effects. Both 
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active immunisation with N-terminal Aβ fragments and passive immunisation with N-
terminal anti- Aβ monoclonal antibodies are now in phase II trials. 
Drugs of the third group, candidates that reduce tau phosphorylation by inhibiting tau 
kinases, such as CDK5 and GSK-3β, are in the preclinical phase. However, since tau 
phosphorylation is regulated by the balance between multiple kinases and phosphates, 
inhibition of a single kinase might be insufficient to normalise tau phosphorylation.  
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2. AIM  
 
 
 
Aim of the research was: 
1. Evaluate the modification of different intracellular transduction pathways and 
extracellular intercommunicating proteins as well as activation of microglia and 
astrocytes in animal models of neuroinflammation, normal aging and AD-related 
neurodegeneration that may lead to memory deficits. To this aim different 
animal models were used. In particular, the molecular mechanisms involved in 
neuron-glia intercommunication during inflammation in the hippocampus were 
studied using the model of LPS-induced neuroinflammation in the rat, developed 
by Prof. Gary Wenk. This part of the work was carried out in Wenk’s Lab, 
Psychology Department, Ohio State University, USA. The differential activation 
of MAPKs intracellular transduction pathways as well as the cellular 
modifications in the hippocampus during aging and AD related 
neurodegeneration were studied in normal aged rats and in TgCRND8 
transgenic mice, an animal model of AD. This part of the work was carried out 
in Giovannini’s Lab, Department of Pharmacology, University of Florence, 
Italy. 
1) Evaluate the efficacy of treatment with novel compounds on differential 
inhibition of acetylcholinesterase/butyrilcholinesterase activity in the brain and 
on cortical acetylcholine release. These experiments were aimed at obtaining a 
proof of concept for the development of these compounds as possible drugs for 
the treatment of memory impairments in neurodegenerative diseases. 
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3. MATERIALS AND METHODS 
 
3.1 Animals 
Male Wistar rats, 220–250 g body weight (Harlan Nossan, Milano, Italy), Tg 
heterozygous TgCRND8 mice with a (C57)/(C57/C3H) genetic background and non-Tg 
littermates hybrid (C57)/(C57/C3H) wild type (Wt) control mice of 7 months of age 
were used. The mice were obtained from the laboratory of Prof. P. St. George-Hyslop 
(CRND, Toronto, ON, Canada) and were bred in the Centre for Laboratory Animals, 
University of Florence, Italy. The animals were individually housed in macrolon cages 
until experiment with ad libitum food and water, and were maintained on a 12 h light–
12 h dark cycle with light at 7:00 am. The room temperature was 23±1°C. All rats were 
kept for at least 1 week in the animal house facility of the University of Florence before 
experiment. All animal manipulations were carried out according to the European 
Community guidelines for animal care (DL 116/92, application of the European 
Communities Council Directive 86/609/EEC). Formal approval to conduct the 
experiments described has been obtained from the animal subjects review board of the 
University of Florence, and the Italian Ministry of Health. All efforts were made to 
minimize animal sufferings and to use only the number of animals necessary to produce 
reliable scientific data. 
 
3.2 Drugs 
Donepezil and rivastigmine were supplied by Novartis (Basel, Switzerland). (−)-
N1phenethyl-norcymserine (PEC) was obtained from Dr. Nigel H. Greig, National 
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Institute on Aging, NIH, Baltimore MD, USA. Donepezil and rivastigmine were 
dissolved in saline and injected i.p. in a volume of 2 ml/kg of body weight. PEC was 
dissolved in saline containing 10% Tween 80-5% ethanol and injected i.p. in a volume 
of 2 ml/kg of body weight. NP-361 and NP-336 were supplied by Neuropharma 
(Madrid, Spain) and dissolved in N-methyl-2Pyrrolidone 5%, Solutol HS15 30%, Saline 
(10 ml/kg) for the enzymatic assays, in N-methyl-2Pyrrolidone 5%, Solutol HS15 30%, 
Saline (10 ml/kg) or Tween 80 2% diluted in Methylcellulose 0.5% (10 ml/kg) for 
behavioural experiments, in DMSO 400 µg/kg for microdyalisis experiments, and 
injected i.p. in a volume of 10 ml/kg of vehicle.  
 
3.3 Microdialysis experiments 
Rats were deeply anesthetized with 4% chloral hydrate and placed in a stereotaxic frame 
(Stellar, Stoelting Co.,Wood Dale, IL, USA) for surgery. At the end of surgery the rats 
were put back in their home cages (one rat per cage) to recover. Transversal 
microdialysis probes (AN 69 membrane, Hospal Dasco, Italy, molecular mass cut-off 
15 kDA) covered with super epoxy glue except for the region corresponding to the 
length of frontal cortices (mm 8) were inserted in the frontal cortex according to the 
following coordinates: AP, 0.0 and H 1.7 mm from bregma (Paxinos and Watson, 
1982). Transversal probes were preferred to vertical probes in order to increase the 
surface through which acetylcholine could diffuse from the extracellular space in the 
perfusing fluid and facilitate basal level determinations (Scali et al., 1997). On the 
following day, the inlets of the membranes were connected to a microperfusion pump 
(CMA/100) and were perfused with artificial cerebrospinal fluid (aCSF), of the 
following composition (in mM): 147 NaCl, 1.2 CaCl2, 3.0 KCl, 4 at a constant flow rate 
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(3 µl/min) with no cholinesterase inhibitors added. The dialysate was collected at 20-
min intervals in minitubes containing 5 µl of 0.05 mM HCl to prevent hydrolysis of 
acetylcholine. After four samples had been collected under basal conditions, the rats 
were injected with the cholinesterase inhibitors or saline and samples were collected for 
3 h after drug treatment. The samples were stored at −80 °C before assaying. At the end 
of the experiments the rats were sacrificed to check probe location visually and the 
brains were stored at −80 °C in case further analyses were necessary. 
 
3.4 Assay of acetylcholine in the dialysates 
Acetylcholine was assayed in the dialysate by HPLC with electrochemical detection 
(Damsma et al., 1987;Giovannini et al., 1994) using an acetylcholine/choline assay 
chromatographic kit purchased by ByoAnalytical System, Inc (Indiana, USA) consisting 
of an analytical column (BAS MF-6150, Bio Analytical Systems Inc., West Lafayette, 
Indiana, USA) and an acetylcholine/choline Immobilized Enzyme Reactor (IMER, BAS 
MF-6151, Bio Analytical Systems Inc., West Lafayette, Indiana, USA) containing 
acetylcholinesterase and choline oxidase. The mobile phase was 50 mM Tris/NaClO4 
containing 0.05% ProClin (BAS CF-2150, Bio Analytical Systems Inc., West Lafayette, 
Indiana, USA), pH 8.5, at 1 ml/min flow rate. Acetylcholine and choline were separated 
in the analytical column, acetylcholine was hydrolized in the IMER by 
acetylcholinesterase to acetate and choline was then oxidized by choline oxidase to 
produce betaine and hydrogen peroxide. 
Hydrogen peroxide was electrochemically detected by a platinum working electrode at 
+500 mV with a Ag/AgCl reference electrode. The sensitivity limit (s/n ratioN3/1) was 
75–100 fmol/injection for acetylcholine. To evaluate the amount of acetylcholine in the 
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samples, a linear regression curve was made with acetylcholine standards and the peak 
heights of this compound in the samples were compared with those of the standards by 
means of an integrator (P.E. Nelson model 1020). Neurotransmitter levels in the dialysis 
samples were calculated as fmol/µl and then expressed as percent variation over basal 
levels, which in each group of experiments was the mean±S.E.M. of the 4 basal samples 
pre drug administration. Since increase in acetylcholine release always returned to basal 
levels after treatment, the evoked acetylcholine release was calculated evaluating the 
areas under the curve (in arbitrary units), between 100 and 200 min after treatment both 
in salineand in drug-treated animals. Statistical analysis among groups was performed 
comparing the areas under the curve. 
 
3.5 Cholinesterase determination 
Acetylcholinesterase and butyrylcholinesterase activity was measured in different 
groups of rats of the same strain and age, kept under the same housing conditions. At 
the time corresponding to the peak increase in acetylcholine levels after drug 
administration (55–60 min after administration), the rats were sacrificed by 
decapitation. Brains were quickly removed and placed in ice-cold saline to dissect out 
the parietal cortices, which were quickly weighted and frozen immediately on dry ice 
and kept at −80 °C until enzyme activity determination. Acetylcholinesterase and 
butyrylcholinesterase activities in the cerebral cortex were determined using three 
methods in different groups of rats:  
 
1) Method of Ellman, (ELLMAN et al., 1961) as previously used by Scali et al. (2002), 
(Scali et al., 2002) with modifications by Chuiko et al. (2003) (Chuiko et al., 2003), 
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using the substrates acetylthiocholine and butyrylthiocholine iodide (5×10−4 M final 
concentration), for acetylcholinesterase and butyrylcholinesterase, respectively. Enzyme 
activity was expressed as µmol substrate hydrolyzed per minute per µg protein. Cortical 
samples of about 50–70 mg were homogenized in 50 mM Na-phosphate buffer, pH 7.2 
(1:5, w:v) in a glass-teflon homogenizer on ice (15 strokes). For acetylcholinesterase 
determination, 25 µl of homogenate were added to 2875 µl of 5,5′-Dithiobis(2-
nitrobenzoic acid) (DTNB) 0.3 mM in 50 mM Na-phosphate buffer, pH 7.2, containing 
100 µl of 15 mM acetylthiocholine as the substrate. The reaction was developed for 2 
min and read at 412 nm. Proper blanks were made up following the same procedure, 
with the exclusion of the homogenate. 
For butyrylcholinesterase determination, the homogenate was added to the reaction 
mixture as above which contained 100 µl of 15 mM BuTCh as the substrate, and the 
sample was read at 412 nm at 2 min. In a few samples, the selective acetylcholinesterase 
inhibitor 1,5-bis(4 allyldimethylammo allyldimethylammoniumphenyl) pentan-3-one 
dibromide (BW 284-C51, Sigma- Aldrich) (10– 5 M) was added to the homogenate, 
reducing the volume of DTNB in order to maintain the total volume of 3 ml. Blanks 
were made up as above. No differences in butyrylcholinesterase activity were found 
between the samples with and without BW 284-C51. The enzyme activity was 
quantified using the following calculations taken from Ellman et al. (ELLMAN et al., 
1961) as modified by Galli et al. (1984) (Galli et al., 1984): 
[(OD412nm/min)/136 x 100 (extinction coefficient of the yellow anion)] x [1/(µl 
sample/µl tot volume) x (µg/µl protein)] x 1000 
which expresses acetylcholinesterase activity in pmol/min x µg protein. 
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2) Method of Ellman modified according to O. Lockridge for butyrylcholinesterase.  
Cortical samples of about 50–70 mg were added to 10 volumes of 0.5% Tween-20 in 50 
mM potassium phosphate buffer, pH 7.4. After homogenization in a glass homogenizer 
on ice (15 strokes), the samples were centrifuged in a microfuge for 10 min at 4 °C and 
100 µl of the supernatant were added to 865 µl of 0.1 M potassium phosphate, pH 7.0 
and 25 µl of 20 mM DTNB. The mixture 
was incubated for 23 min to deplete free sulphydryls. The depletion of free sulphydryls 
was monitored at 412 nm. When the slope was constant (after 23 min), the activity of 
butyrylcholinesterase was monitored by starting the reaction with 10 µl of 0.1 M 
BuThCh to a total volume of 1 ml. The reaction was developed for 5 min and read at 
412 nm. Blank samples were prepared as above, omitting the homogenate. The activity 
of the enzyme was calculated using the formula described by Ellman et al. (1961) 
(ELLMAN et al., 1961). 
 
3) Radiometric method for acetylcholinesterase and butyrylcholinesterase: (Johnson and 
Russell, 1975;Thiermann et al., 2005). Cortical samples of about 50–70 mg were 
homogenized (1:5, w:v) on ice in 50 mM Tris–HCl buffer (pH 7.4) containing 1 M 
NaCl and 1% Triton X-100 (Lysis buffer). [3H-acetyl]acetylcholine working solution 
was made up with the specific activity of 1 mCi/mmol, 10 mM.  
3a) Acetylcholinesterase activity determination. Thirty µl of cortex homogenates or of 
Lysis buffer (blanks) were added to 50 µl of 50 mM phosphate buffer (pH 6.8) in a 
plastic vial. Twenty µl of H]acetylcholine working solution were added, samples were 
vortexed for 15 s and incubated at 37 °C for 15 min in a water bath under slight 
agitation. The enzyme reaction was terminated by adding 100 µl of a stopping solution 
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consisting of 1 M monochloroacetic acid, 0.5 M NaOH and 2 M NaCl. The [3H] acetic 
acid formed by the reaction was extracted into 4 ml of a lipophilic scintillation cocktail 
(OptiScint HiSafe, Perkin Elmer Life Sciences, Inc., Boston, MA, USA), containing 
10% isoamyl alcohol (v:v) by vigorous shaking for 1 min. After separation of the two 
phases, the radioactivity was counted with a Perkin Elmer Life Science scintillation 
counter. The radioactivity of the blanks (b0.5%) was subtracted from the values of the 
samples. 
3b) Butyrylcholinesterase activity determination. Thirty ml of cortex homogenates or of 
Lysis buffer (blanks) were added to 25 µl of 100 µM phosphate buffer (pH 6.8) and to 
25 µl of 40 µM BW 284-C51, a selective inhibitor of acetylcholinesterase, in a plastic 
vial and incubated for 30 min at 37 °C in a water bath under slight agitation. Twenty µl 
of [3H]acetylcholine working solution were added, samples were vortexed for 15 s and 
incubated at 37 °C for 30 min in a water bath under slight agitation. The same procedure 
described above was then followed. Enzymatic activity was quantified using the 
following formula taken from (Potter, 1967) as modified by (Johnson and Russell, 
1975): 
{{{[(sampleDPMaverage - blankDPMaverage)/1000]/2.22(converting factor)} 
/µgprotein}/incubation time} x 1000 
which gives as result acetylcholinesterase or butyrylcholinesterase activity expressed in 
pmol/min×µg protein. 
 
3.6 Protein determination 
Protein determination was performed in the homogenates using a Bio-Rad Protein 
Assay reagent (Bio-Rad, Hercules, CA) with bovine serum albumin as standard. 
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3.7 Step-down inhibitory avoidance task 
In the step-down inhibitory avoidance task rodents, put on an elevated platform placed 
by one wall of an arena, learn to associate exploration of the adjacent compartment with 
a foot shock delivered through the floor grid. On a subsequent exposure to the same 
environment, the animal will avoid stepping down, or will increase the latency before 
“stepping down” onto the floor grid. We used a standard step-down apparatus placed in 
a soundproof room. Rats were handled and habituated to the experimenter and to the 
handling procedure the day before the test. Rats were positioned on an elevated platform 
placed in a dark compartment facing an open arena equipped with an electrified floor 
grid. We recorded the “Acquisition latency,” i.e. the time spent before stepping down 
onto the grid where an aversive stimulus (10 electric shocks, 20 ms/0.5 mA/5 Hz) was 
delivered to the animal. Rats were immediately removed from the arena and placed in 
their home cage for consolidation (“Encoding”). Recall tests, given 60 min after the 
training test, were identical to training sessions, except that the footshock was omitted. 
At the recall test the time spent in the dark compartment before stepping down onto the 
arena was also recorded (“Recall latency”). All trained rats acquired the behavior. A 
300 s ceiling was imposed on recall test latencies. 
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Fig. 7 Rat position on the platform of the step down inhibitory avoidance task. 
 
 
 
 
 
 
 
 
 
3.8 Exploratory behaviour  
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The exploratory behaviour was investigated in an arena formed by a white-colored 
polyvinyl chloride box (70x60x30 cm) with a grid floor which could be easily cleaned. 
The arena was illumined by two 75-W lamps suspended 50 cm above the box. A 
microwave sensor was placed 70 cm above the arena to measure the rats’ motor activity.  
Each animal was taken from it home cage and transferred in the adjacent arena, to 
which it had never been exposed before. To do this, the animal was manually picked up 
from it home cage, lifted approximately 50 cm and placed gently into the open field. 
This procedure lasted less than 5 s. 
Total motor activity in the arena during exploration was recorded every 5 min by means 
of a microwave sensor placed 70 cm above he cage, in order to cover the entire arena. 
The impulses created by movements were recorded every 0.1 s by a counter, which 
added an expressed them in s/5min. No analysis of the movement type was made. 
Statistical analysis was performed on the mean ± SEM using a one way ANOVS 
followed by Newman-Keuls multiple comparison test. 
 
3.9 Rota rod test 
The motor performance was evaluated in the rotarod test for rats (Ugo Basile Rota-
Rod). The day before the test, rats were trained twice in the rotarod treadmill, rotating at 
the speed of 8 rpm for 5 minutes. On the day of the test only the rats tat were able to 
stay balanced on the rotating rod between 70 and 120 s (cut-off time) were selected for 
the trial and randomly assigned to one of the experimental groups. Rats that fell off the 
rod before 70 sec were discarded. The test was then performed 60 min after i.p. 
injection of the compounds under investigation. The time rats spent in balance on the 
rod was measured in sec and statistical analysis was performed on the median ± 
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interquartile range using a non parametric test (Kruskall-wallis test followed by Dunn’s 
multiple Comparison test). 
The following groups were tested: saline, vehicles (N-methyl-2pyrrolidone 5%, Solutol 
HS15 30%, Saline), NP-361 (10 mg/kg and 20 mg/kg) or NP-336 (40 mg/kg and 80 
mg/kg) dissolved in vehicle.  
 
3.10 Fourth ventricle surgical procedure 
Artificial cerebrospinal fluid (aCSF, n=20) or lipopolysaccharide (LPS, Sigma, E. coli, 
serotype 055:B5, TCA extraction, 1.0 µg/µl dissolved in aCSF, n=42) was chronically 
infused through a cannula implanted into the 4th ventricle of the brain that was attached 
(via Tygon tubing, 0.06 O.D.) to an osmotic minipump (Alzet model #2004, to deliver 
0.25 µl/h) as previously described (Rosi et al., 2005). According to the manufacturer’s 
specifications, the model #2004 will produce a continuous infusion for approximately 
42 days (six weeks).  The aCSF vehicle contained (in mM) 140 NaCl; 3.0 KCl; 2.5 
CaCl2; 1.0 MgCl2; 1.2 Na2HPO4, adjusted to pH 7.4.  Two weeks after the infusion 
began, some rats were anesthetized and had a second osmotic minipump implanted 
(model 2ML2, to deliver 2.5 ul/h) containing memantine (15 mg/kg/d); these rats were 
sacrificed two weeks later.  Memantine was purchased from Tocris Bioscience 
(Ellisville, MO).  Body weights were determined daily and general behavior was 
monitored for normal grooming behavior and seizures.  Rats infused with aCSF were 
sacrificed one or eight weeks after surgery.  Rats infused with LPS were sacrificed one, 
four or eight weeks after surgery.  For rats that are sacrificed eight weeks after surgery, 
their exposure to either LPS or aCSF would have ended approximately six weeks after 
surgery. This group was included in order to determine whether microglial activation 
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was still present two weeks after the cessation of the infusion of LPS into the 4th 
ventricle. Serum samples were collected at sacrifice and levels of memantine were 
determined by gas chromatography (Misztal and Paw, 1996).  
 
3.11 Immunohistochemistry 
Antibodies.  
The following antibodies were used: rabbit polyclonal anti-phospho (Thr202/Tyr204)-
ERK1,2 antibody (1:750), anti-phospho-(Thr180/Tyr182)-p38MAPK antibody (1:250), 
antiphospho-(Thr183/Tyr185)-JNK antibody (1:1000) which detect the activated forms 
of ERK1,2, p38MAPK and JNK, respectively (all from Cell Signaling Technology, Inc., 
Danvers, MA, USA). Each antibody specifically recognizes the phosphorylated form of 
the respective kinase, with no cross-reaction with the two other ones. Activated 
microglia was evidenced using monoclonal OX-6 antibody (1:200; Pharmingen, BD 
Bioscience, Franklin Lakes, NJ, USA) against major histocompatibility (MHC) class II 
complex and polyclonal anti-glial fibrillary acidic protein (GFAP) (1:1000; 
DakoCytomation, Glostrup, Denmark) were used to detect activated microglial and 
astrocytes cells, respectively. CD200 was evidenced using monoclonal antibody (1:50; 
AbDserotec, Raleigh, NC), HMGB1 was evidenced using polyclonal antibody (1.500; 
AbCam, Cambridge, MA). Neuronal calcium was visualized using polyclonal antibody 
anti-calbindin (1:500; AbCam, Cambridge, MA). The inducible nitric oxide was 
visualized using the plyclonal antibody anti-iNOS (1:100; AbCam, Cambridge, MA). A 
monoclonal anti-neuronal nuclei (NeuN) antibody (1:200; Chemicon, Temecula, CA, 
USA) was used to detect neurons. 
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Rats were anesthetized with chloral hydrate (400 g/kg) and perfused transcardially with 
500 ml of ice-cold paraformaldehyde (4% in phosphate-buffered saline (PBS), pH 7.4). 
The brains were postfixed for 4 h and cryoprotected in 18% sucrose/PBS solution for at 
least 48 h. Coronal sections (40 _m-thick) were cut with a cryostat, placed in 1 ml of 
anti-freeze solution and stored at -20 °C until immunohistochemistry. 
 
Light microscopy immunohistochemistry.  
Day 1. The antibodies were stained using the free-floating method (Giovannini et al., 
2001b;Giovannini et al., 2003c). Coronal brain sections were placed in wells of 24-well 
plates and were rinsed for 10 min in phosphate buffered saline 0.3% Triton X-100 
(PBS-TX), incubated for 15 min in PBS-TX containing 0.75% H2O2 and blocked with 
blocking buffer (BB) containing 1.5% normal goat serum and 0.05% NaN3 in PBS-TX 
for 1 h. Sections were then incubated overnight at 4 °C with the following primary 
antibodies: ERK1,2, JNK, p38MAPK, GFAP, OX6, iNOS.  
 
Day 2. Slices were incubated in biotinylated goat anti-rabbit secondary antibody 
(Vectastain, Vector Laboratories, Burlingame, CA, USA), diluted 1:333 or anti-mouse 
diluted 1:1000 in BB for 2 h at RT, then for 1 h 30 min in AB solution (Vectastain ABC 
kit, Vector Laboratories) and staining was developed for 2–3 min using 3,3’-
diaminobenzidine (DAB) staining kit (Vectastain, Vector Laboratories) with NiCl2 as 
an enhancer. DAB-stained slices were examined using an Olympus BX40 microscope 
equipped with an Olympus DP 50 (Olympus, Milan, Italy) digital camera.  
For double staining, at the end of the second day, the sections underwent another cycle 
of immunohistochemistry with a polyclonal antibody raised against the β-amyloid(1–
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42) (1:250, Biosource Europe, Nivelles, Belgium) peptide to label amyloid plaques or 
with monoclonal OX-6 antibody (1:200) (Pharmingen, BD Bioscience, San Jose, CA, 
USA) against MHC class II complex to visualize activated microglia. The staining was 
visualized by the use of a Vector NovaRed Kit (Vector Laboratories) and observed by 
means of a light microscopy, as above. 
 
Laser confocal microscopy immunohistochemistry 
Staining was performed with the free-floating method and slices were blocked 10% 
normal goat serum–10% normal horse serum in PBS-TX for 40 min (BB). Astrocytes 
were visualized using an anti– glial fibrillar acidic protein antibody incubated O/N at 4 
°C and then for 2 h at RT with a Texas Red (TR) –conjugated anti-mouse (1:200) in 
BB. Colocalization of activated p38MAPK in neurons and astrocytes was visualized 
using double-labeling confocal microscopy with antibodies against phospho-p38MAPK, 
anti-NeuN for neurons, anti-MHC class II complex for activated microglia and anti-
GFAP for astrocytes. After incubation with the two primary antibodies diluted in BB at 
the above concentrations, O/N at 4 °C under slight agitation, slices were incubated for 2 
h at RT in the dark with fluorescein (FITC) -conjugated anti-rabbit antibody (1:200) and 
then for 2 h at RT in the dark with FITCconjugated anti-rabbit IgG plus TR-conjugated 
anti-mouse (1:200) in BB (Vectastain, Vector Laboratories). After extensive washings, 
slices were then mounted onto gelatin-coated slides for microscopic examination using 
Vectashield (Vectastain, Vector Laboratories) as mounting medium. TR single-labeled 
or FITC/TR double- labeled slices were observed under a BioRad 1024 confocal laser 
scanning microscope (Cambridge, MA, USA) with laser beam excitation at 488 and 568 
nm wavelength. Optical z-sections were taken at 1 µm interval keeping all the 
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parameters (pinhole, contrast and brightness) constant. Image analyses were conducted 
on image z-stacks which contain the field of interest. Images were digitally converted to 
green (phospho-p38MAPK), or to red (OX-6 or GFAP) and digitally combined to 
obtain doublelabeled FITC/TR and then assembled into montages using Adobe 
Photoshop (Adobe Systems, Mountain View, CA, USA). 
 
Immunofluiorescence staining for CD200, Calbindin, HMGB1 
Free floating coronal sections (40 µm) were obtained using a vibratome, mounted on 
slides and air-dried. The tissues were then processed as described previously (Rosi et 
al., 2005). After washing in TBS solution the slides were incubated (4 °C) over night 
with either of the following primary antibody: HMGB1, CD200. Thereafter, the 
sections were incubated for 2h (22 °C) with the secondary antibody, followed by 
incubation with Avidin + Biotin amplification system (Vector) for 45 min. The staining 
was visualized using the TSA fluorescence system CY3 (Perkin-Elmer Life Sciences, 
Emeryville, CA). After washing in TBS solution, the tissues were quenched and 
blocked again and incubated with either of the following antibodies: OX6,NeuN, 
calbindin over night at 4 °C. Before applying the biotinylated secondary antibody rat 
absorbed antibody (Vector,) for 2h, the tissues were incubated with Avidin Biotin 
Blocking Kit (Vector,) for 30 min to block cross-reaction with the primary staining. 
Following treatment with an Avidin + Biotin amplification system (Vector), the staining 
was visualized with a TSA fluorescence system Cyanine 5 (CY5, Perkin-Elmer) and 
nuclei were counterstained with Sytox-Green (Molecular Probes, Eugene, OR). No 
staining was detected in the absence of the primary or secondary antibody. 
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3.12 Western Blot 
Antibodies 
The following antibodies were used: rabbit polyclonal anti-phospho  (Thr202/Tyr204)-
ERK1,2 antibody (1:1000), anti-phospho-(Thr180/Tyr182)-p38MAPK antibody 
(1:500), antiphospho-(Thr183/Tyr185)-JNK antibody (1:1000) which detect the 
activated forms of ERK1,2, p38MAPK and JNK, respectively (all from Cell Signaling 
Technology, Inc., Danvers, MA, USA). Total ERK was visualized using a rabbit 
polyclonal antibody raised against ERK1,2 protein (1:1000, Cell Signaling Technology, 
Inc., Danvers, MA, USA). HMGB1 was visualized using a polyclonal antibody (1:800; 
AbCam, Cambridge, MA). Actin was visualized with a rabbit polyclonal antibody 
(1:10,000; Sigma Chem Co., St. louis, MO, USA). 
Western immunoblotting was carried out as previously described (Giovannini et al., 
2001b). Rats were sacrificed and bilateral samples of hippocampus were dissected and 
transferred to ice-cold microcentrifuge tubes with lysis buffer, homogenized on ice (a 
Potter-Elvehjem homogenizer, 20 strokes, 1 stroke/s). The lysis buffer had the 
following composition (mM): 50 Tris–HCl, pH 7.5, 50 NaCl, 10 EGTA, 5 EDTA, 2 
sodium pyrophosphate, 4-para-nitrophenylphosphate, 1-sodium orthovanadate, 1-
phenylmethylsulfonyl fluoride, plus 20 µg/ml leupeptin and 30 ug/ml aprotinin and 
0.1% SDS 10%.  Immediately after homogenization protein concentration was 
determined (Bio-Rad, Hercules, CA). An appropriate volume of 2× loading buffer was 
added to the homogenates, and samples were boiled (@95 °C) for 5 min. Samples (65 
µg of proteins per well) were loaded onto a 10% SDS-PAGE gel and resolved by 
standard electrophoresis. The proteins were then transferred electrophoretically onto 
nitrocellulose membrane (Hybond-C extra; Amersham, Arlington Heights, IL) using a 
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transfer tank kept at 4 °C, with typical parameters being O/N with a constant current of 
12 mA. Membranes were blocked for 1 h at room temperature with blocking buffer 
(BB, 5% non-fat dry milk in TBS containing 0.05% Tween 20, TBS-T), then probed for 
2 h at room temperature using the following primary antibodies: HMGB1, ERK1,2, 
JNK, p38MAPK. After washing in TBS-T (three washes, 15 min each), the membranes 
were incubated with horseradish peroxidase-conjugated anti-rabbit IgG for HMGB1 
(Pierce, Rockford, Illinois, U.S.A, final dilution 1:7500) or with horseradish peroxidase-
conjugated anti-mouse IgG (Pierce, Rockford, Illinois, U.S.A, final dilution 1:7500), or 
anti-rabbit IgG (Pierce, Rockford, Illinois, U.S.A, final dilution 1:7500) and proteins 
were visualized using chemiluminescence (Super vSignal West Pico 
Chemioluminescent Substrate, Pierce, Rockford, Illinois, U.S.A.). In order to normalize 
the values of the primary antibodies, we detected actin in the same analysis. Membranes 
were stripped by Restore Western Blot Stripping Buffer (Pierce) for 15 min at room 
temperature, blocked in blocking buffer for 1 h at room temperature and probed for 2 h 
at room temperature using antibodies for actin (Sigma Aldrich, final dilution 1:5000) 
and incubated in secondary antibody and developed as above.  After development of the 
film, the bands were acquired as TIFF files, and the density of the bands was quantified 
by densitometric analysis performed using Un-Scan-It software for HMGB1 (Silk 
Scientific Corporation, Orem, UT). Or Scion Image for Windows (Scion Co., MD, 
USA) software for MAPKs. HMGB1 and phospho-MAPKs values were expressed as 
percentage of total actin run in the same Western blot analysis.  
 
3.13 Slice preparation for in vitro carbachol (CCh) stimulation 
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CCh stimulated slices or control slices were used for Western blot analysis or for 
immunohistochemistry of phospho-ERK. Wt mice were anesthetized and decapitated 
and brains were rapidly removed and placed into oxygenated artificial cerebrospinal 
fluid (ACSF: D(+)-glucose monohydrate 9 mM, NaHCO3 24 mM, NaCl 125 mM, KCl 
3,5 mM, NaH2PO4 1,25 mM, CaCl22H2O 1 mM, MgSO47H2O 1 mM), on ice. Brains 
were quickly glued to a vibratome block (Vibratome Series 1000, Sectioning System, 
Redding, CA, USA), placed in a chamber filled with ice-cold ACSF oxygenated with 
95% O2/5%CO2 and 400 µm thick coronal slices were cut. Care was taken to maintain 
the temperature ACSF below 4 °C. Slices were incubated in a 24-well chamber, one per 
well, resting on a net submerged in oxygenated Krebs solution (NaCl 124 mM, KCl 3.3 
mM, MgSO4 1.4 mM, CaCl2 2.5 mM, KH2PO4 1.25 mM, D(+)-glucose monohydrate 
10 mM, NaHCO3 25 mM) and were allowed to equilibrate for at least 45 min at RT. 
After equilibration, control slices used for Western blot, were gently removed from the 
wells, placed on gelatin-coated slides, excess liquid aspirated and slices were quickly 
frozen on dry-ice. For immunohistochemistry, control slices were transferred in 24- 
wells plate, one per well, containing 1 ml of ice-cold 4% paraformaldehyde and fixed 
O/N. 
The remaining slices (one per well) were placed in a bath at 35 °C in a solution 
containing 100 µM CCh and stimulated with the drug for 15 min. After incubation, 
slices were removed and frozen for WB or fixed for immunohistochemistry, as 
described above. Subsequently, slices used for Western blot, maintained on slides on 
dry ice, were dissected under a magnifying glass. The hippocampus was transferred into 
Eppendorff test tubes, kept at -80 °C until Western blot of phospho-ERK, as described. 
Slices used for immunohistochemistry were fixed in 4% paraformaldehyde overnight. 
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The day after, each slice was rinsed with PBS, glued on the Vibratome block and re 
sectioned into 40 µm-thick slices, which were then used for free-floating 
immunohistochemistry of phospho-ERK, as described. Quantitation of the effect was 
performed by counting the neurons blind in selected regions of the hippocampus. Care 
was taken to avoid thawing of the specimens. 
 
3.14 Statistical analysis 
Statistical comparison was performed using Student’s t test, or one way ANOVA 
followed by Newman-Keuls multiple comparison test (if more than two groups were 
compared) or Dunnett multiple comparison test (when drug-treated groups were 
compared to the saline-treated group only). Significance was set at P<0.05.  
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4. RESULTS 
 
4.1 STUDY OF NEURONAL CHANGES IN A MODEL OF LPS-
INDUCED NEUROINFLAMMATION. 
 
4.1.1 LPS induces activation of microglia. 
Control rats, infused with aCSF, had few mildly activated microglia cells evenly  
scattered throughout the hippocampus including the DG (Fig. 8A,C), consistent with 
previous reports from our lab (Hauss-Wegrzyniak et al., 1998;Rosi et al., 2005;Rosi et 
al., 2006). Rats infused with LPS for only 1 week had only a few activated microglia 
cells (Fig. 8B) consistent with our previous findings that a full microglial response to 
LPS requires 10 to 14 days to develop (Willard et al., 1999; Marchalant et al., 2006). 
Infusion of LPS for 4 weeks significantly increased the number of activated microglia in 
the DG (Fig.8E,G, P<0.05) and CA3 (Fig. 8G, P<0.05), similar to  previous reports 
from our lab (Hauss-Wegrzyniak et al., 1998;Rosi et al., 2005). Rats infused with LPS 
and then sacrificed 8 weeks after surgery, i.e. approximately 2 weeks after the cessation 
of the LPS infusion, also showed significantly (one way ANOVA Newman-Keuls post hoc 
test,  P<0.05) increased number of activated microglia in the DG and CA3 regions of the 
hippocampus (Fig. 8D,G). The activated microglia showed bushy morphology with 
increased cell body size and contracted, and ramified processes, characteristic of cells in 
an activated state. 
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Fig.8 Immunoreactivity (IR) of activated microglia in the hippocampus. Note the increase of 
activated microglia cells (red) in the dentate gyrus of LPS infused animals. (A) OX6 IR (red) 
and nuclei (blue) of a 1 week a-CSF animal; (B) OX6 IR and nuceli of a 1 week LPS animal; 
(C) OX6 IR and nuclei of a 4 weeks LPS animal; (D) OX6 IR and nuclei of a 8 weeks a-CSF 
animal; (E) OX6 IR and nuclei of a 8 weeks LPS animal; (F) OX6 IR and nuclei of an LPS + 
memantine animal. Note the increase of activated microglia cells after 4 and 8 weeeks LPS 
treatment and their decrease to control values after 2 weeks of memantine (15mg/kg/d, s.c.) 
administration by osmotic minipump. Size bar=80µm. (G) Counts of OX-6 positive cells in the 
dentate gyrus (DG, *** p<0.05, one way ANOVA Newman-Keuls post hoc test) and CA3 of 
the hippocampus (*** p<0.05, one way ANOVA Newman-Keuls post hoc test); Means ± SD.  
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4.1.2 Memantine attenuates ongoing microglial activation 
Chronic administration of the NMDA receptor antagonist memantine under the 
conditions used in the current study typically produces  a serum concentration of ~1 µM 
within 3 days, an extracellular fluid concentration of 0.5-0.7 µM and a brain tissue 
concentration of 12-15 µM; free drug plasma levels are probably about 20-50% lower 
than this value due to protein binding, similar to the levels reached in humans at 
therapeutic doses of memantine (Rogawski and Wenk, 2003). In our experiments, the 2 
weeks administration of memantine via an osmotic minipump produced a serum level of 
the drug of 0.77 + 0.18 µM (n=7). 
Rats that received memantine treatment for 2 weeks, initiated 2 weeks after the 
commencement of the LPS infusion, showed a significant reduction in the number of 
activated microglia cells within the DG (Fig 8F,G, P<0.05) and CA3 area. The activated 
microglia still present in the LPS-infused animals treated with memantine presented a 
morphology characteristic of a less advanced activation state.   
 
4.1.3 LPS reduces CD200 expression 
CD200 is a membrane glycoprotein, expressed by neurons, that binds to a structurally 
similar receptor that is expressed by microglia. The intercommunication between 
neurons and microglia through CD200 binding to its microglia receptor is believed to 
maintain microglia in a quiescent state (Hoek et al., 2000;Lyons et al., 2007;Frank et al., 
2007). 
Four weeks of LPS infusion (Fig. 9D,F) significantly reduced the number of cells 
expressing CD200 protein in the CA3 region of the hippocampus (one way ANOVA 
Newman-Keuls post hoc test, P<0.05). The number of cells with CD200 immunoreactivity 
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remained significantly reduced in the hippocampus of rats that were infused with LPS 
and sacrificed 8 weeks after surgery (Fig. 9B,F). No changes in the number of CD200-
immunoreactive cells in the CA3 were found after only 1 week of LPS infusion (Fig. 
9C,F) or after 1 or 8 weeks of aCSF infusion (Fig. 9A,B,F) into the 4th ventricle. 
Administration of memantine for 2 weeks restored the number of CD200-
immunoreactive cells to a level similar to that of aCSF treated control rats (Fig. 9E, F). 
The Western blot analysis of CD200 expression did not reveal a statistically significant 
(One way ANOVA, Newman-Keuls post hoc test, p=0.06) change in CD200 protein 
expression between groups (data not shown); the absence of statistical significance may 
be related to the fact that the entire hippocampus was used for this analysis, thus 
diluting and masking the effect that was present in the CA3 area only, according to the 
immunohistochemical results.. 
 
4.1.4 Persistent microglia activation depends on Ca2+ entry through 
NMDA receptors 
We hypothesized that neuron-to-microglia communication influences microglia 
activation through NMDA receptors. Thus, neuronal NMDA receptor activation and the 
ensuing Ca2+ influx may be a key link in the ongoing maintenance of an inflammatory 
environment. We thus predicted that the LPS inflammatory response might increase 
Ca2+ influx through NMDA receptors and blocking this receptor channel, and thus 
reducing Ca2+ entry, would alter the intercommunication between neurons and 
microglia, therefore reducing the number of activated microglia cells caused by LPS 
infusion. Calbindin was used as an indicator of Ca2+ entry. Indeed, in rats infused with 
LPS for 4 weeks, CA3 hippocampal neurons showed increased immunoreactive 
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expression of cytoplasmic calbindin as compared to rats infused with aCSF (Fig. 
10A,D). Blockade of NMDA receptors with memantine restored calbindin 
immunoreactivity to levels similar to those seen in rats infused with aCSF (Fig. 10G).   
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Fig. 9 Immunoreactivity (IR) of CD200 in the CA3 region of the hippocampus. Note the 
diminution of CD200 immunoreactive cells after 4 weeks of LPS exposure (D), and that 
memantine administration (15mg/kg/d, s.c.) (E) restored the number of CD200 immunoreactive 
cells to the same levels observed in a-CSF infused rats (A,B).  No differences in CD200 
immunoreactive cells were found in the 1-week LPS rats (C) as compared to a-CSF rats (A,B). 
Size bar=40µm. (F) Counts of the number of CD200 immunoreactive cells in the CA3 region 
defined by the region of hippocampus defined by the box in the diagram (**P<0.05, one way 
ANOVA Newman-Keuls post hoc test); Mean ± SD  
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Fig. 10 Double immunofluorescence of CD200 and calbindin in the CA3 of the hippocampus. 
Calbindin distribution in the CA3 from an 8 weeks a-CSF rat (A), 4 weeks LPS rat (D) and 
LPS+memantine rat (G). The inserts show single calbindin immunoreactive neurons (size bar 
13µm) .  Note the increased immunoreactivity in the 4 weeks LPS rat as compared to the 8 
weeks a-CSF rat and LPS+memantine rat.  For comparison, the images of CD 200 distribution 
from an 8 weeks a-CSF rat (B), 4 weeks LPS rat (E) and LPS+memantine rat (H) are merged 
(C,F,I) merged from the same rats.  In the 4 weeks LPS rat neurons that have more calbindin 
have less CD200 staining as compared to the other two groups. Size bar=80µm 
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4.1.5 Expression of microglial quiescence signalling molecule CD200 is 
modulated by Ca2+-dependent processes 
Double-immunofluorescence studies revealed that cytoplasmic calbindin levels were 
inversely related to CD200 expression within the same neurons. Rats infused with LPS 
for 4 weeks exhibited elevated calbindin expression and greatly reduced CD200 
expression (Fig. 10 D,E,F), as compared to control rats infused with aCSF (Fig. 10 
A,B,C). Blockade of NMDA receptors by memantine in rats infused with LPS restored 
cytoplasmic calbindin and CD200 immunoreactivity to control levels (Fig 10 G,H,I).  
 
4.1.6 HMGB1 expression is unaltered by chronic neuroinflammation 
HMGB1 is a non-histone DNA-binding protein that has a pro-inflammatory cytokine-
like function that may influence the activation of microglia following injury or insult 
(Kim et al., 2006). It has been demonstrated that HMGB1 levels are low in resting glia 
but are increased in the brains of patients with Alzheimer’s disease (Takata et al., 2004). 
Extracellular HMGB1 has also been described as a mediator of lipopolysaccharide 
(LPS) toxicity (Ulloa & Messmer, 2006).   
We investigated whether extracellular HMGB1 mediates LPS toxicity or whether its 
expression paralleled changes in CD200 expression or microglial activation within the 
hippocampus. Double-immunofluorescence staining for HMGB1 (Fig. 11A) confirmed 
previous reports that HMGB1 is contained within the nucleus of neurons (Guazzi et al. 
2003; Scaffidi et al., 2002); we observed no evidence for extracellular HMGB1 in the 
presence of chronic brain inflammation produced by 4 weeks LPS. Histological and 
Western blot analyses found no significant differences in hippocampal HMGB1 protein 
levels among treatments (Fig. 11B).   
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Fig. 11 HMGB1 colocalizes with neurons but its expression does not change among the 
different treatment groups. (A) Double immunofluorescence of HMGB1 (green) and NeuN 
(red), nuclei are counterstained in blue (magnification 200X). Size bar=80µm. The insert shows 
single HMGB1 immunoreactive neurons (size bar 13µm). (B) Densitometric ratio of HMGB1 
and actin ± SD of the immunoblotting of HMGB1. No differences of HMGB1 expression 
among groups.  
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4.2 STUDY OF CELLULAR CHANGES IN AGED RATS 
COMPARED TO YOUNG RATS. 
 
4.2.1 Latencies in the step down inhibitory avoidance task 
In order to evaluate memory deficits in a model of natural aging, we performed the step 
down inhibitory avoidance in old rats (24 months) compared to young rats (3 months).  
As shown in Fig. 13, recall latencies in a step down inhibitory avoidance are decreased 
in old rats compared to young rats (one way ANOVA and Newman-Keuls multiple 
comparison test,  **P<0.01).  
 
4.2.2 ERK activation in hippocampal slices of old rats 
In a previous paper published by our laboratory in 2005 (Giovannini et al., 2005), we 
demonstrated that the treatment of young rats with the MEK1 inhibitors PD98059 and 
U0126, 30 min before the step down inhibitory avoidance acquisition task, brings about 
impairments in memory encoding, as demonstrated by the decrease of recall latency. 
This result correlates with an involvement of ERK pathway in memory encoding. 
Moreover, in the paper we demonstrated that ACh, acting through muscarinic receptors, 
activated the cascade that leads to ERK phosphorylation (Fig. 12).  
In order to evaluate activation of ERK in hippocampal slices of old rats, we performed 
immunhistochemistry with a selective anti-phospho-ERK antibody in hippocampal 
slices from old rats compared to young rats. Phospho-ERK–positive neurons were 
counted in the CA1 area of aged and young rats. As shown in Fig. 14, while a 
significant increase of activated ERK was present in CA1 of young rats 10 min after 
acquisition, no difference was observed in the aged animals. (one way ANOVA and 
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Newman-Keuls multiple comparison test, *P<0.05). This results indicates that in aged 
animals that do not acquire the step down inhibitory avoidance task, no activation of 
ERK is visible in the CA1 region of the hippocampus, thus posing further basis to the 
hypothesis of the involvement of ERK in this type of memory. 
 
 
 
 
Fig. 12 Schematic representation of the proposed mechanism fo encoding of the step-down 
inhibitory avoidance memory.  
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Fig. 13 Latencies in a step down inhibitory avoidance task. Note the decreased recall 
latencies in a step down inhibitory avoidance of old rats compared to young rats (**P< 
0.01, one way ANOVA and Newman-Keuls post hoc test). 
 
 
 
 
 
 
 
 
 
Fig. 14 ERK activation in old and young rats after acquisition in a step down inhibitory 
avoidance task. While in young rats, 10 min after acquisition, we found a significant increase of 
activated ERK in pyramidal neurons of CA1 region, in old rats  no difference of phospho ERK 
positive neuronsin CA1 was found. Indee, the number of phospho-ERK positive neurons in the 
CA1 region of the aged rats 10 min after acquisition were significantly lower than in young 
rats(*P<0.05, one way ANOVA Newman-Keuls post hoc test).  
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4.2.3 JNK and p38MAPK activation in hippocampal slices of old rats  
We investigated the activation of the other MAPKs, JNK and p38MAPK in the 
hippocampus of aged rats, in comparison to young animals using selective antibodies 
for the phosphorylated form of the enzymes. As shown in Fig. 15, no differences of  
JNK activation in the three regions of the hippocampus between old (Fig. 15B) and 
young rats (Fig. 15A) were observed. On the contrary, marked differencesof p38MAPK 
activation in CA3, CA1 and DG of old rats compared to young rats were found. As 
shown qualitatively by immunohistochemistry in Fig. 16, old rats (Fig. 16B) presented 
an increased number of phospho p38MAPK positive cells in all three regions of the 
hippocampus compared to the young rats (Fig.16A). The bar graphs of Fig. 16  show 
the quantitative analysis of phospho p38MAPK positive neurons in CA3 (Fig. 16 panel 
A), CA1 (Fig. 16 panel B) and DG (Fig. 16 panel C) of old and young rats. As shown in 
the figure, we found statistically significant differences in the number of phospho 
p38MAPK positive neurons in the three region of the old rats hippocampus, as 
compared to the young rats hippocampus (Student’s t-test, *P<0.05; **P<0,01, 
***P<0,001).  
 
4.2.4 Evaluation of neuroinflammatory markers in the hippocampus of 
old and young rats  
As previously shown in the model of LPS-induced neuroinflammation, young rats 
infused with LPS show an increase of the number of activated microglia, particularly in  
CA3 and DG of the hippocampus. Thus, we looked at activated microglia and other 
neuroinflammatory markers in old rats to verify whether a form of neuroinflammation 
might also be present in the old rats model. Fig. 17 shows representative images of 
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iNOS immunohistochemistry in CA3 of young (Fig. 17A) and old rats (Fig. 17B) 
hippocampus. It appears in the images that old rats have more iNOS positive cells as 
compared to young rats. And indeed, quantitative analysis in Fig. 17C shows that  iNOS 
positive cells are significantly more numerous in CA3 area of old rats, compared to 
young rats (Student’s t-test, **P<0.01).  
Since astrocytes and microglia are part of CNS immune system, and are thus involved 
in neuroinflammatory mechanisms, we looked at their activation using GFAP and OX6 
antibodies, respectively.  
GFAP (Glial Fibrillary Acidic Protein) is a protein specifically expressed by astrocytes, 
GFAP immunostaining of astrocytes is shown in Fig. 18A-H. A difference in the 
number and morphology of GFAP positive cells between young and old rats is evident 
in DG (Fig. 18C,F) CA3 (Fig. 18D,G) and CA1 (Fig. 18E,H) regions of the 
hippocampus. Indeed, in the three regions of the hippocampus of old rats we found that 
the number of GFAP immunopositive cells was significantly less (Fig 18F,G,H) as 
compared to young rats (Fig. 18C,D,E). In Fig. 10I the quantitative counting of  GFAP 
positive cells in the three regions of the hippocampus is presented. The bar graph shows 
a statistically significant decrease of GFAP positive cells in CA3, DG and CA1 of old 
rats compared to youg rats (** p<0.001, two way ANOVA and Bonferroni post hoc 
test). Furthermore, images taken at higher magnification (20X) show that old rats 
astrocytes have a smaller cell body and shorter and thinner branchings, compared to 
young rats astrocytes that have densely arborized cell bodies, a phenotype typical of 
activated astrocytes (Fig. 19A,B). 
OX6 antibody is a selective antibody that binds to the MHCII complex expressed by 
activate microglia and it is thus used tovisualize activated microglia. Fig. 20 shows the 
immunohistochemistry of activated microglia in the DG of young (Fig. 20A) and old 
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(Fig. 20B) rats. As shown in the figure, old rats present an increased number of 
activated microglia in DG as compared to young rats. The quantitative counting of OX6 
positive cells (Fig. 20C) indicate a statistically significant increment of activated 
microglia in CA3, DG and CA1 of old rats compared to young rats (One way ANOVA 
and Bonferroni post hoc test, **P<0.001). As shown in the graph, the number of 
activated microglia cells in CA1 is lower compared to CA3 and DG, as previously 
shown in the LPS-induced neuroinflammation model.  
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Fig. 15 Immunoreactivity of phospho JNK in the hippocampus of young rats (A) and old rats 
(B). No differences between the two groups were observed. Size bar=500µm 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 16 Immunoreactivity of phospho p38MAPK in hippocampal slices of young (A) and old 
(B) rats. Note the increased number of phospho p38MAPK positive cells in old rats as 
compared to young rats in the three regions of the hippocampus.Size bar=500µm. (C,D,E) 
Phospho p38MAPK positive cells in CA3 (C,*P< 0,05, Student’s t-test), DG (D,** p<0.001 
Student’s t-tes) and CA1 of the hippocampus of old and young rats, Mean ± SEM. The number 
of p38MAPK positive cells is significantly increased in the three region of the hippocampus of 
old rats as compared to the same areas of the young rats (E, *** p<0.001, Student’s t-test).  
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Fig. 17 Immunoreactivity of iNOS in hippocampal slices of young (A) and old (B) rats. Note 
the increased number of iNOS positive cells in the CA3 of the old rats hippocampus as 
compared to the young rats. Size bar=400µm. (C) Counting of iNOS positive cells in CA3 of 
the hippocampus of old and young rats (** p<0.01, Student’s t-test); Mean ± SEM 
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Fig. 18 Immunoreactivity of GFAP in hippocampal slices of young (A) and old (B) rats. Note 
the different density and morphology of GFAP positive cells in dentate gyrus (DG), CA3 and 
CA1 (F, G, H) of the old rats as compared to the same areas of  young rats (C, D, E). Size 
bar=500µm for A,B; size bar=125µm for C, D, E, F, G, H,. (I) Counting of GFAP positive cells 
in CA3, DG and CA1 of the hippocampus of old and young rats, Mean ± SEM. The density of 
GFAP positive cells in the three areas of the hippocampus of old rats is significantly decreased 
as compared to the same areas of young rats (** p<0.001,two way ANOVA and Bonferroni post 
hoc test).  
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Fig. 19 Immunoreactivity of GFAP in hippocampal slices of young (A) and old (B) rats. Note 
the different density and morphology of GFAP positive cells in dentate gyrus  of the old rats (B) 
compared to the same area of  young rats (A). Size bar=100µm. 
 
 
 
 
 
 
Fig. 20 Immunoreactivity of OX6 in 
hippocampal slices of young (A) and 
old (B) rats. Note the increased  number 
of activated microglia in the DG of old 
rats as compared to young rats. Size 
bar=100µm. (C) Counting of OX6 
positive cells in CA3, CA1 and DG of 
the hippocampus of old and young rats, 
Mean ± SEM. The number of OX6 
positive cells in the three region of the 
hippocampus of old rats is significantly 
increased as compared to the same 
areas of the young rats (** p<0.001,two 
way ANOVA and Bonferroni post hoc 
test).  CA3 CA1 DG
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4.3 DIFFERENT ACTIVATION OF MITOGEN-ACTIVATED 
PROTEIN KINASE PATHWAY IN THE TgCRND8 TRANSEGNIC 
MOUSE MODEL OF ALZHEIMER DISEASE. 
 
4.3.1 Activation of p38MAPK in the hippocampus of TgCRND8 mice 
As reported in previous paper (Bellucci et al., 2006, 2007), TgCRND8 mice at 7 months 
of age show the presence of numerous β-amyloid deposit in the hippocampus and other 
brain areas, as well as astrocytes and microglia activation, inflammatory markers, 
nitrosative stress, neuronal damage hyperphosphorylated tau, cholinergic dysfunction 
and impairment in learning and memory functions. Therefore, we decided to look at the 
intracellular pathways that might be switched on/off in the hippocampus of the Tg 
mouse compared to wild type (Wt) littermates. Three major protein kinase pathways 
have been demonstrated to be responsive to environmental stress, inflammatory stimuli 
or other insults: ERK1,2, p38MAPK and JNK.  
Immunohistochemistry showed higher activation of P38MAPK in cells distributed in 
the hippocampus of the Tg (Fig. 21A,C) than of Wt mouse (Fig. 21B,D). In particular, 
phospho-p38MAPK immunopositive cells were located mainly in the pyramidal layer 
of the CA1, in the stratus radiatum, in the stratum lacunosum molecularis and to a less 
extent in the dentate gyrus (DG) (Fig. 21C).  
Quantification of p38MAPK activation was performed by Western blot (WB) analysis 
of homogenates of the entire hippocampus. In Fig. 21E WB analysis of the 
hippocampus of Tg and Wt mice shows one single major band at an apparent molecular 
weight of 38 kDa. The quantitative analysis was performed comparing the 
immunopositive bands of phospho-p38MAPK with that of actin run on the same gel and 
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the results are shown in Fig 21F. Data presented in Fig 21F show that the levels of 
phospho-p38MAPK in Tg mouse hippocampus were two fold higher than in Wt 
littermates and the increase was statistically significant (*P<0.05, Student’s t-test).  
Images taken at higher magnification show that activated p38MAPK was present in 
different cell types in the hippocampus of Tg mice. Both neurons and glia were positive 
for phospho-p38MAPK. Indeed, phospho-p38MAPK immunoreactivity was present in 
the nuclei of CA1 pyramidal cells (Fig. 22A-E, open arrows) as shown by DAB staining 
(A,B) and fluorescence staining revealed by double labelling confocal microscopy (C-E, 
z-stacks reconstructed images of a single cell by confocal laser microscopy; red 
labelling NeuN; green labelling phospho-p38MAPK). Fig 22A and B shows that 
phospho-p38MAPK immunopositive CA1 pyramidal neurons were localized in the 
vicinity of amyloid plaques (evidenced by the asterisks). Furthermore, the parenchyma 
surrounding the amyloid plaques was also characterized by infiltration of numerous, 
hypertrophic phospho-p38MAPK immunopositive cells (Fig. 22A, B, F black arrows) 
with densely arborized cell bodies with a phenotype typical of activated astrocytes. 
Amyloid plaques induced massive activation of astrocytes (Fig. 22G, white arrows), 
visualized by the immunoreactivity for the specific marker GFAP (red), as well as 
transformation of astrocytes from a resting to an activated state, highlighted by 
phenotypic changes characterized by cell hypertrophy and long, thick branchings (Fig 
22G, I, white arrows). From their shape and position in the surroundings of the amyloid 
plaques, it appeared that these phospho-p38MAPK immunopositive cells in the 
hippocampus of Tg mice were activated astrocytes, as also demonstrated by 
colocalization of phospho-p38MAPK immunoreactivity in GFAP-positive cells by 
confocal laser microscopy (green labelling phospho-p38MAPK, red labelling GFAP).  
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Activated microglia cells immunopositive for the MHC type II, with round-shape 
appearance (Fig. 23A, black staining, arrows), infiltrated the amyloid plaques, 
(evidenced in Fig. 23A by staining with an antibody raised against β-amyloid(1-42), 
brown-red staining, red arrows). Furthermore, phospho-p38MAPK positive cells with 
round cell bodies and intensely stained short processes and “bushy” appearance were 
present in the stratum radiatum of Tg mice, not only infiltrating the Aβ plaques (Fig. 
23B, white arrows) but also in the parenchyma distant from the plaques (Fig. 23C, E, 
black arrow). Phospho-p38MAPK positive cells were also present in the stratum 
radiatum of Wt mice but had smaller cell bodies and thinner processes (Fig 23D, I), 
indicative of lower state of activation From their shape the phospho-p38MAPK positive 
cells present in Tg mice hippocampus resembled activated microglia. Indeed, double-
labeled confocal microscopy for phospho-p38MAPK (Fig. 23F) and MHCII complex 
(Fig. 23G) showed colocalization of the staining (Fig. 23H, z-stacks reconstructed 
images of a single cell by confocal laser microscopy; the yellow-orange colour is 
indicative for colocalization), demonstrating that the phospho-p38MAPK positive cells 
are microglial cells in an activated state.  
 
4.3.2 JNK activation in the hippocampus of TgCRND8 mice. 
As shown in Fig. 24B no staining for phospho-JNK was found in the hippocampus of 
Wt mice at the age of 7 months. However, several phospho-JNK immunopositive, 
round-shaped cells surrounded the plaques in the hippocampus of Tg mice, as shown in 
the insert of Fig 24A. Double-labeled immunohistochemistry for phospho-JNK (Fig. 
24C, blue-gray) and MHC class II complex (Fig. 24C, brown-red) showed 
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colocalization of phospho-JNK in most, but not all, activated microglial cells around 
plaques.  
Quantitation of JNK activation was performed by Western blot analysis in homogenates 
of the hippocampus. As shown in Fig 24D, a typical WB analysis of the hippocampus of 
Tg and Wt mice with the primary antibody raised against phopsho-JNK, shows only 
two major bands at an apparent molecular weight of 46 kDa and 54 kDa. The 
quantitative analysis was performed separated on the two bands of phospho-JNK which 
were compared with actin run on the same gel. The results are shown in Fig. 24E. Data 
presented in the figure show that in the homogenates of Tg mouse hippocampus the 
activation of phospho-JNK significantly increased in comparison to Wt littermates 
(*P<0.05, Student’s t-test).  
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Fig. 21 Activation of p38MAPK in the hippocampus of TgCRND8 and Wt mice. Activation of 
p38MAPK was visualized using a specific antibody for its phosphorylated form and DAB 
staining followed by light microscopy. (A–C) Immunohistochemical staining of activated 
p38MAPK in the hippocampus of TgCRND8 (A, C) and Wt (B, D) mice. Note the phospho 
p38MAPK-positive cells in all the subregions of the hippocampus. Selected photographs (A, C 
and B, D) were shot from stained slices taken from different mice. The figure shows 
representative photomicrographs obtained from three to six independent experiments. Scale 
bars=250 µm A, B; C, D: 125 µm. (E) Representative Western blot analysis of phospho-
p38MAPK on homogenates of the entire hippocampus of Tg and Wt mice. One major band at 
an apparent molecular weight of 38 kDa is present. Western blot analysis of actin, performed on 
the same gel, is shown for comparison. (F) Quantitative analysis of activated p38MAPK 
performed comparing the immunopositive band of phospho-p38MAPK with that of actin run on 
the same gel. The levels of phospho-p38MAPK in TgCRND8 hippocampus were significantly 
higher than in Wt (* P<0.05, Student's t-test). Tg: n=8; Wt: n=6. 
 106
 
  
Fig. 22 Phospho-p38MAPK colocalizes in neurons and astrocytes in the hippocampus of 
TgCRND8 mice. All images were obtained from 40 µm-thick coronal slices of the hippocampus 
of Tg mice and show representative photomicrographs obtained from three independent 
experiments. (A, B, F) Immunohistochemical staining of activated p38MAPK in the 
hippocampus of Tg mouse visualized using a specific antibody for its phosphorylated form and 
DAB staining followed by light microscopy. Scale bar=50 µm. (C–E) Double-labeled confocal 
microscopy images obtained from CA1 pyramidal cell layer of TgCRND8 mouse labeled using 
antibodies anti-phospho-p38MAPK and anti-NeuN for neurons. NeuN labeling is indicated by 
red (C, E), phospho-p38MAPK labeling is indicated by green (D, E), and combined labeling is 
indicated by yellow–orange (E). The images were obtained stacking 15 z-step scans (1.5 µm 
depth each) acquired using a ×60 objective. Images were then flattened on one plane, and 
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converted into false colors. Scale bar=10 µm. The digitally combined image (E) shows that 
phospho-p38MAPK is localized in CA1 pyramidal cells and translocates to the nuclear region. 
G: astrocytes, labeled using the anti-GFAP antibody, in the surroundings of an amyoloid plaque 
(asterisk) in the hippocampus of TgCRND8 mice. Scale bar=50 µm. (H, I, L) Double-labeled 
confocal microscopy images obtained from hippocampal slices of TgCRND8 mice labeled 
using antibodies specific for phospho-p38MAPK and astrocytes. Activated astrocytes labeling is 
indicated by red (I, L), phospho-p38MAPK labeling is indicated by green (H, L), and combined 
labeling is indicated by yellow–orange (L). The images were obtained stacking 15 z-step scans 
(1.5 µm depth each) acquired using a ×60 objective. Images were then flattened on one plane, 
and converted into false colors. Scale bar=10 µm. The digitally combined image (L) shows that 
phospho-p38MAPK colocalizes in astrocytes where it is not localized solely to the nucleus. 
 
                
Fig. 23 Phospho-p38MAPK colocalizes in activated microglia in the hippocampus of 
TgCRND8 mice. All images were obtained from 40 µm-thick coronal slices of the stratum 
radiatum of Tg mice and show representative photomicrographs obtained from three 
independent experiments. (A) Double staining of activated microglia cells (labeled with 
antibodies against the MHC type II, black staining, arrows), and amyloid plaques (labeled with 
an antibody raised against β-amyloid(1–42), brown–red staining, red arrow). Activated 
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microglia cells infiltrated the amyloid plaques. Scale bar=25 µm. (B–E, I) Immunostaining of 
phospho-p38MAPK positive cells (B, white arrows) infiltrating the Abeta plaque (B, asterisk), 
and in the parenchyma distant from the plaques (C, E, black arrow). Phospho-p38MAPK 
positive cells were also present in the stratum radiatum of Wt mice (D) but were smaller and 
had thinner processes (I). Scale bars=25 µm B; C, D, 50 µm; E, I: 10 µm. (F–H) Double labeling 
confocal microscopy immunohistochemistry of phospho-p38MAPK (F, green labeling) and 
MHC type II (G, red labeling); z-stacks reconstructed images of a single cell in the 
hippocampus of TgCRND8 mice; combined labeling is indicated by yellow–orange (H). The 
images were obtained stacking 15 z-step scans (1.5 µm depth each) acquired using a ×60 
objective. Images were then flattened on one plane, and converted into false colors. Scale 
bar=10 µm. The digitally combined image (H) shows that phospho-p38MAPK colocalizes in 
activated microglial cells where it is not localized solely to the nucleus. 
      
Fig. 24 Activation of JNK in the hippocampus of TgCRND8 and Wt mice. Activation of JNK 
was visualized using a specific antibody for its phosphorylated form and DAB staining followed 
by light microscopy. (A, B) Immunohistochemical staining of activated JNK in the 
hippocampus of Tg (A, inset) and Wt (B) mice. Note the complete lack of phospho-JNK-
positive cells in the hippocampus of Wt mice, and the presence of phospho-JNK-positive cells 
around the plaques in Tg mice. The figure shows representative photomicrographs obtained 
from three to six independent experiments. Scale bars=400 µm A, B; inset: 30 µm. (C) Double 
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staining of phospho-JNK (labeled with an antibody raised against β-amyloid(1–42), blue–gray 
staining, white arrow) and of activated microglia cells (labeled with antibodies against the MHC 
type II, brown–red staining, black arrow). Scale bar=25 µm. (D) Representative Western blot 
analysis of phospho-JNK on homogenates of the entire hippocampus of Tg and Wt mice. Two 
major bands at an apparent molecular weight of 46 and 54 kDa are present. Western blot 
analysis of actin, performed on the same gel, is shown for comparison. (D) Quantitative analysis 
of activated JNK performed comparing the immunopositive band of phospho-JNK with that of 
actin run on the same gel. Each band density was calculated separately. The levels of phospho-
JNK in TgCRND8 hippocampus were significantly higher than in Wt (* P<0.05, Student's t-
test). Tg: n=3; Wt: n=3. 
4.3.3 ERK activation in the hippocampus of TgCRND8 mice in basal 
and stimulated condition. 
 
We evaluated whether ERK activation was modified in the hippocampus of TgCRND8 
mice in comparison to Wt littermates, both in basal and cholinergic-stimulated 
conditions.  
In basal conditions, very few phospho-ERK immunopositive neurons were present in 
the hippocampus of Wt mice, and localized mainly in the DG, where scattered phospho-
ERK positive granule cells were stained (Fig. 25B, D), but not in CA1 and CA3. In the 
DG of TgCRND8 mouse hippocampus, phospho-ERK positive neurons were 
significantly less numerous than in Wt mice, as shown in Fig. 25A and C. Some 
immunopositive staining was also present in the mossy fibres of Wt mice (Fig 25D). 
Quantitative analysis of ERK activation was performed by means of Western blot on 
homogenates of the entire hippocampus, shown in Fig 25E.  
We used a primary polyclonal antibody raised against phospho-(Thr202/Tyr204)-ERK, 
selective for the two isoforms of the enzyme, not showing any further bands than those 
corresponding to phospho-ERK1 and phospho- ERK2 (at an apparent molecular weight 
of 44 kDa and 42 kDa, respectively, see Fig. 25E). However, as also shown by others 
(Berman et al., 1998; Patterson et al., 2001), activated ERK1 appeared to be less 
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conspicuous than activated ERK2 in both mice strains, as evidenced by the very faint 
phospho-ERK1 band in Western immunoblots (Fig. 25E), notwithstanding the presence 
of total ERK1 protein both in Wt and in Tg mice hippocampus (Fig. 25G), Thus, we 
took into consideration only the variations of the activation of the ERK2, and not of the 
ERK1, isoform that might ensue in the two mouse strains. Quantitative data, reported in 
Fig. 25F, indicate that in basal conditions ERK2 was significantly less activated in the 
hippocampus of Tg mice in comparison to Wt mice (-45%, ** P<0.02, Student’s t-test). 
In order to verify whether the differential activation of ERK2 in Tg mouse hippocampus 
might be due to lower expression of the ERK protein, we analyzed total ERK protein in 
mouse hippocampus by means of WB, using antibodies against the non-phosphorylated 
form of ERK1,2. A typical WB analysis is shown in Fig. 25G, where the two bands 
corresponding to ERK1 (44 kDa) and ERK2 (42 kDa) are present. Quantitative analysis 
of ERK2, performed comparing the density of the corresponding band to that of actin 
run in the same gel is shown in Fig. 25H. No significant difference in the level of total 
ERK was found between Tg and Wt mice hippocampus (n.s., Student’s t-test). 
Furthermore, immunohistochemistry revealed that total ERK was expressed 
homogeneously in the entire hippocampus of Tg and WT mice (not shown). 
Since it has been demonstrated in different systems that ERK activation is downstream 
of cholinergic stimulation, via both muscarinic (Rosenblum et al., 2000) and nicotinic 
receptors (Dineley et al., 2001), we verified whether cholinergic stimulation might 
activate ERK in a comparable manner in the hippocampus of Wt and Tg mice ex vivo. 
Slices (400 µM) of fresh mouse brain containing the hippocampus were cut and 
stimulated in vitro using the non-selective cholinergic agonist CCh (100 µM). In order 
to verify whether ERK is activated by cholinergic stimulation and in which subregion(s) 
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of the hippocampus phospho-ERK immunopositive neurons are located, activation of 
ERK was first studied by immunohistochemistry in Wt mice hippocampus after 
stimulation with CCh (Fig. 26B, B1, B2). Cholinergic stimulation with CCh strongly 
increased ERK activation in the cell bodies of CA1 pyramidal neurons and of DG 
granule cells (Fig. 26B1 and B2) of Wt mice. No activation of ERK was found in the 
cell bodies of CA3 pyramidal neurons (Fig. 26B, arrow). Quantitation of the effect was 
performed by counting the neurons blind in selected areas of the CA1 and DG (framed 
areas in Fig. 25A and B, shown at higher magnification in the insets A1, A2 and B1, 
B2). Stimulation of Wt mouse hippocampus with CCh induced significant activation of 
ERK in the cell bodies of DG and CA1 (Fig. 25C, D; ** P<0.02 vs. respective non-
treated controls, Student’s t-test). Stimulation of ERK activation by CCh in the 
hippocampus of Tg mice was visualized in CA1 pyramidal cell layer and DG by 
immunohistochemistry (Fig. 27A1 and A2). Activation of ERK by CCh was present 
both in CA1 and DG of Tg mice, which however appeared less intense than in Wt 
mouse hippocampus, as confirmed by quantitative analysis performed on homogenates 
of the entire hippocampus of Wt and Tg mice, with and without CCh stimulation, by 
WB analysis. A typical WB analysis of homogenates of the hippocampus of Tg and Wt 
mice after stimulation with CCh is shown in Fig. 26B, in comparison with actin run in 
the same gel. Statistical evaluation of the differences among the four experimental 
groups (Wt and Tg, no drug; Wt and Tg stimulated with CCh) was performed by two-
way ANOVA followed by Bonferroni post hoc test and shown in Fig. 27C. Two-way 
ANOVA revealed that higher activation of ERK in Wt mice in comparison to Tg mice 
was present in all experimental conditions (Strain: F1,20=33.57, P=0.0014; * P<0.05, vs. 
Wt No drug, Bonferroni post hoc test) and that CCh stimulation significantly activated 
ERK (Treatment: F1,20=23.32, P=0.0059, # P<0.05 vs. all other groups, Bonferroni post 
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hoc test, Fig. 27C). It is interesting to note that cholinergic stimulation by CCh caused 
an increase of ERK activation in both mouse strains, as indicated by the not significant 
interaction between Strain and Treatment (interaction: F1,18=6.36, P=6.36, not 
significant), indicating that the pathway is still functioning in the hippocampus of Tg 
mice. However, ERK activation evoked by CCh was significantly increased in Wt 
hippocampus (# P<0.05 vs. all other groups, Bonferroni post hoc test), while a non-
significant trend toward an increase was found in Tg mouse hippocampus (Tg CCh vs. 
Tg No drug, not significant, Bonferroni post hoc test). These results show that 
activation of ERK in CA1 pyramidal neurons and in the granule cells of the DG is 
downstream of cholinergic activation. However, this effect is significantly less 
conspicuous in the hippocampus of Tg mice, indicating a possible mechanism 
responsible for the memory deficits present in TgCRND8 mice (Bellucci et al., 2006), 
possibly due to the strong connections between the cholinergic system and the ERK 
pathway in the mechanisms of memory (Giovannini, 2006). 
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Fig. 25 ERK2 is less activated in the hippocampus of TgCRND8 than in Wt mice. (A–D) 
Immunohistochemical staining of activated ERK in the hippocampus of Tg (A, C) and Wt (B, 
D) mice. Note the phospho-ERK-positive granule cells in the DG of the hippocampus. Selected 
photographs (A, C and B, D) were shot from stained slices taken from different mice. The figure 
shows representative photomicrographs obtained from three to six independent experiments. 
Scale bars=250 µm A, B; C, D: 50 µm. (E) Representative Western blot analysis of phospho-
ERK1,2 on homogenates of the entire hippocampus of Tg and Wt mice. The two typical bands 
at apparent molecular weights of 42 (phospho-ERK2) and 44 (phospho-ERK1) kDa are present. 
Phospho-ERK2 is more abundant than phospho-ERK1. Western blot analysis of actin, 
performed on the same gel, is shown for comparison. (F) Quantitative analysis of activated 
ERK2 performed comparing the immunopositive band of phospho-ERK2 with that of actin run 
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on the same gel. The levels of phospho-ERK2 in TgCRND8 hippocampus were significantly 
lower than in Wt hippocampus (** P<0.02, Student's t-test). Tg: n=7; Wt: n=8. (G) 
Representative Western blot analysis of total-ERK1,2 on homogenates of the entire 
hippocampus of Tg and Wt mice. The two typical bands at apparent molecular weights of 42 
(total-ERK2) and 44 (total-ERK1) kDa are present. Western blot analysis of actin, performed on 
the same gel, is shown for comparison. (H) Quantitative analysis of total ERK2 performed 
comparing the immunopositive band of total ERK2 with that of actin run on the same gel. The 
levels of total ERK2 in TgCRND8 hippocampus were not significantly different to those in Wt 
hippocampus (not significant, Student's t-test). Tg: n=7; Wt: n=7. 
 
Fig. 26 Activation of ERK in the hippocampus of Wt mice by cholinergic stimulation ex vivo. 
Immunohistochemical staining of phospho-ERK in slices of fresh mouse hippocampus of Wt 
mice in control conditions (Wt no drug) and after stimulation with CCh (100 µM, 15 min, Wt 
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CCh). (A, B) Activation of ERK studied by immunohistochemistry; A1, A2 and B1, B2 show 
enlarged photographs of framed areas in A and B, respectively. CCh-activated ERK in neurons 
of CA1 and DG (B1 and B2), but not of CA3 (B, arrow). Scale bars=250 µm A, B. A1–B2: 50 
µm. (C, D) Counts of phospho-ERK positive neurons in areas corresponding to the framed areas 
in A and B (each experimental group n=3). Counts of phospho-ERK positive neurons in the DG 
(C) and in CA1 (D). ** P<0.02 vs. respective No drug slices, Student's t-test. 
 
  
 
Fig. 27 Activation of ERK in the hippocampus of TgCRND8 mice by cholinergic stimulation 
ex vivo. (A) Immunohistochemical staining of phospho-ERK in slices of fresh mouse 
hippocampus of Tg mice after stimulation with CCh (100 µM, 15 min). Scale bar=50 µm. (B) 
Representative Western blot analysis of phospho-ERK1,2 on homogenates of the entire 
hippocampus of Tg and Wt mice. The two typical bands at apparent molecular weights of 42 
(phospho-ERK2) and 44 (phospho-ERK1) kDa are present. Phospho-ERK2 is more abundant 
than phospho-ERK1. Western blot analysis of actin, performed on the same gel, is shown for 
comparison. (C) Quantitative analysis of ERK activation in homogenates of hippocampi of Wt 
and Tg mice in control conditions (No drug) and after 100 µm CCh stimulation, performed 
comparing the immunopositive band of phospho-ERK2 with that of actin run on the same gel. 
Statistical analysis was performed by two-way ANOVA followed by Bonferroni post hoc test. 
Strain: F1,20=33.57, P=0.0014; * P<0.05, vs. Wt, Bonferroni post hoc test; Treatment: 
F1,20=23.32, P=0.0059, # P<0.05 vs. all other groups, Bonferroni post hoc test. Cholinergic 
stimulation by CCh activated ERK in both mouse strains (Strain and Treatment interaction: 
F1,18=6.36, P=6.36, not significant). ERK activation by CCh was highly significant in Wt 
hippocampus (+96%; Wt CCh vs. Wt No drug, # P<0.05 vs. all other groups, Bonferroni post 
hoc test), while it did not reach significance in Tg mouse hippocampus (+53%; Tg CCh vs. Tg 
No drug, not significant, Bonferroni post hoc test). Wt CCh: n=4; Wt No drug: n=7; Tg CCh: 
n=4; Tg No drug: n=7. 
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4.4 EFFECT OF PEC ON ACh RELEASE FROM THE CEREBRAL 
CORTEX AND CHOLINESTERASE ACTIVITY  
 
4.4.1 Determination of inhibitory doses of PEC on AChE and BuChE 
In order to measure the activity of AChE and BuChE, we used the colorimetric method 
first developed by Ellman et al. (1961). However, using this method, the measurements 
of BuChE activity ex vivo did not give reproducible and reliable results in the crude 
brain homogenate preparation. In such a tissue, indeed, BuChE activity is more than ten 
times lower than that of AChE. Such a low level of activity may give too little 
variations of the OD read at 412 nm, resulting in high variability of the determinations 
which may confound the results. For this reasons, in order to obtain reliable data on 
BuChE inhibition, BuChE activity was determined both using a modification of the 
Ellman method, by Dr. O. Lockridge (O. Lockridge, personal communication), in which 
Tween 20 was added to the homogenate (Li et al., 2000), and using a radiometric 
method (Thiermann et al., 2005). The radiometric method was also used to validate the 
results AChE activity obtained with the Ellman method. The enzymatic activities of 
AChE and BuChE in cerebral cortex homogenates of control rats are shown in Table 1. 
The results shown were obtained with the radiometric method, with the method of 
Ellman et al. (1961) for AChE activity, and with Lockridge's modification of Ellman's 
method for BuChE activity. It is noteworthy that the results obtained for AChE (Table 
1, first column) and BuChE (Table 1, second column) using the Ellman methods were 
comparable with those obtained with the radiometric methods. Furthermore, the 
different quantification methods show that the activity of BuChE in the cortex of control 
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rats is much lower than that of AChE, ranging between 5% (Lockridge's modification of 
Ellman) and 9% (radiometric method), of AChE activity (Table 1, third column). Fig. 
28 shows the inhibition of brain AChE activity 55–60 min after administration of the 
drugs, the time point corresponding to the peak increase in extracellular ACh levels 
found in the microdialysis experiments. The results obtained with Ellman method are 
shown in panel A. A statistically significant inhibition of AChE activity was found after 
rivastigmine (0.6 mg/kg,–40% vs saline, one way ANOVA and Newman–Keuls 
multiple comparison test, **P<0.001) and donepezil (1.0 mg/kg,–22% vs saline, one 
way ANOVA and Newman–Keuls multiple comparison test, *P<0.05). PEC (5.0 
mg/kg) administration was followed by a 5% inhibition of AChE activity, which was 
statistically not significant (one way ANOVA and Newman–Keuls multiple comparison 
test, P>0.05). Comparable results on AChE inhibition were obtained with the 
radiometric method, as shown in Fig. 28, panel B. Rivastigmine caused a 37% AChE 
inhibition (one way ANOVA and Newman–Keuls multiple comparison test, **P<0.02 
vs saline), a 26% inhibition was found after donepezil (one way ANOVA and 
Newman–Keuls multiple comparison test, *P<0.05 vs saline) while PEC decreased by a 
non significant 12% AChE activity (one way ANOVA and Newman–Keuls multiple 
comparison test , P>0.05).  
The determinations of BuChE activity were carried out using both a radiometric method 
with [3H]ACh as a substrate, and the Lockridge's modification of Ellman method. As 
shown in Fig. 29A, using the radiometric method, PEC administration resulted in a 
significant 39% inhibition of BuChE activity (one way ANOVA and Newman–Keuls 
multiple comparison test, **P<0.01 vs saline). Rivastigmine and donepezil inhibited 
BuChE activity by 18% and 8%, respectively (one way ANOVA and Newman–Keuls 
multiple comparison test, both not statistically different vs saline). As shown in Fig. 
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29B, using the Lockridge's modification of the Ellman colorimetric method, with 
butyrylthiocholine as the substrate, both PEC and rivastigmine caused a statistically 
significant 25% inhibition of BuChE activity (one way ANOVA and Newman–Keuls 
multiple comparison test, *P<0.01 vs saline), while donepezil induced a 10%, not 
significant, inhibition (one way ANOVA and Newman–Keuls multiple comparison test, 
P>0.05 vs saline).  
 
 
 
 
 
Table 1. AChE and BuChE activity in the cerebral cortex of control rats.  
Values are expressed as pmol substrate hydrolized per µg protein per min (mean ± S.E.M.). 
a AChE activity calculated with the method of Ellman.  
b BuChE activity calculated with the method of Ellman modified according to O. Lockridge.  
 
 
 
 
 
 
 
 
 
 
 AChE BuChE % 
Ellman Method 1.06 ± 0.1a 0.058 ± 0.004b 5.5 
Radiometric Method 0.97 ± 0.1 0.084 ± 0.008 9 
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Fig. 28. A: Inhibition of acetylcholinesterase activity in the cerebral cortex of the rat 60 min 
after drug administration, determined ex vivo with the method of Ellman et al. (1961). Drugs 
were administered i.p. The columns indicate the pmol of acetylthiocholine hydrolyzed per min 
per µg protein. Saline (i.p. injection of 2 ml/kg of saline solution; yellow bar, n=9); Donepezil, 1 
mg/kg (light blue bar, n=8); Rivastigmine, 0.6 mg/kg (pink bar, n=9); PEC, 5.0 mg/kg (orange 
bar, n=11). *P<0.05 and ***P<0.001 vs saline; AChE activity in the cerebral cortex of the rat 
60 min after drug administration, determined ex vivo with the radiometric method. The columns 
indicate the pmol of acetylthiocholine hydrolyzed per min per µg protein. Saline (i.p. injection 
of 2 ml/kg body weight of saline; yellow bar, n=6); Donepezil, 1 mg/kg (light blue bar, n=8); 
Rivastigmine, 0.6 mg/kg (pink bar, n=6); PEC, 5.0 mg/kg (orange bar, n=8). *P<0.05 and 
**P<0.02 vs saline; one-way ANOVA followed by Newman–Keuls multiple comparison test. 
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Fig. 29 A: Inhibition of BuChE activity in the rat cerebral cortex 60 min after drug 
administration, determined ex vivo with the radiometric method after the addition of a selective 
AChE inhibitor. The columns indicate the pmol of acetylthiocholine hydrolyzed per min per µg 
protein. Saline (i.p. injection 2 ml/kg body weight of saline; yellow bar, n=15); Donepezil, 1 
mg/kg (light blue bar, n=4); Rivastigmine, 0.6 mg/kg (pink bar, n=9); PEC, 5.0 mg/kg (orange 
bar, n=11). **P<0.01 vs saline; one-way ANOVA followed by Newman–Keuls multiple 
comparison test. B: Inhibition ofBuChE activity in the rat cerebral cortex 60 min after drug 
administration, determined ex vivo with the Lockridge's modification of the Ellman method. The 
columns indicate the pmol of butyrylthiocholine hydrolyzed per min per µg protein. Saline (i.p. 
injection 2 ml/kg body weight of saline; yellow bar, n=6); Donepezil, 1 mg/kg (light blue bar, 
n=3); Rivastigmine, 0.6 mg/kg (pink bar, n=8); PEC, 5.0 mg/kg (orange bar, n=8). **P<0.01 vs 
saline; one-way ANOVA followed by Newman–Keuls multiple comparison test. Please note the 
different scale of the y axes. 
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4.4.2 Effect of PEC on cortical ACh extracellular levels 
The extracellular level of ACh in the rat cerebral cortex before the administration of the 
cholinesterase inhibitors was 2.90 ± 0.28 fmol/µl (n=28). The value is similar to those 
previously reported (Scali et al., 1997). In saline-treated rats, ACh extracellular level 
remained practically constant for the entire duration of the experiment (±10% vs basal 
values, variation not significant, Fig. 30). The time course of the increase in ACh 
release from the cortex of rats after drug administration is shown in Fig. 30A. Both 
donepezil (1.0 mg/kg) and rivastigmine (0.6 mg/kg) brought about a 4-fold increase in 
ACh levels within 40 min after administration. PEC (5 mg/kg) administration was 
followed by a 2.5 fold increase in ACh release within 40 min which was slightly smaller 
than those evoked by donepezil or rivastigmine. The increase in ACh extracellular 
levels brought about by the three drugs faded gradually within 2 h. Quantitative analysis 
of the effect of the three drugs in comparison to saline was performed by calculating the 
areas under the curve between 100 and 200 min after treatment (shown in Fig. 30B). 
The areas under the curve after donepezil and rivastigmine administration were about 3 
times larger than that of the saline-treated rats. The area under the curve after PEC 
administration showed a 2-fold increase over the saline-treated rats. Statistical analysis 
performed on the areas under the curves indicated that the three treatments increased 
significantly cortical ACh extracellular levels, in comparison to saline-treated rats (one 
way ANOVA and Newman–Keuls multiple comparison test; *P<0.05 vs saline). 
However, no significant difference was found among the increases evoked by the three 
drugs (one way ANOVA and Newman–Keuls multiple comparison test; n.s.). 
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Fig. 30 Effect of cholinesterase inhibition on rat cortical extracellular levels of ACh. A: Time 
course of the effect of donepezil, rivastigmine or PEC administration on ACh levels in the 
dialysate. The drugs were administered i.p. after collecting four basal samples (administration 
time shown by the arrow). ACh release is expressed as percent changes over the mean of all 
pre-drug determinations (basal levels). Control rats received i.p. injection of 2 ml/kg of saline 
solution (open square; n=6); Donepezil, 1 mg/kg (open circle; n=7); Rivastigmine, 0.6 mg/kg 
(black triangle; n=7); PEC, 5 mg/kg (black square; n=6). B: Areas under the curve were 
calculated between time 100 min and time 200 min. *P<0.05 vs saline; one way ANOVA 
followed by Newman-Keuls multiple comparison test. 
 
 
 
4.4.3 Determination of cholinesterase inhibitors concentrations in the 
brain 
The concentrations of two of the three cholinesterase inhibitors (donepezil and 
rivastigmine) in the brain are shown in Table 2. At the time point at which a peak effect 
of ACh release was found (55-60 min after drug administration) the concentration of 
donepezil in the rat brain was 177 nM while that of rivastigmine amounted to 14 nM. 
Due to the mechanism of AChE inhibition by rivastigmine (carbamate interaction with 
the catalytic centre) the concentration of the catalytically generated metabolite NAP 
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226-90 was added to that of native compound. The total concentration of the two drugs 
adds up to 72 mM.  
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.  Concentrations of the cholinesterase inhibitors in the rat cortex  
a including the rivastigmine metabolite NAP 226-90 
 
 
4.5 EFFECT OF NP-0361 AND NP-0336 ON ACh RELEASE AND 
CHOLINESTERASE ACTIVITY IN THE CEREBRAL CORTEX OF 
YOUNG RATS  
 
4.5.1 Rotarod test 
As shown in Figure 31A and B, treatment with NP-0361 at 20 mg/kg or NP-0336 at 80 
mg/kg significantly impaired the rat’s ability to perform on a rotarod test. Both drugs at 
the lower doses tested showed a non significant tendency to decrease the rat ability to 
balance on the rotarod test. The vehicle used (N-methyl-2pyrrolidone 5%, Solutol HS15 
Drug Dose 
mg/kg i.p. 
Time after 
drug 
N° rats Concentration 
nM ± S.D. 
Donepezil 1.0 60 min 3 177.1 ± 40.6 
Rivastigmine 
NAP 226-90 
Sum of Riva+NAP 
0.6 60 min 4 14.1 ± 21.9 
58.5 ± 11.9 
72a 
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30%, Saline) inhibited motor activity in the rotarod test in 3/7 rats tested (effect not 
significant). 
 
4.5.2 Exploratory behaviour 
The experiments on the effect of the two drugs on exploratory activity were started at 
the lower dose of the two drugs, both dissolved in MP/solutol/saline. The results are 
shown in Figure 32A. It is evident that the vehicle MP/solutol/Saline used to dissolve 
the drugs (10 ml/kg) has an impairing effect on the spontaneous motor activity of the 
animals, significantly inhibiting the exploration of the arena in comparison to saline 
treated rats. We therefore decided to use a different vehicle to dissolve the two drugs 
(Tween 80 2% diluted in Methylcellulose 0.5%). The results obtained is shown in 
Figure 32B. The new vehicle used significantly decreased motor activity in comparison 
to saline treated rats, although by a lesser extent than MP/solutol/saline. Treatment with 
NP-0336 at 40 mg/kg did not vary motor activity in comparison to vehicle treated rats 
(MC 0.5%/Tween 80 2%). On the other hand, NP-0361 at the doe of 10 mg/kg further 
decreased rat motor activity in the arena (P<0.001 vs vehicle treated rats). 
Following these results we explored the possibility to use DMSO as a vehicle to 
dissolve the two drugs for the microdialysis experiments. Since the two drugs are both 
very insoluble, we decided to dissolve them in pure DMSO in order to inject small 
quantities of the pure solvent. The effect of DMSO on the rat behaviour was defined in 
the open field arena test. Indeed, administration of DMSO (400 µl/kg) did not modify 
the rat behaviour in the spontaneous rat mobility test, as shown in Figure 33. Therefore 
we decided to use DMSO as the solvent to dissolve the drugs for the microdialysis 
experiments.  
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Fig. 31 Effect of treatment with NP-0361 ad NP-0336 on rotarod test. (A) treatment with 10 
mg/kg NP-0361 (purple diamonds) does not show a significant tendency to decrease the rat’s 
ability to balance on the rotarod test, while treatment with 20 mg/kg NP-0361 (blue triangles) 
shows a significantly tendency to impair the rat’s ability to balance on the rotarod test versus 
saline (yellow squares) (Krusal-Wallis and Dunn’s post comparison test, *P<0.05), treatment 
with vehicle (yellow triangles) inhibits motor activity in the rotarod test in 3/7 rats tested (not 
significant). (B) treatment with NP-0336 at 40 mg/kg (grey diamonds) does not show a 
significant tendency to decrease the rat’s ability to balance on the rotarod test, while treatment 
with NP-0336 at 80 mg/kg (red triangles) shows a significant tendency to impair the rat’s ability 
to balance on the rotarod test (yellow squares) (Krusal-Wallis and Dunn’s post comparison test, 
*P<0.001 vs saline; #P<0.05 vs vehicle)Treatment with vehicle (yellow triangles) inhibits motor 
activity in the rotarod test in 3/7 rats tested (not significant). 
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Fig. 32 Effect of treatment with NP-0336 and NP-0361 on spontaneous rat mobility in an open 
field arena. (A) treatment with the lowest doses of either drug (NP-0361 at 10 mg/kg, purple 
bar, and NP-0336 at 40 mg/kg, grey bar) dissolved in the vehicle MP/solutol/saline (yellow bar) 
has an impairing effect on the spontaneous motor activity of the animals as compared to saline-
treated rats (light yellow bar) (one way ANOVA, F3,16 = 44.22, P<0.0001, #<0.01 versus all 
other groups, Newman-Keuls post hoc test). (B) treatment with the lowest doses of either drug 
(NP-0361 at 10 mg/kg, purple bar, and NP-0336 at 40 mg/kg, grey bar) dissolved in the vehicle 
Tween 80 2%diluted in Methylcellulose 0.5% (yellow bar) has an impairing effect on the 
spontaneous motor activity of the animals as compared to saline-treated rats (light yellow bar), 
although by a lesser extent than MP/solutol/saline (one way ANOVA, F3,14 = 20.80, P<0.0001, 
#P<0.01 vs all other groups, *P<0.05 vs vehicle and NP-0336, Newman-Keuls post hoc test). 
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Fig. 33 Effect of treatment with DMSO on spontaneous rat mobility in an open field arena. 
Administration of DMSO (400ml/kg) did not modify the rat behaviour in the spontaneous rat 
mobility test. 
 
 
4.5.3 Determination of inhibitory doses of NP-0361 and NP-0336 on 
AChE and BuChE activity 
The effect of two novel compounds, NP-0361 and NP-0336, was tested ex vivo on 
AChE and BuChE activity in the cerebral cortex of the young rat. Initially, a dose of 10 
mg/kg of NP-0361 and 40 mg/kg of NP-0336 was tested on 6 rats in order to verify 
whether inhibition of AChE and/or BuChE activity could be detected. 
As shown in Fig. 34 and 35, at the doses of 10 mg/kg of NP-0361 and 40 mg/kg of NP-
0336, no significant inhibition of AChE or BuChE activity was found. Therefore, we 
decided to increase the dose of the two drugs to 20 mg/kg for NP-0361 and 80 mg/kg 
for NP-0 d336. AChE activity in rats treated with vehicle used to dissolve the two drugs 
did not significantly differ from enzyme activity in naïve rats (vehicle alone -12% vs 
naïve, P=0.3637, two-tailed Student’s t test).  
The results obtained after treatment with NP-0361 at the doses of 10 and 20 mg on 
AChE activity are shown in Fig. 34A. A statistically significant inhibition of AChE 
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activity was found after administration of NP-0361 20 mg/kg (-39% vs vehicle; one way 
ANOVA: F2,16= 6.72; P<0.01, and Newman-Keuls post hoc test, **P<0.01 vs all others 
group). No inhibition of AChE activity was found after treatment with NP-0361 10 
mg/kg (+5% vs vehicle, not significant). 
Fig. 34B shows the results obtained after administration of NP-0336 at the doses of 40 
and 80 mg/kg on AChE activity. NP-0336 80 mg/kg caused an inhibition of 22% of 
AChE activity, not statistically different from vehicle, while no effect was observed 
after treatment with 40 mg/kg NP-0336 (+5% vs vehicle, not statistically different, one-
way ANOVA: F2,16= 2.212; P=0.1419).  
The effect of rivastigmine at the dose of 1.0 mg/kg, as positive control, is shown in 
panel C. As expected, we found a statistically significant inhibition of AChE activity 
after rivastigmine administration (-50% vs vehicle, **P<0.01, two-tailed Student’s t 
test). Fig. 35 shows that in rats treated with vehicle alone BuChE activity did not 
significantly differ from enzyme activity in naïve rats (vehicle alone -4% vs naïve; 
P=0.5903, two-tailed Student’s t test). 
The results obtained after treatment with NP-0361 and NP-0336 on BuChE activity are 
shown in Fig. 35. The results obtained after treatment with NP-0361 at the doses of 10 
and 20 mg/kg are shown in panel A. No effect on BuChE activity was observed with 
NP-0361 10 mg/kg (+13% vs vehicle, not significant), whereas an inhibition of 13.6% 
(not statistically significant) was observed with NP-0361 20 mg/kg (one way ANOVA, 
F2.15= 9.239, P<0.05, and Newman-Keuls post hoc test, +P<0.05). The results obtained 
after treatment with NP-0336 at the doses of 40 and 80 mg/kg are reported in panel B. 
No effect was observed with 40 mg/kg NP-0336 (+10%vs vehicle, not statistically 
significant), while treatment with 80 mg/kg NP-0336 caused an inhibition of 15% on 
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BuChE activity, statistically significant, both versus vehicle and 40 mg/kg NP-0336 
(one way ANOVA F2,15=9.239, P<0.05, and Newman-Keuls post hoc test, +P<0.05). 
The effect of rivastigmine at the dose of 1.0 mg/kg on BuChE activity is shown in panel 
C. We found that rivastigmine at this dose caused a significant 15% inhibition of 
BuChE activity (P<0.05, two-tailed Student’s t test). 
 
4.5.4 Effect of NP-0361 and NP-0336 on cortical ACh extracellular 
levels 
The extracellular levels of ACh before the administration of cholinesterase inhibitors 
were 2.82 ± 0.27 fmol/µl (n=25). This basal value is similar to that reported in previous 
papers from our laboratory (Scali et al., 1997).  
The doses of the cholinesterase inhibitors (80 mg/kg NP-0336 and 20 mg/kg NP-0361) 
chosen to study variations of cortical ACh extracellular levels by microdialysis were 
selected on the basis of AChE and BuChE inhibition described above.  
The results are shown in fig 36A. In rats treated with vehicle alone ACh extracellular 
levels remained practically constant throughout the experiment (4 h, yellow line). Both 
NP-0336 at the dose of 80 mg/kg (red line) and NP-0361 at the dose of 20 mg/kg (blue 
line) brought about a significant increase of cortical ACh extracellular levels. The effect 
of 80 mg/kg NP-0336 (maximum +73% vs basal) was observed between 120 and 140 
min after administration. The effect disappeared gradually and levels returned to basal 
within 1 h. Rivastigmine at the dose of 1.0 mg/kg (green line) increased ACh 
extracellular levels by about 600% with a maximum 80 min after administration and a 
gradual decrease of the effect to basal levels within the following 2 h. Significativity of 
the effect was defined using the areas under the curve (AUC) at the maximum peak 
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effect (between 100 and 160 min after administration of NP-0.361, Figure 36C and 
between 160 and 220 min after administration of NP-0336, Figure 36B). The 
corresponding AUC were also calculated for the control groups, and used as controls in 
the statistical analysis. The AUC of rivastigmine was calculated between 100 and 160 
min (Figure 36D). Comparing the AUCs, the effect of the two drugs on ACh 
extracellular levels was statistically different from vehicle treated rats and controls (NP-
0336: *P< 0.05 vs controls; NP-0361 **P< 0.02 vs controls, Student’s t test). 
Furthermore, the effect of NP-0336 was similar to that of NP-0361 (not statistically 
different with the Student’s t test, P= 0.95). However, both drugs evoked a much 
smaller increase of ACh extracellular levels than that of rivastigmine (AUC of the two 
drugs P< 0.001 vs rivastigmine, one way ANOVA and Newman Keuls multiple 
comparison test).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 34 Acetylcholinesterase (AChE) activity in young rats. Panel A: treatment with 10 mg/kg 
NP-0361 (purple bar) does not significantly inhibit AChE activity versus vehicle (yellow bar), 
while treatment with 20 mg/kg NP-0361 (blue bar) causes an inhibition of 39% on AChE 
0.000
0.005
0.010
0.015
0.020
0.025
0.030
0.035
0.040
0.045
**
A
C
hE
ac
tiv
ity
(p
m
ol
/µ
g 
pr
ot
ei
n
x 
m
in
)
A
C
hE
ac
tiv
ity
(p
m
ol
/µ
g 
pr
ot
ei
n
x 
m
in
)
0.000
0.005
0.010
0.015
0.020
0.025
0.030
0.035
0.040
0.045
A
C
hE
ac
tiv
ity
(p
m
ol
/µ
g 
pr
ot
ei
n
x 
m
in
)
A
C
hE
ac
tiv
ity
(p
m
ol
/µ
g 
pr
ot
ei
n
x 
m
in
)
A
C
hE
ac
tiv
ity
(p
m
ol
/µ
g 
pr
ot
ei
n
x 
m
in
)
0.00
0.01
0.02
0.03
0.04
**
A
C
hE
ac
tiv
ity
(p
m
ol
/µ
g 
pr
ot
ei
n
x 
m
in
)
A B 
C 
 131
activity, statistically significant versus vehicle and NP-0361 (one way ANOVA, F2,16 = 6.725, 
P<0.05, and Newman-Keuls post hoc test, **P<0.01). Panel B: treatment with 40 mg/kg NP-
0336 (grey bar) and with 80 mg/kg NP-336 (red bar) does not significantly inhibit AChE 
activity versus vehicle (yellow bar). Panel C: treatment with 1.0 mg/kg rivastigmine (green bar) 
causes an inhibition of 50% on AChE activity, statistically significant versus vehicle (yellow 
bar).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 35 Butirylcholinesterase (BuChE) activity in young rats. Panel A: treatment  with 10 
mg/kg NP-0361 (purple bar) and with 20 mg/kg NP-0361 (blue bar), does not change BuChE 
activity compared to vehicle(yellow bar). Panel B: treatment with 40 mg/kg NP-0336 (grey bar) 
does not change BuChE activity while treatment with 80 mg/kg NP-0336 (red bar) causes an 
inhibition of 15% on BuChE activity, statistically significant versus vehicle (yellow bar) and 40 
mg/kg NP-0336 (one way ANOVA, F 2,15 = 9.239, P<0.05, and Newman-Keuls post hoc test, 
*P<0.05). Panel C: treatment with 1.0 mg/kg rivastigmine (green bar) causes an inhibition of 
15% on BuChE activity, statistically significant versus vehicle (yellow bar).  
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Fig. 36 Effect of AChEI or BuChEI administration on cortical ACh release. (A) treatment with 
vehicle does not change ACh extracellular levels throughout the experiment (4h, yellow line); 
treatment with 80 mg/kg NP-0336 (red line) and 20 mg/kg NP-0361 (blue line), causes a 
significant increase of ACh extracellular levels, of 80% and 73% versus basal respectively.; 
treatment with 1.0 mg/kg rivastigmine (green line) causes a significant increase of ACh 
extracellular levels. ACh release is expressed as percent changes over the mean of all pre-drug 
determinations (basal levels). . (B) area under the curve (AUC) at the maximum peak effect of 
80 mg/kg NP-0336 (red bar), calculated between 160 and 220 min, *P<0.05 versus vehicle 
(yellow bar), (Student’s t-test). (C) AUC at the maximum peak effect of 20 mg/kg NP-0361 
(blue bar), calculated between 100 and 160 min; **P<0.02, versus vehicle (yellow bar) 
(Student’s t-test). (D) AUC) at the maximum peak effect of 1.0 mg/kg rivastigmine (green bar), 
calculated between 100 and 160 min; ***P<0.005, versus vehicle (yellow bar) (Student’s t-
test).The effect of both NP-0361 and NP-0336 on the increase of ACh extracellular levels is 
much smaller than the effect of rivastigmine. 
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5. DISCUSSION 
 
Aim of the research was to valuate the modification of different intracellular 
transduction pathways and extracellular intercommunicating proteins as well as 
activation/deactivation of microglia and astrocytes in animal models of 
neuroinflammation, normal aging and AD-related neurodegeneration that lead to 
memory deficits. To this aim different animal models were used. In particular, the 
molecular mechanisms involved in neuron-glia intercommunication during 
inflammation in the hippocampus were studied using the model of LPS-induced 
neuroinflammation in the rat. The differential activation of MAPKs intracellular 
transduction pathways as well as the cellular modifications in the hippocampus during 
aging and AD related neurodegeneration were studied in normal aged rats and in 
TgCRND8 transgenic mice, respectively. In the last part of this research it was 
evaluated the efficacy of treatment with novel compounds on differential inhibition of 
AChE/BuChE activity in the brain and on cortical ACh release. These latter 
experiments were aimed at obtaining a proof of concept for the development of these 
novel compounds as possible drugs for the treatment of memory impairments in 
neurodegenerative diseases. 
 
5.1 MODEL OF LPS-INDUCED NEUROINFLAMMATION  
 
The animal model of chronic neuroinflammation used in this thesis is produced by a 
slow long-term infusion of the pro-inflammogen LPS. LPS selectively binds to a signal-
transduction receptor complex (CD14/Toll-like receptor 4) that is expressed only by 
microglia (Lehnardt et al., 2003). By activating microglia through LPS infusion, young 
rats can show pathological, biochemical and behavioral changes that are similar to those 
Commento [n1]:  
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observed in several neurodegenerative diseases associated with neuroinflammation. 
These include impaired spatial memory, reduction of NMDA-R1 receptors, astrocytosis, 
elevated cytokines and proinflammatory transcription factors (Hauss-Wegrzyniak et al., 
1998, 2000; Rosi et al., 2004, 2005, 2006). The results obtained in this thesis using this 
model demonstrate an important regulatory intercommunication that involves glutamate 
and neuronal NMDA receptor-dependent influx of Ca2+ in the control of the release of 
CD200, a molecular messenger that maintains the response of microglia to ongoing 
brain inflammation.  
Because chronic neuroinflammation results in increased levels of glutamate, it is 
possible that a significant proportion of NMDA channels may thus be relieved from the 
Mg2+ block by the high glutamate, thus allowing elevated Ca2+ entry into postsynaptic 
neurons (Brown and Bal-Price, 2003). Therefore, further increases in glutamatergic 
activity induced by behavior could lead to excessive influx of Ca2+ ions (Albin and 
Greenamyre, 1992).  
In these experiments we have shown that chronic infusion of LPS into the 4th ventricle 
increased the number of activated microglia in the hippocampus, mainly within the DG 
and CA3 regions, in accordance to our previous report (Rosi et al, 2006) in which we 
also showed that activation of microglia within the hippocampus can be significantly 
reduced by memantine, a low to moderate-affinity non competitive NMDA receptor 
antagonist (Rosi et al, 2006). NMDA receptors have an important physiological role in 
learning and memory, but receptor overactivation owing to increased glutamate release 
leads to excessive Ca2+ entry, triggering neuronal death, a phenomenon termed 
'excitotoxicity'. Memantine is postulated to exert its therapeutic effect through its action 
as a low to moderate affinity uncompetitive (open-channel) NMDA receptor antagonist 
which binds preferentially to the NMDA receptor-operated cation channels, (Ferris SH. 
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Evaluation of memantine for the treatment of Alzheimer's disease. Expert Opin 
Pharmacother. 2003 Dec;4(12):2305-13), thus blocking pathological, but not 
physiological, activation of the NMDA receptor. The current study extended the 
discovery by Rosi et al. (2006) that showed that blockade of the NMDA receptor by 
memantine can reduce microglia activation even if the inflammatory processes were 
fully initiated prior to the beginning of drug therapy. This finding is consistent with the 
hypothesis that the maintenance of microglial activation in the presence of an 
inflammogen requires continuing activation of NMDA receptors. Thus, because of its 
unique biophysical and pharmacological properties, memantine, given at low doses, can 
selectively block the pathological influx of Ca2+ through NMDA receptors without 
affecting the voltage-dependence of NMDA receptor transmission, which is critical for 
learning and memory (Rogawski and Wenk, 2003). In addition, it has been 
demonstrated that during LPS infusions elevated levels of glutamate activate 
phospholipase A2 which increases the release of arachidonic acid from neurons and thus 
the formation of prostaglandins that act on microglia to augment a vicious cycle of cell 
inflammation (Lee et al., 2004). By restoring normal Ca2+ entry through the NMDA 
receptor channels, memantine also prevents the release of arachidonic acid and the 
consequent elevation of prostaglandins, resulting in lowered activation of microglial 
cells.  
The results of the current study lead us to hypothesize that the following series of events 
are set in motion under the conditions of a pro-inflammatory environment that is 
initiated by the slow long term infusion of LPS: increased release of cytokines by 
resident microglia that express the TLR4/CD14 receptor complex (Quan et al., 1994); 
cytokines in turn induce the production of other proinflammatory mediators including 
prostaglandins (Katsuura et al., 1989); prostaglandins induce the release of glutamate by 
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astrocytes (Bezzi et al., 1998); increased extracellular levels of glutamate activate its 
receptors leading to the unblocking of the NMDA receptor channel, thus allowing the 
entry of Ca2+ ions into neurons with increased synaptic activity (Viviani et al., 2003).  
It has been demonstrated that chronic neuroinflammation significantly increases the 
behaviourally-induced expression of the immediately early gene Arc (Rosi et al., 2005) 
in hippocampal cell fields containing the highest numbers of activated microglia 
induced by LPS infusion (Rosi et al., 2005). Given that Arc mRNA transcription is 
induced by NMDA receptor activation (Steward and Worley, 2001) and Ca2+-mediated 
activation of cAMP (Waltereit et al., 2001), it was speculated that the overexpression of 
Arc was due to excess Ca2+ influx through postsynaptic NMDA receptors (Rosi et al., 
2005). Furthermore, this disruption in glutamate-dependent Ca2+ regulation is associated 
with impaired learning and memory abilities (Rosi et al., 2006). NMDA receptor current 
is also potentiated by increased levels of arachidonic acid that also characterize the pro-
inflammatory environment (Miller et a., 1992). In the current study, the elevated entry 
of Ca2+ ions, as confirmed by increased cytoplasmic levels of immunoreactive 
calbindin, initiated a cascade of molecular processes, possibly involving activation of a 
mitogen-activated protein kinase (MAPK) signaling pathway (Haddad, 2005), that leads 
to reduced expression of CD200 (Hoek et al., 2000; Lyons et al., 2007; Stamenkovic et 
al., 1991; Frank et al., 2006). CD200 is a membrane glycoprotein, expressed by 
neurons, that binds to a receptor expressed by microglia. The intercommunication 
between neurons and microglia through CD200 binding to its microglia receptor is 
believed to maintain microglia in a quiescent state (Hoek et al., 2000; Lyons et al., 
2007; Stamenkovic et al., 1991; Frank et al., 2006). 
Indeed we have demonstrated in these experiments that chronic LPS infusion 
significantly reduced the number of CD200 positive cells in the CA3 region of the 
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hippocampus. We speculate that the decrease of CD200 may create a permissive 
environment which will last not only during active inflammation, but also after the 
levels of LPS have decreased, thus permitting persistent activation of microglia, as 
evidenced in the 8-weeks rats that presented OX-6 immunoreactive microglia even after 
the end of LPS treatment..  
The fact that memantine administration restored CD200 expression to normal levels 
suggests that the increased influx of Ca2+ ions through open NMDA channels is 
necessary for maintenance of a pro-inflammatory environment. Consistent with this 
hypothesis, we found that the reduced Ca2+ ions entry into CA3 neurons in memantine-
treated rats infused with LPS was associated with reduced cytoplasmic calbindin 
immunoreactivity. Taken together, our results indicate that in the presence of 
memantine, neurons are able to produce and release CD200 in order to communicate 
with microglia to reduce its expression of MHCII and become quiescent. Consistent 
with our hypothesis, a recent report demonstrated that enhanced expression of CD200 in 
an animal model of experimental autoimmune encephalomyelitis is associated with 
neuroprotection from LPS-induced microglia-mediated toxicity, while treatment with 
anti-CD200 antibodies increase neurotoxicity (Chitnis et al., 2007).   
HMGB1 is a non-histone DNA-binding protein that has a pro-inflammatory cytokine-
like function that may influence the activation of microglia following injury or insult 
(Kim et al., 2006). It has been demonstrated that HMGB1 levels are low in resting glia 
but are increased in the brains of patients with Alzheimer’s disease (Takata et al., 2004). 
Extracellular HMGB1 has also been described as a mediator of lipopolysaccharide 
(LPS) toxicity (Ulloa & Messmer, 2006). These experiments demonstrate that 
hippocampal HMGB1 expression did not differ across groups when examined by 
immunofluorescence and western blot analyses. As reported by others, the protein was 
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expressed in the nucleus of hippocampal neurons within the CA3 regions (Lo Coco et 
al., 2007). HMGB1 can be released by neurons undergoing necrosis and retained in the 
nucleus by cells undergoing apoptosis (Scaffidi at al., 2002). Taken together with the 
current findings, the long term, low dose infusion of LPS or low dose administration of 
memantine, does not induce necrosis or apoptosis, a conclusion that is consistent with 
our previous reports (Rosi et al., 2005, 2006), thus demonstrating that this protein is not 
involved in LPS-induced neuroinflammation. 
Our results offer a novel molecular mechanism to explain how inflammation can disturb 
the intercommunication between neurons and glia.  
Which comes first in the process of reduction of neuroinflammation, the signal from 
neurons or the signal from microglia? Our results are consistent with the hypothesis that 
under resting conditions, the neuron continually informs the resident microglia that 
activation is not necessary. This communication ceases when the neuron experiences an 
injury that leads to the activation of the surrounding microglia. Many neurodegenerative 
diseases that involve diffuse brain inflammation occur in aged humans and the number 
of activated microglia increase with aging. A decline in CD200 mRNA levels with 
aging may underlie these changes (Frank et al., 2006; Lyons et al., 2007). Therefore, 
therapeutically relevant doses of memantine delivered at any stage in the progression of 
age-associated neuroinflammation-influenced diseases may confer neuroprotection by 
partially restoring normal communication between neurons and microglia.  
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5.2 CELLULAR CHANGES IN AGED RATS COMPARED TO 
YOUNG RATS. 
Since LPS-induced neuroinflammation is a model that reproduces a condition present in 
patients with neurodegenerative disorders, such as AD, we arose the question about the 
possible differences on inflammatory markers activation in old rats compared to young 
rats. In order to verify the activation status of neuroinflammatory markers, activated 
microglia, astrocytes and iNOS were studied in old and young rats.  
Consistent with the results of the LPS–induced neuroinflammation model, in the 
hippocampus of  old rats, a natural model of neuroinflammation, we found an increase 
of activated microglial cells in comparison to the same brain region of young rats. As 
already reported for the LPS-induced neuroinflammation model, the activation of 
microglial cells was mainly observed in the CA1 and the hilus of the dentate gyrus of 
the hippocampus. These results are consistent with the hypothesis that there are aging-
related neuronal changes in the brain. Several studies have reported significant age-
related changes in microglial expression of MHC class II antigens in rats (Ogura et al., 
1994; Perry et al., 1993), and changes in microglial morphology (Conde et al., 2005; 
Streit et al., 2005).  
The reasons that determine the regional gradient of microglia activation are actually 
unknown. However, it is interesting to consider the topographic overlap of the 
architecture of hippocampal vascularisation and distribution of activated microglial cells 
observed in aged hippocampus. The hilar and CA3 region displayed a higher capillary 
density compared to CA1 (Cavaglia et al., 2001) Thus, it is possible to conseive the 
existence of aged-related structural and functional alterations in the blood-brain barrier 
(BBB) leading to an increase in permeability, with serum leakage and leukocyte 
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infiltration into the neuronal parenchyma, all supported by the increased expression of 
the mRNA coding for interferon-gamma, synthesized by T-cells observed in aged rats 
hippocampus (Gavilàn et al., 2007). 
Other studies report also an aged-related increment of astrogliosis (Duffy et al., 1980; 
Anderson et al., 1983). On the contrary our results show a decrease of astrocytes in the 
regions of the hippocampus (CA3, CA1 and DG) of old rats. Furthermore, hippocampal 
astrocytes of old rats show an apparent morphology, as stained using GFAP antibodies, 
that is different from that seen in young rat hippocampus. Indeed, old rats astrocytes 
have smaller cell bodies and shorter and thinner branchings, compared to young rats 
astrocytes that, on the contrary, have stellate morphology, hyperthrophic body and  
dense, long arborizations departing from cell bodies. These results are at variance with 
what one might be expecting, since this latter phenotype is usually typical of activated 
astrocytes. It is also evident from the images taken that a dysregulation not only of 
astrocytes morphology, but also of their distribution in the hippocampal parenkyma is 
present in aged rats. Contrary to the original belief that astrocytes mainly represent 
support elements in the CNS, (Peuchen, S., Bolanos, J.P., Heales Jr., S., Almeida, A., 
Duchen, M.R., Clark, J.B., 1997.. Prog. Neurobiol.52, 261–281.), in recent years it has 
started to emerge the crucial roles that astrrrocytes may play in maintaining normal 
brain physiology, such as production of neurotrophic factors, conservation of glycogen 
as energy reserve, regulation of extracellular ionic composition, and uptake and 
degradation of neurotransmitters (Takuma, K., Baba, A., Matsuda, T., 2004.. Prog. 
Neurobiol. 72, 111–127.). It has recently been demonstrated (Lü  et al, Neurochemistry 
International 52 (2008) 282–289) that an oxidative stress leads to  inadequate peroxide 
detoxification by astrocytes in colture. This is followed by astrocytes death, and 
possibly by damage to the neurons. These effect may play a role in aging of the central 
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nervous system, since the production of reactive oxygen species increases with age. 
Thus, the results obtained in the present work may be explained hypothesizing that in 
aged rat hippocampus astrocytes decrease in number because of increased oxidative 
stress thus loosing  their normal trophic activity towards hippocampal pyramidal 
neurons and granule cells. However, these findings need to be further investigated to 
better understand the mechanisms underlying the decrease in astrocytes present in the 
hippocampus of aged rats and the functional meaning of the morphological changes.  
Finally, we studied the expression of iNOS, another inflammatory marker, commonly 
overexpressed in different cell types during inflammation. Our results show an 
increased iNOS expression in the CA3 of the hippocampus of old rats in comparison to 
young rats, mainly in pyramidal neurons. These results are consistent with published 
studies where an increased iNOS expression was mainly found in the CA3 of the 
hippocampus, the same area where there is the highest activation of microglial cells 
(Gavilàn et al., 2007).  
In conclusion we can say that age-related differences in the structure of the BBB, in the 
changes of inflammatory markers, together with other genetics and environmental 
factors, could constitute summatory risk factors of multifactorial disease such as AD, 
for which aging represents the most important risk factor.  
 
5.2.1 The ERK1/2, p38MAPK, and JNK pathways 
Three main mammalian MAPK subfamilies have been described: ERK1,2, JNK, and 
p38MAPK kinase (Pearson et al., 2001). MAPKs are implicated in various cellular 
processes (Raman et al., 2007), and dysfunction of specific MAPKs is associated with 
diseases such as cancer and immunological disorders. In the nervous system, as well as 
in other tissues, activation of JNK and p38MAPK has often been correlated with death 
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in various cell types, including neurons (Xia et al., 1995; Kummer et al., 1997; 
Willaime- Morawek et al., 2003), while it is widely accepted that activation of neuronal 
ERK1,2 has protective effects and leads to memory formation (Sweatt, 2001, 2004). 
Nevertheless, the genuine in vivo physiological functions of MAPK still remain to be 
fully unraveled. We have demonstrated that the three main MAPK pathways are 
differentially activated in cells of the hippocampus of old rats in comparison to young 
rats and in the hippocampus of transgenic TgCRND8 mice in comparison to Wt 
littermates. Indeed we found that the ERK pathway, both in basal and stimulated 
conditions is less activated in the hippocampus of old rats and of TgCRND8 mice in 
comparison to young rats and Wt littermates, respectively. On the contrary the 
p38MAPK pathway is more activated in the hippocampus of old rats and of TgCRND8 
mice in comparison to young rats and Wt littermates, respectively. The third MAPK 
under investigation, the JNK pathway was highly activated in the surroundings of the 
amyloid plaques in the hippocampus of TgCRND8 mice, but was not activated in the 
hippocampus of aged rats. 
 
5.3 DIFFERENTIAL ACTIVATION OF MAPK PATHWAYS IN 
THE HIPPOCAMPUS OF AGED RATS.  
Old rats showed high levels of phospho-p38MAPK in neurons of the entire 
hippocampus. The distribution of activated p38MPAK is mainly in pyramidal neurons 
of CA3, CA1 and DG. On the contrary, in our experiments no differences on JNK 
activation in the hippocampus of old animals compared to young animals were 
observed, in contrast with other results reported in the literature in which it was found 
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an 3.5 fold increment of phospho-JNK in old animals compared to young animals 
(Yousin, 2001). 
As known, JNKs and p38MAPKs are collectively termed the stress-activated protein 
kinases (SAPKs) because they are activated by similar stress-related stimuli (Karin, 
1995; Paul et al., 1997). Activation of SAPKs has been associated wit stress responses 
that promote either cell recovery and cell survival or apoptotic death after cellular 
damage (Paul, 1997; Ono and Han, 2000). Studies have demonstrated that activation of 
microglia by adenovirus vector induces activation of p38MAPK pathways (Narayan and 
Fan Fan, 2002).Thus, in our study, activation of microglia by normal aging, leads to 
activation of p38MAPK. 
Aged rats have memory impairment in a step down inhibitory avoidance test, as 
demonstrated by the significantly shorter time spent to step down from the platform 
during the recall test, in comparison to young animals. Activation of the ERK pathway 
was studied 10 min after the acquisition of the step down inhibitory avoidance test in 
old and young rats. Our results show no activation of ERK in the hippocampus of old 
rats 10 min after the acquisition, in comparison with young rats.  
The components of the Extracellular signal Regulated Kinases-1 and -2 (ERK1/2) signal 
transduction pathways are ubiquitous and well conserved protein kinases involved in 
relaying extracellular signals into intracellular responses, and are involved in the 
mechanisms of synaptic plasticity, learning and memory. ERK activation is required for 
the full expression of LTP (English and Sweatt, 1997, Giovannini et al., 2001), the 
principal cellular mechanism thought to underlie neuronal plasticity. Furthermore, ERK 
is activated in and is necessary for the development of several forms of memory, such as 
fear conditioning (Atkins et al., 1998), conditioned taste aversion memory (Berman et 
al., 1998), spatial memory (Blum et al., 1999; Selcher et al. 1999), step-down inhibitory 
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avoidance (Walz et al., 2000; Cammarota et al., 2000) and object recognition memory 
(Kelly et al., 2003). In a previous paper published by our laboratory in 2005 
(Giovannini et al., 2005), we demonstrated that ERK activation is secondary to 
neurotransmitter release and activation of the forebrain cholinergic neurons during and 
immediately after acquisition of an inhibitory avoidance response, revealed by increased 
release of ACh, which in turn activates ERK in neurons located in the CA1 of the 
hippocampus. Increased release of ACh and ERK activation are events mechanistically 
related to each other, as demonstrated by the use of scopolamine, a muscarinic receptor 
antagonist, and by inhibitors of ERK activation, which all blocked memory encoding 
and ERK activation. A critical function of activated ERK downstream of  the increased 
ACh release occurring during learning is to promote cellular integration of divergent 
downstream effectors which may trigger different responses, depending upon which 
subsets of scaffolding anchors, target proteins and regulatory phosphatases are involved.   
In the present study, the results obtained demonstrate that in old rats, after the 
acquisition of a inhibitory avoidance memory task, there is a lower activation of ERK as 
compared to young rats in CA1, and this low activation is correlated to a worse 
performance of the task as compared to young rats, as shown by the graph of the 
latencies. Taken together these results demonstrate a correlation between memory 
deficit of the rats, and low activation of ERK pathway. The hope is that by studying 
how ERK is activated by different neurotransmitter systems and the ensuing 
downstream cellular modifications, the molecular basis of memory encoding and 
memory impairment will be better understood. 
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5.4 DIFFERENTIAL ACTIVATION OF MAPK PATHWAYS IN 
TRANSGENIC TgCRND8 MICE, MODEL OF AD. 
 
5.4.1 The p38MAPK and JNK pathways 
Our results show that in the hippocampus of 7-month-old TgCRND8 mice a significant 
activation of p38MAPK and JNK was present in comparison to Wt littermates. High 
levels of phospho-p38MAPK were present not only in activated microglia and 
astrocytes localized in the parenchyma surrounding amyloid plaques, but also in 
neurons of the CA1 hippocampal region. On the contrary, activated JNK was localized 
only in round-shaped cells surrounding the amyloid plaques. Similar distribution of 
activated p38MAPK and JNK around the plaques was also found in other brain areas 
outside the hippocampus (data not shown). The presence of phospho-p38MAPK in 
astrocytes and activated microglia not only surrounding and infiltrating the plaques, but 
also localized in the more distant parenchyma of the hippocampus of TgCRND8 mice, 
support the idea that this transduction pathway may contribute to the neurodegenerative 
process. We found that phospho-p38MAPK was localized diffusely in the cell body of 
activated astrocytes and microglia thus implicating that downstream targets may be 
intracellular enzymes and cytosolic proteins (Xia et al., 1995). Indeed, given that 
activated p38MAPK is both upstream and downstream of proinflammatory agents, it 
appears that conditions exist in the AD brain for a self-propagating cycle of stimulation 
(Hull et al., 2002; Sun et al., 2003), in which p38MAPK plays a prominent role through 
the production of pro-inflammatory cytokines, IL-1β and others, cyclooxygenase-2, 
iNOS (Gonzalez- Scarano and Baltuch, 1999; Harris et al., 1995; Markesbery, 1999; 
Kaminska, 2005). We also demonstrated the presence of activated p38MAPK in the 
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pyramidal neurons of CA1. Phospho-p38MAPK may render these neurons more 
susceptible to neurodegenerative damage through activation of further intracellular 
signaling pathways. It is interesting to note that in the CA1 pyramidal neurons phospho-
p38MAPK presented solely a nuclear localization, implying downstream activation of 
transcription factors such as ATF-2 (Kaminska, 2005) and increased expression of 
proteins, among which TNF-α (Takeda and Ichijo, 2002).  
Three genes encoding for JNKs have been identified (JNK1, JNK2 and JNK3). Neurons 
from JNK3_/_ mice are more resistant than normal mice neurons to β-amyloidinduced 
apoptosis (Morishima et al., 2001) and to glutamate- induced excitotoxicity. In human 
postmortem brains from AD patients, JNK phosphorylation is markedly increased and 
there is pronounced redistribution of JNK compared with age-matched controls. JNK2 
and JNK3 are associated with neurofibrillary pathology, and JNK upregulation has a 
complete overlap with phosphorylated tau (Zhu et al., 2001b). Indeed, increased 
activation of JNK and p38MAPK has been found in brain homogenates in all the 
tauopathies (Ferrer et al., 2005) and aberrantly activated p38MAPKs and JNK have 
been reported to be associated with cells that contain filamentous tau in AD (Atzori et 
al., 2001; Ferrer et al., 2001), suggesting that β-amyloid triggers activation of stress 
kinases which may phosphorylate tau in neurites surrounding β-amyloid deposits and 
form tau fibrils (Churcher, 2006). Moreover, activated JNK and p38MAPK 
phosphorylate c-Jun, AP1 and their target genes in AD (Ferrer et al., 2005). 
Unfortunately, it was not possible to confirm that phosphop38MAPK and phospho-JNK 
are colocalized in the same cellular species in TgCRND8 mice. Our results showing the 
presence of activated JNK in cells surrounding the amyloid plaques, are in agreement 
with other studies which demonstrate that in a different model of AD, namely 
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Tg2576/PS1 mice, APP is an excellent substrate for JNK3, and phosphorylation of this 
peptide is thought to be one of the factors mediating its cleavage by secretases (Savage 
et al., 2002). JNK activation is associated with amyloid deposits and phospho-tau 
staining (Savage et al., 2002; Bellucci et al., 2007). An overlap between activated JNK 
and p38MAPK in severe AD cases has been reported, implying that JNK and 
p38MAPK are both activated by the same signal and seem to work synergistically in 
vivo (Zhu et al., 2001a). Comparing these results with those obtained in the aged 
animals it appears that highly stressful conditions might be necessary for JNK to be 
activated within cells. These conditions can evidently be found in the surroundings of 
amyloid plaques but not in a normal aging brain. 
 
5.4.2 The ERK pathway 
Our findings demonstrate for the first time that the ERK2 isoform of the ERK pathway 
was less activated in the hippocampus of TgCRND8 mice both in basal conditions and 
after cholinergic stimulation, suggesting a mechanism responsible for the memory 
deficits typical of AD, possibly due to the interplay between the cholinergic system and 
the ERK pathway in the mechanisms of memory (Giovannini, 2006). We found that in 
basal conditions very sparse phospho-ERK immunopositive neurons were present in the 
hippocampus of the two mouse strains, mainly localized in the DG. However, ERK was 
more activated in the DG of Wt than Tg mice. Immunopositive staining was also 
present in the mossy fibers of Wt mice only. ERK is likely to participate in diverse 
forms of neuronal plasticity by virtue of its ability to regulate both transcription, once it 
is rapidly translocated into the nucleus (Impey et al., 1998), and translation at the 
dendritic level (Kim et al., 1998; Chen et al., 1998). The effects of ERK activation are 
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somehow controversial, since, while activation of ERK is widely believed to confer 
survival advantage to cells (Xia et al., 1995; Guyton et al., 1996), there are conditions in 
which ERK activation may result in cell death (Murray et al., 1998). However, it has 
been shown that in AD ERK seems to be highly activated (Webster et al., 2006; 
Swatton et al., 2004). Thus, the hypothesis as to whether ERK activation might exert 
beneficial or detrimental effects on neuronal activity, depending on the cellular context, 
the duration of activation, the presence of scaffolding proteins (Pouyssegur et al., 2002) 
should be taken into consideration. Indeed, differential durations of ERK 
activation/disactivation are regulated by different molecular/cellular components and 
can elicit unique gene expression profiles (York et al., 1998; Corbit et al., 1999), which 
result in different cellular functions (Marshall, 1995), and final cellular outcomes. For 
instance, transient activation of ERK triggers cell differentiation in PC12 cells, whereas 
prolonged activation results in cell proliferation (Traverse et al., 1992). In accordance 
with our data, the basal levels of phospho-ERK1,2, measured in cell lines from AD 
patients and age-matched controls, were lower in AD cell lines suggesting that the 
intrinsic phosphorylation of ERK was dysfunctional in AD patients (Khan and Alkon, 
2006). Similarly, it has been demonstrated that β-amyloid generates oxidative species 
that can activate p38MAPK and JNK and decrease ERK activity (Troy et al., 2001), 
possibly leading to cell death (Daniels et al., 2001). Furthermore, lower activation of 
ERK in hippocampal neurons may lead to memory deficits (Kelleher et al., 2004; 
Atkins et al., 1998; Selcher et al., 1999). It should also be pointed out that in the brains 
of double Tg mice, expressing both the mutant APPsw and PS1, it was found that 
ERK1,2 was not significantly activated while activation of JNK-1 and p38MAPK were 
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increased (Hwang et al., 2005) indicating that JNK and p38MAPK activation may be 
required for β-amyloid –induced cell death, while ERK is not involved (Hwang et al., 
2005). The rationale for a signaling pathway being responsible at the same time for 
survival/plasticity/memory and/or neuronal degeneration is not clear. However it 
appears (Pouyssegur et al., 2002) that the kinetics and duration of ERK activation may 
play an important role in influencing its effect on cell fate. Obviously, differential 
durations of ERK activation are regulated by different molecular players (York et al., 
1998; Corbit et al., 1999), and can elicit unique gene expression profiles, which 
consequently result in different cellular function (Marshall, 1995). The possibility that 
sustained ERK can activate death programs independent of caspases in neurons 
(Subramaniam et al., 2004) suggests that ERK activation appears to be involved in non-
apoptotic modes of neuronal death. On the contrary, activation of ERK and Akt has 
been found to confer neuroprotection in several models of apoptosis (Hetman et al., 
1999). Similarly, both Akt and ERK have been reported to play a role in regulating 
hippocampal neurogenesis (Aberg et al., 2003). Most interestingly, our experiments 
demonstrated that ex vivo incubation with the non-selective cholinergic agonist CCh, 
mimicking a cholinergic stimulation, induced much lower activation of ERK in Tg mice 
hippocampus than in Wt littermates. This effect was not ascribable to lower levels of the 
ERK protein, similar in the two mouse strains, but possibly to modifications upstream 
of ERK, among which a decrease in the number of muscarinic receptors, significantly 
less numerous in TgCRND8 mice (Bellucci et al., 2006), might play a role. The 
“cholinergic hypothesis” of AD (Bartus et al., 1982) posits degeneration of cholinergic 
neurons and loss of cholinergic transmission as the principal cause of cognitive 
dysfunction in patients with AD (Perry et al., 1978; Bartus et al., 1982). Studies in 
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animal models of AD (Hsiao et al., 1996; Calhoun et al., 1998; Bondolfi et al., 2002; 
Giovannini et al., 2002; Geula et al., 1998; Bellucci et al., 2006), reinforce the notion 
that overexpression of β-amyloid may induce subcellular alterations and cholinergic 
loss in specific brain regions such as the basal forebrain. The ERK pathway has been 
demonstrated to be activated in neurons in vitro by several G-protein-coupled receptors, 
among which the M1 muscarinic receptors in rat (Rosenblum t al., 2000) and mouse 
(Berkeley et al., 2001) brain as well as by nicotinic receptors (Dineley et al., 2001), 
indicating strong connections between these two systems whose dysregulation is 
involved in AD pathogenesis. Indeed, activation of the cholinergic system and of the 
ERK pathway is necessary for memory formation (Giovannini, 2006). Thus, the loss of 
basal forebrain cholinergic neurons in the Tg mouse (Bellucci et al., 2006) may lead to 
decreased tonic cholinergic input to the hippocampus which, together with the decrease 
of muscarinic receptors (Bellucci et al., 2006), might be responsible for the lower 
activation of ERK, thus causing the memory deficits observed in this mouse strain, 
which resemble the memory deficits typical of AD (Bellucci et al., 2006). Thus, our 
findings may pose a molecular basis for the memory disruption of AD, since memory 
function requires proper functioning of the basal forebrain cholinergic neurons (Pepeu, 
1983; Sarter and Bruno, 1997) and ERK2 activation (Adams and Sweatt, 2002; Atkins 
et al., 1998; Kaminska et al., 1999; Blum et al., 1999; Walz et al., 2000; Cammarota et 
al., 2000). Since all MAPK pathways transduce intracellular signalling to increase 
expression of different proteins, dysregulation of MAPK-dependent pathways suggests 
a systematic disorder of protein translation regulation in AD brains. Thus, the exact 
knowledge of the MAPK role and of the complex molecular interactions between 
MAPKs and proteins associated with the evolution of neurodegeneration, among which 
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a role might be played by CD200, may be a cornerstone in the burgeoning field of AD, 
and the outcome of basic research aimed at understanding the role of MAPKs in 
neurodegeneration is also of significant interest to find new therapies for AD. 
 
5.5 EFFECT OF PEC,  NP-0361 AND NP-0336 ON ACh RELEASE 
AND CHOLINESTERASE ACTIVITY IN THE CEREBRAL 
CORTEX OF YOUNG RATS  
Colinergic neurons of the basal forebrain are known to be involved in cognitive and 
behavioral functions that are widely disturbed in Alzheimer’s disease (AD). In 
particular, AD is characterized by a forebrain cholinergic neuron loss and a progressive 
decline in ACh (Perry, E., Perry, R., Blessed, G. & Tomlinson, B. (1978) Neuropathol. 
Appl. Neurobiol. 4, 273–277.; Geula, C. & Mesulam, M. M. (1995) Alz. Dis. Assoc. Dis. 
9, Suppl. 2, 23–28.). Activity of ACh in the brain is terminated by the hydrolytic action 
of ChEs. Inhibitors of these enzymes have been developed to augment the availability 
of synaptic ACh in patients with AD. All ChEIs currently available for AD inhibit 
AChE, and, to a varying extent, BuChE,, a second ChE in brain (Lahiri, D., Farlow, M., 
Sambamurti, K., Greig, N., Giacobini, E. & Schneider, L.(2003) Curr. Drug Targets 4, 
97–112.). AChE and BuChE have numerous physiological functions depending on their 
localization and time of expression (Soreq, H. & Seidman, S. (2001) Nat. Rev. 
Neurosci. 2, 294–302). In healthy human brain, AChE predominates over BuChE 
activity (Giacobini, E. (2003) Int. J. Geriatr. Psychiatry 18, S1–S5.), but the latter likely 
has been previously underestimated (Li, B., Stribley, J., Ticu, A., Xie. W., Schopfer, L., 
Hammond, P., Brimijoin, S., Hinrichs, S. & Lockridge, O. (2000) J. Neurochem. 75, 
1320–1331.). 
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While AChE is localized mainly to neurons, BuChEis associated primarily with glial 
cells, as well as to endothelial cells and neurons (Darvesh, S., Hopkins, D. & Geula, C. 
(2003) Nat. Rev. Neurosci. 4, 131–138.). The close spatial relationship of glial BChE 
would allow synergistic BuChE-mediated hydrolysis to assist in the regulation of local 
ACh levels to permit the maintenance of normal cholinergic function. The survival of 
AChE knockout mice (Li, B., Stribley, J., Ticu, A., Xie. W., Schopfer, L., Hammond, 
P., Brimijoin, S., Hinrichs, S. & Lockridge, O. (2000) J. Neurochem. 75, 1320–1331.) 
with normal levels and localization of BuChE (Mesulam, M., Guillozet, A., Shaw, P., 
Levey, A., Duysen, E. & Lockridge, O. (2002) Neuroscience 110, 627–639) supports 
the concept that BuChE has a key role that can partly compensate for the action of 
AChE. In the AD brain, increasing levels of BChE correlate positively with the 
development of hallmark cortical and neocortical amyloid rich neuritic plaques and 
neurofibrillary tangles (Geula, C. & Mesulam, M. M. (1995) Alz. Dis. Assoc. Dis. 9, 
Suppl. 2, 23–28., Guillozet, A., Smiley, J., Mash, D. & Mesulam, M. (1997) Ann. 
Neurol. 42, 909–918).  In light of the suggested role of BChE in central cholinergic 
transmission, its altered expression in AD brain, and probable association with the 
development of neuropathologic changes, inhibiting this enzyme would be of clinical 
value. We tested novel BuChE inhibitors on cortical ACh release and AChE/BuChE 
activity. 
Our results show that donepezil (1 mg/kg) and rivastigmine (0.6 mg/kg) administration 
is followed by 4 fold, while PEC administration (5 mg/kg) by 2.5 fold increase in 
cortical ACh release. At the doses used, when peak ACh levels were reached in the rat 
cerebral cortex, donepezil inhibited significantly only AChE activity, PEC inhibited 
only BuChE activity, while rivastigmine inhibited both AChE and BuChE. The different 
inhibitory profiles of the three drugs “in vivo” correspond to their “in vitro” affinity for 
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AChE and BuChE. Donepezil is a selective AChE inhibitor (Giacobini, 2000), 
rivastigmine is a dual inhibitor exerting a comparable inhibition on both AChE and 
BuChE (Giacobini, 2000), while PEC is a selective BuChE inhibitor with a 
BuChE/AChE ratio of 0.0002 (Giacobini, 2003). We also demonstrated that the brain 
concentration of donepezil measured at peak effect (1 h) is about 180 nM which is in 
good agreement with earlier measurements by Kosasa et al. (2000). The experimentally-
determined concentration of donepezil in the rat brain after administration of 1 mg/kg is 
10 to 20 times higher than the reported in vitro IC50 ranging from 5 to 11 nM according 
to Rogers et al. (1991) and Enz (unpublished data), respectively. The brain rivastigmine 
concentration, measured after administration of 0.6 mg/kg, at peak ACh releasing effect 
(1 h after administration), was lower than that of donepezil, but still in the nM range (14 
nM). Given that rivastigmine is rapidly metabolized by AChE and BuChE to the 
metabolite NAP 226-90 (Bar-On et al., 2002), we added up the concentration of both 
the parent drug and its metabolite, resulting in a total drug concentration of 72 nM. It is 
difficult to perform a direct comparison of the experimental brain concentration of 
rivastigmine plus NAP 226-90 with the in vitro rivastigmine IC50 value because of the 
time-dependent inhibition occurring with drugs of this kind. As reported by Ogura et al. 
(2000), an IC50 value of 4.3 nM for rivastigmine was estimated in rat brain in vitro 
after 48 h incubation. The increases in ACh extracellular levels observed in our 
experiments after the administration of donepezil and rivastigmine are comparable with 
those reported in the literature. Liang and Tang (2004), administering donepezil 4.0 
µmol/kg, a dose about twice as high as that used in the present experiments, obtained an 
80% increase in acetylcholine levels in the rat cortex, and similar increase was obtained 
with rivastigmine 1.1 µmol/kg, about one third of the dose used in our experiments. 
Giacobini et al. (1996) observed a 200% increase after the administration of donepezil 
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0.5 mg/kg s.c. In the present experiments the activity of PEC was about half as large 
than that reported by Greig et al. (2005). These variations are common in microdialysis 
experiments, given the variability in ACh release between rats, and other 
methodological variables such as the difference in the properties and preparation of the 
microdialysis membranes (Khan and Shuaib, 2001). The question arises whether a 
simple relationship between the increase in ACh levels and cholinesterase inhibition 
exists. In our experiments, the 3.5 fold increase of extracellular ACh levels found after 
donepezil and rivastigmine administration was associated with an AChE inhibition 
between 22 and 40%, respectively. It should be mentioned that, as shown by Kosasa et 
al. (1999) in the hippocampus, the maximum increase in ACh levels does not 
necessarily correspond to the maximum AChE inhibition, but the enzyme inhibition 
tends to anticipate the acetylcholine increase. Giacobini et al. (1996), investigating the 
effects of donepezil on extracellular acetylcholine levels, observed a 200% increase 
with a 15% AChE inhibition, and a 2100% increase with a 35% AChE inhibition. Scali 
et al. (1997), studying the effect of metrifonate, an irreversible non selective 
cholinesterase inhibitor, reported no significant cortical ACh increase with 30 mg/kg 
which inhibited cholinesterase activity by 16% but a 5-fold increase with 80 mg/kg 
which caused a 77% cholinesterase inhibition. Liang and Tang (2004) observed an 80% 
increase in ACh levels after the administration of donepezil and rivastigmine temporally 
associated with an AChE inhibition of 15 and 40%, respectively. We may therefore 
conclude that the data present in the literature show that no simple and straightforward 
correlation between the degree of cholinesterase inhibition and the increase in ACh 
levels seems to exist. Age-related differences in sensitivity to cholinesterase inhibitors, 
preferential affinity for different AChE molecular forms (Ogane et al., 1992; Zhao and 
Tang, 2002), relative abundance of the two enzymes and difference in their tissue 
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distribution (Ballard et al., 2005), as well as dilution effects during cholinesterase 
determination are some of the factors which may account for the lack of a precise 
relationship between ACh increase and AChE inhibition found after inhibitors 
administration. Therefore, the data so far available do not allow to define which is the 
minimal cholinesterase inhibition resulting in a significant increase in ACh extracellular 
levels (Pepeu, 2000).  
PEC caused a 25–39% inhibition of BuChE which was accompanied by about two fold 
increase in cortical ACh extracellular level. The possibility to increase ACh levels by 
inhibiting BuChE was shown by Giacobini (2003) by infusing the selective BuChE 
inhibitor MF-8622 directly in the cortex of the rat. The present experiments demonstrate 
that a partial inhibition of BuChE is sufficient to increase ACh release to levels 
comparable to those obtained with the inhibition of AChE. However, BuChE activity in 
the brain is less than 10% of AChE activity, as shown in Table 1, or 20% as reported by 
Giacobini and Holmstedt (1958) in the rat spinal cord. Mesulam et al. (2002) 
demonstrated that AChE knockout mice are vital, and utilize BuChE to hydrolyze ACh. 
In our experiments the rats were normal, with full AChE activity, nevertheless partial 
inhibition of BuChE activity was able to increase ACh levels in the cortex. This finding 
suggests that the importance of BuChE as a “co-regulator” of synaptic ACh levels 
should be reconsidered, particularly under the light of the diffuse (volume) transmission 
which is a feature of central cholinergic mechanisms (Steriade and Descarries, 2006). 
PEC at the dose of 5 mg/kg did not significantly inhibit AChE. A non significant 5–
12% inhibition, possibly ascribable to the variability of the two different detection 
methods used, was observed. This degree of inhibition is not usually accompanied by 
any increase in acetylcholine level (Pepeu, 2000).  
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Furthermore, our experiments confirm that NP-0361 at the dose of 20 mg/kg i.p. only 
exerts a statistically significant 39% inhibition of AChE. Conversely, the administration 
of NP-0336 at the dose of 80 ,g/kg i.p. is followed by statistically significant 15% 
BuChE inhibition only. Lower doses of the two drugs (10 mg/kg of NP-0361 and 40 
mg/kg of NP-0336) were ineffective. 
Both AChE and BuChE  inhibitions were accompanied by an almost doubling of the 
extracellular levels of cortical ACh, lasting about 1 h, measured by transversal 
microdialysis coupled to HPLC detection and quantification. 
The increase in ACh extracellular levels elicited by the administration of NP-0361 is 
smaller than the expected from a 39% AChE inhibition. By comparison, treatment with 
rivastigmine 1.0 mg/kg increases about 6 fold the ACh levels accompanied by a 50% of 
AChE inhibition. It is possible that the sedation observed in the rats treated with NP-
0361 20 mg/kg, is also accompanied by the decrease activity of the cortical cholinergic 
system and the ensuing reduction in ACh release.  
Conversely, it is remarkable that 15% BuChE inhibition is sufficient to increase ACh 
extracellular levels, considering that BuChE activity is only 10% of total cortical 
cholinesterase activity (Cerbai et al., 2007). However, the above results on BuChE 
inhibition, obtained after the administration of the selective BuChE inhibitor PEC, show 
a 3 fold increase in ACh extracellular levels (Cerbai et al., 2007). 
A role of BuChE in neurotransmission is demonstrated also by the increase sensitivity 
to AChE inhibitors observed in BuChE knockout mice (Duysen et al., 2007). The 
increase in ACh levels after BuChE inhibition supports the hypothesis, proposed by 
O'Brien et al. (2003), that BuChE might be a major regulator of attention, based on 
studies on Alzheimer's patients with reduced BuChE activity due to polymorphism. Our 
results may also help explaining the findings by Bartorelli et al. (2005), that AD patients 
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deteriorating on selective AChE inhibitor treatment can benefit from switching to a dual 
AChE–BuChE inhibitor, such as rivastigmine, in terms of stabilization of disease and 
improvement in cognitive functions. Finally, it is pertinent to mention that BuChE is 
increased in the cerebral cortex of Alzheimer's disease patients (Perry et al., 1978) and it 
is associated with the amyloid plaques. It has been suggested that BuChE, together with 
AChE (Alvarez et al., 1997), may participate in the transformation of the β-amyloid 
deposit into neuritic plaques (Guillozet et al., 1997). Inhibition of the enzyme may 
therefore delay plaque formation, thus suggesting the possibility to use BuChE 
inhibitors in the treatment of Alzheimer's disease not only to increase the availability of 
ACh at the synapses, but also to reduce the number of plaques. 
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